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Abstract 
 
Telomerase is best known for its nuclear telomere maintenance function via its 
enzymatic activity requiring the two major components TERT (protein) and TERC 
(RNA). However, telomere and TERC-independent functions for TERT have been 
described recently. 
Our group and others have previously shown that telomerase shuttles to 
mitochondria improving their function and decreasing cellular oxidative stress. 
Oxidative stress and mitochondrial dysfunction are well known to increase during 
ageing and have been implicated as a cause for age-related neurodegenerative 
diseases.  
I report that TERT protein localises in mammalian brain mitochondria 
specifically in neurons. Moreover, although telomerase activity is negligible in brain, 
I found considerable amounts of the telomerase protein TERT in mouse and human 
brain by independent techniques. 
Dietary restriction (DR) is known as a condition that improves mitochondrial 
function, delays or prevents age related diseases and improves cognitive function. In 
this study mTert was detected in brain mitochondria under basic conditions, and it 
becomes elevated in brain mitochondria of animals in three independent experiments 
of short term (3-6 months) DR.  
Decreased signalling through mTOR has been described as a major 
mechanism of the DR response. Accordingly, I found that mTOR phosphorylation 
was down regulated in brains from DR animals. Moreover, to analyse whether 
decreased mTOR signalling causes mitochondrial redistribution of mTert, mTert wild 
type and mTert knock-out mice were treated with rapamycin what resulted in 
increased mTert protein in brain mitochondria and correlated with decreased 
mitochondrial ROS production. The conclusion is that down-regulation of mTOR is 
a possible mechanism to increase mTert protein levels within mitochondria under 
DR.  
Together, this data shows that mitochondrial mTert might be an important 
new player in the protection of neurons and improve brain function during ageing. 
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Chapter1 – Introduction 
1.1. Cellular senescence and organismal ageing 
Ageing research is one of the fastest growing fields within biomedical science - 
mainly due to the impact it has on the costs of public health care. Advanced age 
remains the highest risk factor for chronic diseases such as Alzheimer’s and diabetes. 
Reduction in mental and physical ability of older people is also important in the 
perspective of demographic challenges in aged western societies [1]. Moreover, it is 
thought that improvements in health of older people will increase their general life 
satisfaction and comfort. Despite improvements in human longevity in the last 
decades, disabilities and age related disorders are still unsolved challenges for 
biomedicine. Moreover, basic mechanisms of ageing still remain elusive.  
Cell senescence was originally defined in vitro as the irreversible loss of 
replicative potential without loss of metabolic capacity [2-4]. This  definition is used 
to describe ageing-associated molecular changes in human cells and might have 
relevance to the ageing process in vivo [5]. Ageing of an organism is described as the 
decreased ability to respond to stress, increased homeostatic imbalance and increased 
risk of diseases accompanied by decreased fertility and increased mortality, all 
correlated with chronological age [6].  
A proposed evolutionary function of senescence is tumour suppression since 
the main feature of cell senescence is cell cycle arrest via the p53 and p16
INK4a
 
pathways [3]. Internal and external factors may induce/ accelerate senescence. It is 
believed that senescence is closely linked with damage. Macromolecules like DNA 
and proteins are exposed to damage from factors like UV and Reactive Oxygen 
Species (ROS). The origin and role of ROS will be discussed in the following 
chapter. To initiate cellular senescence a DNA damage response is required and it 
can be triggered by uncapping of telomeres or by DNA damage in non-telomeric 
regions of chromosomes [7]. Among the manifestations of a senescent cell, the most 
apparent is shortening of telomeres (ends of chromosomes) and accumulation of 
DNA damage [3, 8]. Furthermore, senescence is associated with a variety of 
phenotypic changes including growth arrest, altered gene expression, apoptosis 
resistance and autophagy inhibition [3, 9-11]. Moreover, recent research by Judith 
Campisi’s group shows that cells when they senesce exhibit a Senescence-Associated 
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Secretory Phenotype (SASP) which involves the secretion of specific signalling 
factors [12, 13]. For instance, it was shown that senescent cells secrete interleukins 
(i.e. IL-6, IL-7), inflammatory cytokines (i.e. IL-8), and growth factors (i.e. bFGF) 
that can affect surrounding cells and are mostly associated with inflammation and 
cancer development [13]. Furthermore, a new term SIPS (Stress-Induced Premature 
Senescence) was used do define senescence induced by exogenous oxidative factors 
which leads to irreversible growth arrest of proliferative cells. However, there is still 
open discussion whether SIPS shows the same characteristics as replicative 
senescence [4, 14].  
Although a common molecular marker for all senescent cells has not been 
found, a wide range of senescent cells show DNA damage foci with activated 
γH2A.X, increased p16 INK4a expression and often are Senescence Associated β-
Galactosidase (SA-β-Gal) – positive [15].  
Apart from molecular mechanisms and manifestations of cell senescence, 
there is still an unanswered question as to how these processes contribute to age-
related diseases and what is their influence on tissue decline as well as organ 
dysfunction in vivo? It was shown recently in a mouse model by Baker et al., (2011) 
that clearance of p16
 INK4a
 –positive (senescent) cells might delay age-related 
phenotypes in various tissues i.e. skeletal muscle or bone marrow [16]. Furthermore, 
it is thought that senescence of stem cells might significantly contribute to age-
related decline in tissue renewal and homeostasis [17]. During ageing, a deterioration 
of stem cell function and sometimes a decline in quantity has been observed [18]. For 
example, it was shown in a mouse model that depletion of the Neural Stem Cells 
(NSCs) pool in brain is responsible for age-related phenotypes, such as loss of 
olfactory and cognitive functions [19-22]. Molecular manifestations of stem cell 
senescence are similar to somatic cells; however, telomere shortening is significantly 
slower due to reactivation of telomerase in ageing stem cells [23, 24]. The dynamic 
of telomerase in stem cells will be discussed in the forthcoming chapter.   
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1.2. Mitochondria 
1.2.1. Structure and function of mitochondria 
A close connection between mitochondria and ageing has been discussed and studied 
for decades. It was shown that defects in mitochondria function may be a cause and 
an effect of accelerated senescence and ageing at the same time [25].   
Mitochondria are “the powerhouse of the cell” and are responsible for 
production of ATP during OXPHOS (Oxidative phosphorylation), cell signalling 
regulation, Ca
2+
 storage and cellular pH maintenance. Mitochondria are enclosed by 
an outer- and inner-membrane, which forms numerous cristae. In addition, 
mitochondria contain nucleic acids like RNA and mitochondrial DNA (mtDNA) 
coding some of the mitochondrial proteins as well as rRNAs and tRNAs. Since only 
13 proteins are coded in mitochondria, most of the polypeptides necessary for 
mitochondria function are transported from the cytoplasm to the mitochondrial 
matrix in an unfolded form by complexes of the TOM and TIM protein family 
(Translocator of the Inner- and Outer- Membrane). The signal sequence on the N-
terminus of polypeptides synthesized in the nucleus is recognized by TOM complex. 
Next, the transported polypeptide chain is inserted in the TOM complex, then TIM 
complex, which is linked at sites of contact between two membranes, translocates 
molecules into the matrix of mitochondria  [25]. 
The main function of mitochondria is the production of easily accessible 
energy in the form of ATP (Adenosine Triphosphate) through OXPHOS. The 
machinery for oxidative phosphorylation contains the Electron Transport Chain 
(ETC), which includes five large protein complexes. Each complex contains 
multiple polypeptides, and changes in their expression are currently analysed for 
their role in mitochondria bioenergetics and potential impact on ageing [25]. 
Complex I (properly referred to as NADH-ubiquinone oxidoreductase) is a structure 
of 46 protein subunits and 7 of them are encoded by mtDNA. Complex I is a 
provider of electrons from oxidation of NADH carried by ubiquinone to complex II 
and protons H
+ 
which
 
are
 
released to IMS (Inner Membrane Space). Complex II 
(succinate - ubiquinone oxidoreductase) is the simplest polypeptide in the ETC 
consisting of only four peptides coded by nuclear DNA. This complex catalyses the 
oxidation of succinate to fumarate, which is another source of electrons carried by 
ubiquinone. The receiver of electrons from complex I and II is ubiquinone (Q) which 
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passes electrons to complex III. Also known as ubiquinone-cytochrome c 
oxidoreductase, complex III is assembled from 11 peptides in mammals (only one – 
cytochrome b is encoded by mtDNA) and its role is to pass electrons through 
cytochrome c to complex IV. Cytochrome c oxidase, as complex IV is often referred 
to, catalyses the reaction where cytochrome c is a terminal acceptor of electrons 
which results in H2O and H
+
 release to the IMS. Proton efflux to IMS coupled with 
reactions catalysed by complex I, III and IV causes an electrochemical gradient also 
referred as mitochondrial membrane potential (ΔΨm). This potential is a source of 
energy for the ATP synthase complex (also called complex V). Reflux of protons 
accumulated in the IMS through complex V releases energy for the phosphorylation 
of ADP. This reaction is coupled with redox reactions in complex I, III and IV as 
well as with electron transport (Figure 1. 1 A.) [25].  
The electron transport chain is coupled with the Tricarboxylic Acid Cycle 
(TCA) also known as the Krebs cycle or citric acid cycle. The role of these series of 
chemical reactions occurring in the mitochondrial matrix is to convert pyruvate 
obtained from glucose to carbon dioxide. Furthermore, TCA is a source of protons 
carried in molecules of NADH and FADH2 used in the ETC (Figure 1. 1 A.)[25].  
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Figure 1.1. Electron transport chain and superoxide generation sites. A. Electron transport chain 
with forward electron transport. B. Superoxide production during reverse electron flow is caused by 
excess of succinate (substrate) and accumulation of electrons. Reverse electron flow in vitro might be 
increased by rotenone which blocks ubiquinone binding site of complex I and inhibit electron passing.   
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1.2.2. The role of mitochondria in senescence and ageing  
There is a plethora of published data describing the role of mitochondria in the 
senescence process [26-29]. It has been shown that mtDNA mutation, disruption in 
the electron transport chain and decrease in membrane potential may lead to cell 
dysfunction, senescence and – potentially – death. A wide discussion about the role 
of mitochondria in senescence started in 1954 with the work of Denham Harman and 
his “free radical theory” where he suspected that ageing is a result of molecular 
damage accumulation generated by ROS [30].  
Reactive oxygen species include the superoxide radical (O2
.-
), hydroxyl 
radical (OH
.
), and hydrogen peroxide (H2O2). Mitochondria are responsible for the 
majority of overall cellular ROS production [31, 32]. The majority of free radicals 
are generated due to “leakage” of electrons from the ETC (mostly from complex I 
and III) and by deriving them from molecular oxygen [33-35]. Complex I appears to 
be the prime producer of ROS in cells. It can form superoxide during forward 
electron flow (NADH – oxidizing) ,described in the subchapter 1.2.1 as well as 
during reverse electron transport (NAD
+
 – reducing) which is caused by 
accumulation of electrons from complex II (due to excess of substrate – succinate) 
during the resting state of mitochondria (Figure 1. 1 B.) [36]. Moreover, significant 
amounts of ROS are also produced in the cytosol during metabolic reactions which 
use oxygen as a substrate [25]. 
There is a continuous discussion on role of ROS in senescence and ageing 
[37, 38]. Most importantly, ROS generated in mitochondria is thought to be 
responsible for generating mtDNA damage leading to mitochondrial dysfunction. It 
has been shown that point mutations and deletions in mtDNA accumulate with age in 
mammalian tissue causing respiratory disruption that leads to dysfunction of somatic 
stem cells and premature ageing [39, 40]. Interestingly, a very recent study from our 
institute, shows that ROS production in mitochondria and nuclear DNA damage can 
be amplified by a positive feedback loop through the p21 pathway [7]. According to 
this theory, repair mechanisms and defence systems become overwhelmed with 
accumulating damage, leading to mitochondrial damage causing permanent 
senescence changes. Direct evidence for the connection between mitochondria 
dysfunction and ageing was provided by Trifunovic et al., (2004) and Kujoth et al., 
(2005) using a mouse model. Both groups showed elegant experiments on a 
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progeroid effect of proofreading deficiency by mutated mitochondrial DNA 
polymerase γ (POLG) causing a number of age related changes like reduced life 
span, hair loss, anaemia, osteoporosis, reduced fertility and induction of apoptotic 
markers in different tissues (no senescence, mainly apoptosis)  [41, 42]. Furthermore, 
it was shown that mitochondrial lipid oxidation (i.e. cardiolipin) may affect 
membrane fluidity and disrupt the electron chain transport, thus impairing respiration 
and as a consequence, ROS generation might be accelerated [43]. Interestingly, there 
is evidence that ROS can act as a signalling molecule, enabling adaptation to stress 
[44]. For example, Hekimi and colleagues have formulated an interesting hypothesis 
in which ROS generation is not a cause of ageing, but rather characterises a stress 
signal in response to damage [45].  
Abundance of ROS in healthy cells is continuously controlled by antioxidant 
enzymatic defence. Antioxidants like superoxide dismutase, catalase or peroxidases 
are able to inactivate free radicals, however, with age their activity might be reduced 
and oxidative stress becomes more apparent [46-48]. Additionally, it was shown that 
over-expression of antioxidant genes might increase – while its deletion might reduce 
lifespan of mouse models [49-51]. However, on the other hand, diet supplementation 
with antioxidants did not show a clear pro-survival effect in many models so far [52]. 
Furthermore, it was shown by Perez and colleagues that over-expression of different 
combinations of SOD1, SOD2 or catalase decreases oxidative damage in transgenic 
mice without extending lifespan [51]. In addition, similar studies on fruit flies and C. 
elegans also showed that over-expression or deletion of antioxidant genes may have 
no influence on the survival of these animals leading to a conclusion that the role of 
ROS in ageing is still not explained sufficiently [53, 54].  
In humans, there is evidence that ATP production and respiratory capacity of 
mitochondria decrease with age [55]. Moreover, mitochondrial dysfunction is 
associated with many age related brain diseases (encephalopathy) and muscular 
disorders (myopathy) [56, 57]. However, there is still no agreement in the role of 
mitochondria in neurodegenerative diseases. It was shown that disruption of complex 
I in mitochondria in the substantia nigra of the human brain can lead to the death of 
dopaminergic neurons and may be a cause of Parkinson’s disease (PD) [58, 59]. In 
contrast, the role of mitochondrial dysfunction in death of cholinergic neurons in 
Alzheimer’s disease (AD) is still not fully eluded. Observed mutations of mtDNA 
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and mitochondrial dysfunction in AD are recognised as an effect of the disease rather 
that one of primary causes [60]. To conclude, damage of mtDNA and respiration 
deficiency appear as a main contributor to age related dysfunction of mitochondria. 
Nonetheless the cause-effect relationship between malfunction of mitochondria and 
neurodegenerative diseases still needs to be elucidated [27-29, 61].  
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1.3. Dietary restriction and related signalling pathways  
1.3.1. Dietary restriction 
Dietary restriction (DR) is the only non-genetic manipulation able to significantly 
increase life span of many animal models. Thus, DR is an attractive intervention to 
analyse lifespan, ageing and age-related diseases.  
It was proposed for the first time in 1935 by McCay that DR may be able to 
prolong lifespan. He observed that laboratory rats, who were fed a reduced calorie 
diet while maintaining micronutrient levels, had extended life spans when compared 
to controls [62]. There is a plethora of reports from yeast, throughout invertebrate 
animals such as worms (C. elegans) and flies (D. melanogaster) to a variety of 
mammalian species, including rodents, dogs and monkeys that DR is beneficial for 
health improvement and lifespan extension [63-70]. The term Dietary Restriction or 
caloric restriction (CR) refers to the limitation of food intake by an organism without 
malnutrition or starvation. CR is a category of DR where only caloric food 
components are reduced. Other dietary modifications used in ageing research include 
alterations in protein intake (or some amino acids), and changes of fat content in the 
diet. For example, experiments on mice with reduction of selected amino acids 
(tryptophan, methionine) in their diets, increased life span of rodents but not to the 
same extent as DR [71-74].  
The most important physiological benefits of DR include body mass 
reduction, fat content decrease, lower blood glucose and improved insulin sensitivity 
[75, 76]. It was shown on many animal models that DR improves mitochondrial 
function and biogenesis [77]. An important feature of DR is the significant reduction 
of the mitochondrial ROS production and decreased level of oxidative stress in liver, 
muscle and brain in rodents and primates [32, 78-81]. Furthermore, recently Miwa et 
al., (2008) showed that dietary restriction significantly increases mitochondrial 
turnover rate in mouse liver compared to ad libitum (AL) feed controls, this may 
help explain improved mitochondrial function after DR [82]. Another example of the 
beneficial effect of DR on mitochondria was described by Jang and colleagues who 
have shown that DR can reduce oxidative damage in rodent muscle and protects 
against sarcopenia even with a deletion of a key antioxidant enzyme (Sod1-/-) [83]. 
On the other hand, it has been shown that DR may actually increase transient ROS 
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production. For instance, Shultz et al., (2007) reported that reduced nutrients in C. 
elegans increased production of ROS which induced catalase activity, leading to 
increased oxidative stress resistance and survival [84]. The authors propose the 
explanation that DR transiently promotes ROS production, which leads to ignition of 
stress defence mechanisms, resulting in long term reduction of oxidative damage 
[84]. It is thought that many of these mitochondrial and metabolic benefits of DR are 
observed due to increased expression of the transcriptional co-activator PGC-1α, 
which modulates activity of transcription factors [85, 86]. PGC-1α was shown to 
increase mitochondrial biogenesis under DR due to its ability to modulate the activity 
of several transcription factors and co-activators involved in mitochondrial 
respiration and biogenesis e.g nuclear respiratory factor 1 (NRF-1), NRF-2, PPARc, 
steroid receptor coactivator-1, and mitochondrial transcription factor A [87, 88].  
Interestingly, DR was shown to have a protective effect on the brain. For 
example, short term DR resulted in a delayed occurrence of neurodegenerative 
syndromes in animal models of Parkinson’s and Alzheimer’s disease [89, 90]. 
Several studies suggested that inflammation might be an important cause of the age 
related cognitive decline and neurodegeneration. It was reported that the anti-
inflammatory effect of DR might suppress age related deterioration of the central 
nervous system [91]. Furthermore, Morgan et al., (1999) showed that DR is able to 
attenuate the activation of astrocytes and microglia, which are recognised as factors 
related to synaptic atrophy, demyelination and neurodegeneration [92]. In addition, 
several studies have revealed that generation of new neurons can be stimulated by 
dietary restriction. It has been shown that DR is efficient with restoration of neuronal 
plasticity and improves cognitive abilities of ageing animals [93]. Moreover, DR 
may improve immune function of T-lymphocytes and reduce cancer occurrence in 
rodent and primate models what might be another cause of average lifespan 
extension in restricted animals [94-96].  
Surprisingly, food intake limitation is not always as efficient as life extending 
manipulation. Hempenstall et al., (2010) and other groups have reported that some 
strains of rodents do not show a life extending effect of DR. Specifically, the 
laboratory mouse strain DBA/2 shows some improvements in health span but there 
was no prolongation of lifespan under DR [97]. Furthermore, large scale studies by 
two independent groups on ILSXISS recombinant heterogeneous inbred mice strains, 
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showed inconclusive results on DR influence on longevity [98, 99]. In both studies, 
performed on male and female animals, an unexpected pattern was observed. For 
instance, DR decreased the lifespan of 20–25% strains tested, increased the lifespan 
of only 5–25% of strains, and had no significant result on lifespan on the majority of 
strains [98, 99]. Therefore, the genetic background of laboratory rodents required for 
a positive DR response is under intensive research [91, 97, 100, 101]. Similarly, 
recent research presented by Mattison et al., (2012) on Rhesus monkeys showed that 
caloric restriction does not extend life span [102]. Nonetheless, the control group in 
the study was not fed a standard ad libitum diet. It was stated, that AL Rhesus 
monkeys in this study were slightly restricted to avoid obesity [102]. However, a 
number of experiments on long-lived species in laboratories around the world are 
still not finished. Nevertheless, all data so far suggests that DR is beneficial for the 
health span of many animal models, including non-human primates and humans 
[103]. 
 
1.3.2. The role of mTOR pathway in DR response 
There are several pathways known to be altered as a molecular response to DR. The 
most extensively analysed at the moment are the mTOR/S6K1 pathway, the 
insulin/IGF signalling, sirtuin regulation and the PGC-1α pathway [104-107]. 
Most indications so far suggest that the life span extension mechanism 
induced by DR could be explained by down-regulation of the mTOR pathway. 
Mammalian Target of Rapamycin (mTOR) is a kinase that regulates signals for 
cellular growth control in response to nutrients. Furthermore, the mTOR pathway is 
widely studied due to its key role in apoptosis and cancer development. It was shown 
that elevated activation of mTOR signalling reduces apoptosis and increases 
proliferative capacity of cancer cells [108].  Furthermore, it was shown that mTOR 
can be a link between nutrients and energy signalling pathways [109]. Recently, the 
kinase was also described as a regulator of nutritional and hormonal signals in the 
brain [110]. There are reports suggesting that inhibition of the mTOR pathway 
extends life span of yeast, worms, flies and mice [111-113].   
The kinase mTOR is a catalytic subunit in two protein complexes: mTORC1 
and mTORC2. The first complex, consist of mTOR kinase, Raptor protein, mLST8, 
PRAS40 and DEPTOR. The function of mTORC1 is to regulate protein synthesis 
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and to coordinate nutrient/energy/redox signalling. This complex is stimulated by 
insulin, growth factors, amino acids and oxidative stress. The downstream targets of 
mTORC1 are S6K1 (activated) and 4E-BP1 (supressed), which are both known for 
the regulation of protein synthesis and cell proliferation [114, 115]. The second 
complex – mTORC2 – is formed by mTOR, Rictor, GβL and mSIN1. Its main 
function is the phosphorylation of Akt protein kinase, which is known for its role in 
the regulation of glucose metabolism and cell proliferation [116]. 
It is known that the downstream targets of mTOR are engaged in the 
reduction of oxidative stress as well as the response to DNA damage and induction 
of apoptosis. Schieke et al., (2006) reports that mTOR co-purifies with mitochondrial 
fraction and plays a significant role in oxidative capacity and mitochondrial oxygen 
consumption [117, 118]. In the study of Schieke and colleagues, treatment with 
rapamycin resulted in the disruption of the mTOR-raptor complex that caused lower 
mitochondrial membrane potential (ΔΨm), oxygen consumption and decreased ATP 
synthesis [117]. Furthermore, Anisimov et al., (2011) showed that inhibition of 
mTOR by rapamycin slows ageing and increases lifespan in mice [119]. More 
recently, Wilkinson et al., (2012) confirmed that rapamycin supplementation could 
increase lifespan in mice, decrease tumour incidence as well as decrease 
degenerative age related changes in liver and heart [120]. However, in the same 
study animals fed with rapamycin had an increased cataract severity and increased 
testicular degeneration – both not reported before in comparable studies [120]. Direct 
evidence that mTOR/S6K1 pathway is involved in mammalian lifespan regulation 
was provided by Selman et al., (2009) [113]. The authors showed in a mouse model 
that deletion of the S6K1 kinase, a downstream target of mTOR pathway, increased 
lifespan; improved insulin sensitivity and increased blood glucose clearance. 
Moreover, in S6K1
-/-
 neuromuscular function was improved in comparison to the 
wild type litter mates. Furthermore, S6K1
-/-
 animals had reduced body weight and 
total body fat content compared to control animals which all together makes the 
mTOR pathway a prime candidate for further study on longevity and dietary 
restriction [113]. Interestingly a recent publication by Fok et al., (2012) suggests that 
indeed treatment with rapamycin and dietary restriction may have a similar effect on 
mice [121]. In the experiments mice were dietary restricted or supplemented with 
rapamycin, the authors reported a similar inhibition of the S6K1 – mTOR pathway 
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downstream target as well as similar increase in autophagy in liver after both 
treatments. However, animals from the DR group and rapamycin treated group 
showed the opposite effect on blood glucose clearance and different insulin 
tolerance, showing the benefits of dietary restriction and deteriorative effect of 
rapamycin [121]. Thus, it is still debatable as to whether inhibition of mTOR 
pathway might mimic the effects of dietary restriction on health and lifespan. 
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1.4. Structure and canonical function of telomerase 
1.4.1. TERT and TERC complex 
Telomerase is a ribonucleoprotein and reverse transcriptase, well known for 
protecting the ends of chromosomes (telomeres) during cell proliferation and for 
preventing senescence [122]. Telomerase was first described in the ciliate 
Tetrahymena by Nobel Prize winners Elizabeth Blackburn, Carol Greider and Jack 
Szostak in 1985 [123]. It attracted the attention of the public and scientists from 
different fields of molecular biology and medicine due to the popular belief that 
telomerase may hold the secrets of human immortality. Telomerase contains the 
catalytic subunit TERT and an RNA component TERC including the template region 
for telomere synthesis as well as other protein components including heat-shock 
protein 90 (hsp90) and dyskerin (Figure 1.2) [124-126]. Both TERT and TERC 
elements are required and sufficient for its canonical function, which is the 
maintenance and elongation of telomeres (catalytic activity) [124]. Since mouse and 
human telomerase will be analysed in this thesis, only mammalian telomerase 
structure is going to be described here. 
 The human gene hTERT is located on chromosome 5 while mouse mTert is 
located on chromosome 13 [127]. Mammalian TERT mRNA consists of 16 exons 
and 15 introns extending over 35kb [128]. There are a number of publications 
showing that mouse and human TERT gene have a similar promoter region, although 
are differently regulated [129]. The sequence of the hTERT promoter comprises a 
core region from -330bp to +37bp numbered from transcription start codon ATG of 
the hTERT gene and contains E-boxes (CACGTG) but does not contain TATA or 
CAAT boxes and is comparable to the mTert promoter [127, 128]. It was shown that 
only hTERT but not mTert transcription is activated by c-Myc – a well-known 
oncogene. Furthermore, hTERT expression is up-regulated by SP1, AP-2, and HIF-1 
transcription factors [128, 130-132]. Human TERT gene is repressed by a number of 
factors including: MEN1, WT1, Mad1 (by blocking c-Myc), E2F, AP-1, HDAC1, 
and p53 (by repression of SP1) [133-136]. In contrast, transcription of mTert is not 
sufficiently described. Formerly, it was suggested that c-Myc might also be a mTert 
transcriptional activator, although nowadays, despite the lack of direct evidence, 
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proteins NFAT5, Sp1, Sp3 and NFκB appear to be the most probable regulators of 
mTert transcription [137-140].  
On the protein level, human TERT consists of 1132 and mouse Tert of 1122 
amino acids, encoding a ~127 kDa polypeptide [125, 127, 141]. The structure of the 
protein revealed four conserved domains: the telomerase essential N-terminal domain 
(TEN), the telomerase RNA-Binding Domain (TRBD) including T-motif, the RT 
repeats and the C-terminal extension (CTE) (Figure 1. 2 A.). The tertiary structure of 
the TERT protein consists of fingers, palm and thumb which allow telomerase to 
attach by the TEN domain to single stranded telomeric DNA (Figure 1. 2 B.) [124, 
125, 142].  
The non-coding RNA component of telomerase (TERC or TR) also shows a 
high degree of similarity between mouse and human, and both hTERC and mTerc are 
located on chromosome 3. Mature mammalian TERC contains 451 nucleotides and 
its template part contains 11 nucleotides (5'-CUAACCCUAAC-3’) complementary 
to the telomeric sequence [143, 144]. Apart from high structural similarity, Martin-
Rivera et al., (1998) have shown a high functional similarity between mouse and 
human telomerase. In their experiments mTerc knockout mouse cells (telomerase 
activity deficient) were transfected with hTERC that fully restored telomerase 
activity, indicating that mouse and human telomerase components are functionally 
interchangeable and thus structurally conserved [141]. Interestingly, in most adult 
human tissues there is a very low expression level of hTERT protein and negligible 
telomerase activity, while in mouse the enzyme is expressed in a wide range of adult 
tissues [127]. It was shown that altered post-translational regulation is responsible for 
the different in vivo expression of hTERT and mTert proteins [145]. Furthermore, in 
mammals, tissue specific alternative splicing variants are possibly responsible for a 
lack of telomerase activity even when both TERT and TERC are detected [146, 147]. 
Interestingly, accumulating evidence suggests that alternative splicing of hTERT 
mRNA is involved in the carcinogenesis of gastric cancer, melanoma and kidney 
cancer [148-150].  
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Figure 1.2. The structure of human telomerase. A. Functional domains of the hTERT protein. 
Drawing based on Cong et al., (2002) [133] B. Model of telomerase. Both subunits TERT and RNA 
template TERC are required for catalytic/enzymatic activity. Picture adapted from Lingner et al., 
(1997) [124].  
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1.4.2. Canonical function of telomerase    
To understand the canonical function of telomerase it is important to explain the 
biology of telomeres – the ends of chromosomes. In mammals, telomeres are specific 
5-15 kb repetitive DNA sequences (TTAGGG), and are bound by a multi protein 
complex, known as shelterin. This protein complex comprised of TRF1, TRF2, 
Rap1, TIN2, TPP1 and POT1 [151-153]. The function of these proteins is to arrange 
structures to stabilise the end of a chromosome known as T-loop and D-loop. The 
proteins TRF1 and TRF2 associate with Rap1, and bind to the double stranded 
telomeric sequence, catalysing the folding of telomere DNA into the centromere 
direction forming a large telomere loop (T-loop) [154, 155]. The heterodimer 
POT1/TPP1 binds to the 3’ end of single stranded DNA to bind to the double 
stranded telomeric sequence of the 5’end and form a displacement loop (D-loop). 
The TIN2 protein is a linchpin of telomeric loops by facilitating assembly of 
TPP1/POT1 to TRF1 and TRF2 (Figure 1. 3 A.) [153, 156-159]. 
With each cell division chromosomes must be replicated to share nuclear 
DNA between two daughter cells. The end of chromosomes (telomeres) become 
shorter due to the “end of replication problem”, which occurs when during 
replication the DNA of the lagging 3’ – strand cannot be elongated by DNA 
polymerase continuously and gets shorter than the leading 5’ – strand [160]. To 
clarify, on the lagging strand, replication cannot be continuous at the end of 
chromosomes due to the semiconservative replication of DNA (which occurs only in 
the 5' to 3' direction). On the 3’ to 5’ strand DNA polymerase α uses short RNA 
sequences as primers, and initiates replication of short DNA sequences from a 3’ 
hydroxyl group on the lagging strand (Okazaki fragments). Afterwards the RNA 
primers are removed and DNA ligase connects the DNA of the Okazaki fragments 
(Figure 1. 3 B.). However, at the very end of the 3’ strand in the telomeric region, the 
RNA primer is dissociated and the DNA polymerase cannot fill the gap leaving a 3’ 
overhang what results in the shortening of the telomere in the next cell division. 
Thus, a short fragment of the telomere (~20bp) is lost during each cycle of 
replication. Once the length of the telomeric DNA reaches a critical level the cell is 
facing replicative senescence and cell cycle arrest [161]. Telomerase has the ability 
to recognise the strand (3’ – G-rich) and elongate it with telomeric repeats 5' 
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TTAGGG which are complementary to the RNA template on the TERC component 
(Figure 1. 3 C.) [162]. 
Interestingly, experimentally measured loss of telomere length with each cell 
division in mammalian somatic cells without telomerase is higher than would be 
expected from the “end replication problem”. It was shown by von Zglinicki et al., 
(1995, 2000) that telomere shortening is significantly accelerated with each cell 
division by oxidative stress (~50-100 bp) [163, 164]. 
Telomerase through its primary function (telomere elongation) protects 
against erosion of telomeres, instability of chromosomes, and against chromosome 
end fusion. Hence, an active enzyme is necessary to keep an indefinite potential of 
proliferation in immortal cells (i.e. cancer cells, germ cells, embryonic stem cells and 
in vitro immortalized cells) [127, 141, 165]. In the absence of telomerase (i.e. in 
human somatic cells) telomeres become shorter and activate, at a critical point, a 
p53-dependent DNA damage response (DDR) in the telomeric region and may lead 
to cell cycle arrest and senescence or apoptosis [166-168]. The DDR is activated by 
the sensor kinases as ATM/ATR or DNA-PK, phosphorylation of histone γH2A.X, 
and as a result, activation of p53/p21 pathway or Chk1 and Chk2 – cell cycle check 
point proteins which leads to a cell-cycle arrest [169]. Thus, telomerase through its 
telomere dependent function is involved in a number of processes in cells; most 
importantly in development, carcinogenesis and senescence.  
The level of telomerase activity is tissue specific in mammals. In mice it 
remains active in different cells and tissues (i.e. lymphocytes, intestine, muscle, 
testes, and liver) throughout life. Furthermore, mus musculus maintain significantly 
longer telomeres (~50-70kb) than in humans (~10kb). Telomerase is active during 
human embryonic development and decreases gradually after 20 weeks of gestation 
in the embryo. However, in adult humans, telomerase activity is still detectable in 
lymphocytes, endothelial cells, germ cells and adult stem cells. [170, 171]. 
Telomerase activity during differentiation of stem cells was shown to be regulated by 
epigenetic modifications including: methylation/demetylation as well as 
acetylation/deacetylation of histone H3 and H4 in the promoter region of hTERT and 
histone H3 at the hTERC promoter [172-174].  
Interestingly, telomerase is a crucial factor in ageing through its role in 
rejuvenating stem cells by telomere maintenance. Age-related tissue degeneration 
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might be enhanced by stem cell ageing that diminishes the regeneration potential of 
tissues. Interestingly, it was shown that adult stem cells are telomerase positive and 
are characterised by longer telomeres than the surrounding tissue [175]. Reduced 
telomerase activity and shortening of telomeres in senescent stem cells is a crucial 
cause of tissue atrophy and age-related phenotypes [176]. There is direct evidence 
from mTert-/- mice that telomere shortening impairs proliferation capacity and 
differentiation of somatic and germ cell lines [177]. Furthermore, in vitro 
experiments revealed that over-expression of hTERT in embryonic stem cells 
improved differentiation, enhanced proliferation and enriched resistance for 
apoptosis and oxidative stress [172, 178].  
Mutations or changes in expression of telomerase genes are linked to several 
diseases. For example, telomerase was found active in over 90% of human 
malignancies and is responsible for indefinite proliferative capacity of cancer cells. 
Therefore, a plethora of in vitro and in vivo studies suggests that telomerase might be 
a major pharmacological target for new cancer therapies
 
[179, 180]. However, about 
10% of tumours exhibit telomere stabilization without detectable telomerase activity, 
via the alternative lengthening of telomeres (ALT) mechanism [181]. In addition to 
cancer, a number of diseases are related to dysfunctional telomerase genes. For 
example, dyskeratosis congenita syndrome, which shows some features of premature 
ageing, is a human phenotype of an autosomal dominant deletion (821bp) in the 
hTERC gene with accelerated telomeres shortening [182, 183]. Other examples of 
diseases where mutations in telomerase genes plays a role of risk factors include: 
aplastic anaemia, pulmonary fibrosis and hepatic cirrhosis, which are all 
characterised by abnormally short telomeres [184]. 
Apart from the influence of telomerase on rejuvenation and disease, as 
predicted just after discovery, lack of telomerase expression and telomere shortening 
is an essential contributor to cellular senescence and ageing [171]. It is established 
that telomerase activity is a key factor for senescence of cells through maintenance of 
telomeres [26]. However, first generation mTert or mTerc knock-out mice do not 
show reduced lifespan and health span or significant shortening of telomeres [185-
187]. Interestingly, late generation telomerase knock-outs show an increased 
incidence of age-related diseases and premature tissue degeneration that affects 
tissues with high cellular turnover such as the bone marrow or intestine [188]. It was 
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shown on late generation mTert-/- mice that lack of functional telomerase decreases 
fertility, reduces testis mass and increases intestinal cell apoptosis [177, 189, 190]. 
Furthermore, late generation mTerc knock-out mice when compared to wild type 
littermates show shorter lifespan, impaired regeneration of organs (i.e. liver, spleen, 
skin), decreased body weight, kyphosis and skewed differentiation of stem cells 
[186, 191, 192]. 
More recently, Sahin et al., (2010) have shown in vivo that lack of telomerase 
activity (generation f4 of mTert or mTerc knock-out mice), causes telomere 
dysfunction, that is associated with impaired mitochondrial biogenesis and function. 
Furthermore, in this study mTert-/- animals showed decreased gluconeogenesis, 
cardiomyopathy, and increased reactive oxygen species production in liver, heart and 
hematopoietic stem cells. These results were explained by a telomere dependent 
activation of p53 that contributes, through a PGC-1α – dependent pathway, to 
accelerated failure of organs and metabolism [193]. Interestingly, the same group 
engineered a reversible mTert knock-out by introducing an allele encoding a 4-OHT 
– inducible telomerase reverse transcriptase-oestrogen receptor (TERT-ER) and 
showed that telomerase reactivation by 4-OHT (4-Hydroxytestosterone) treatment in 
the f4 generation of mTert knock-out mice was sufficient to reduce DNA damage 
signalling and restore tissue function, mostly due to the re-established population of 
stem cells e.g. in brain or in intestinal crypts [194].  
Currently, there is a number of laboratories working on reactivation of 
telomerase by gene therapy or natural and chemical telomerase activators in animal 
models. For instance, recent data published by Maria Belasco’s group shows that 
telomerase gene therapy might substantially reduce or delay age-related decline of 
mouse health-span. In this study, introduction of an adeno-associated virus (AAV) 
carrying mTert to mature and old mice resulted in improved insulin sensitivity, better 
neuromuscular coordination, reduced biomarkers of ageing and, most importantly, 
this gene therapy increased median lifespan. Interestingly, all these beneficial effects 
were observed without increase in the incidence of cancer, making telomerase gene 
therapy a strong candidate to combat age-related diseases [195, 196].  
Apart from genetic manipulation, there is accumulating data on compounds 
enhancing telomerase. For example, de Jesus et al., (2011) have shown that TA-65 (a 
natural extract isolated from Astragalus membranceus) was able to induce 
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telomerase activity in vitro and increase mRNA of mTert in vivo in adult and old 
mice. In the study, supplementation with TA-65 resulted in elongation of short 
telomeres and increased health-span without increase in cancer incidence [197]. 
More recently, Eitan et al., (2012) reported that a novel polyaryl compound – AGS-
499 – increased telomerase activity and protein abundance in mouse forebrain, brain 
stem and spinal cord. The authors of this publication show that treatment with AGS-
499 has a neuroprotective effect on motor neurons after treatment with N-methyl-D-
aspartic acid (NMDA) and delays onset of amyotrophic lateral sclerosis (ALS) in a 
transgenic mutant SOD1 mice [198]. However, there are no reports so far explaining 
the molecular mechanism of telomerase activation neither by TA-65 nor AGS-499. 
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Figure 1.3. The structure of telomeres and canonical function of telomerase. A. Shelterin complex 
protects the telomere by forming t-loop and d-loop from telomeric DNA, (picture adapted from Deng 
et al., (2008) [153]; B. Scheme of the DNA replication fork. Synthesis of the Okazaki fragments on 
the lagging strand causes the “end of replication problem”; C. Telomere elongation by telomerase. 1) 
Telomerase binds to 3’-overhang. 2) Telomerase extends 3’ – end strand with TTAGGG repeats. 3) 
DNA polymerase synthesise new lagging 5’ – end strand of telomeres.  
 
  
23 
 
1.4.3. Non-canonical functions of telomerase 
In addition to the mentioned canonical function of telomerase, there is a growing 
number of studies for new non-telomeric functions of TERT [26, 61].    
TERT was shown to act as a transcriptional co-activator and integrator of 
signalling pathways like Wnt/β-catenin and Myc [199, 200]. For example, Choi et 
al., (2008) have shown that TERT controls tissue progenitor cells by transcriptional 
regulation of a developmental program controlled by the Myc and Wnt pathways 
[199]. Furthermore, Park et al., (2009) have shown that TERT plays a role as a co-
factor at the promoters of Wnt downstream genes (i.e. SWI/SNF family) [201]. 
Interestingly, more recently Hoffmeyer et al., (2012) suggested that β-catenin 
(effector in Wnt signalling) might be a direct regulator of mTert expression, showing 
a regulatory feedback loop between the two genes [202].  
Evidence for a telomere independent function of telomerase in cell survival 
was shown by Lee et al., (2008) in an mTert knock-out mouse model. The authors in 
this study analysed the role of mTert and telomerase activity on apoptosis induced by 
staurosporine (STS) and on exitotoxicity caused by NMDA. Interestingly, in this 
study the induction of apoptosis was only efficient on first generation mTert knock-
out mice/cells while there was no sensitivity to apoptosis induction on mTert wild 
type or mTerc knock-out mice both in vitro (MEFs) and in vivo (animal survival). 
Thus, along with no changes in telomere length in mTert-/- animals, this data 
strongly supports a non-telomeric, protective function of mTert [203].  
Another elegant study on a double knock-out (mTert -/- and ATM-/-) mouse 
model published by Nitta et al., (2011), demonstrated that expression of mTert is 
required for stem cell (HSCs) function and tissue renewal during ageing. Moreover, 
they showed increased senescence markers (i.e. p16 and γH2AX), occurrence of 
apoptosis and increased oxidative stress in hematopoietic stem cells from double 
knock-out (mTert-/- and ATM-/-) mice, not observed in single knock-out animals 
mTert-/- or ATM-/-. Furthermore, the authors showed no decrease of telomere length 
and no increase in damage foci in telomeric areas of hematopoietic stem cells, which 
strongly supports a protective function of mTert against apoptosis and oxidative 
stress independently of telomere maintenance [204].  
An additional function of telomerase in the nucleus, independent of telomere 
elongation, was provided previously by Maida et al., (2009) [205]. Authors of this 
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publication showed that hTERT is able to interact with the RMRP (mitochondrial 
RNA processing endoribonuclease), the gene that is mutated in the inherited 
pleiotropic syndrome cartilage-hair hypoplasia. However, the name “mitochondrial” 
may be misleading since its function is in processing ribosomal RNA in the nucleus. 
Experiments in vitro revealed that the complex hTERT-RMRP has the ability to 
produce dsRNA molecules which might be used as a substrate for production of 
siRNA that regulates the level of the RMRP in mitochondria by a negative feedback 
control mechanism. Thus, authors suggest a critical role of the hTERT-RMRP 
complex in cartilage-hair aplasia [205]. In addition, it shows the great flexibility of 
functions which TERT can have independent of TERC.  
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1.5. TERT in mitochondria  
1.5.1. TERT shuttling and localisation 
Functions of telomerase related to its nuclear localisation are well described and are 
reviewed in chapter 1.4.1. However, recent studies report cytosolic and 
mitochondrial telomerase localisation and show new non-telomeric functions of 
telomerase outside the nucleus [61, 206, 207]. Controversially, there is still a strong 
group of scientists who claim that the reported telomere-independent functions are de 
facto linked to pathways responding to telomere length (i.e. p53) [187, 193, 208].  
Haendeler et al., (2003) showed for the first time that the enzymatic 
(catalytic) subunit of telomerase hTERT localised in the cytoplasm of HEK293 cells 
(human embryonic kidney cells) after treatment with H2O2 [207]. The cytoplasmic as 
well as mitochondrial localisation of hTERT was later confirmed independently by 
other groups in a number of human cell lines including fibroblasts and cancer cells 
[61, 209, 210]. Data from Haendeler’s group suggests that upon oxidative stress 
nuclear TERT is phosphorylated by Src kinase on tyrosine 707. This activation leads 
to binding of the GTPase Ran to TERT protein [207]. After that, TERT is exported 
through nuclear pores into the cytoplasm what is controlled by protein 14-3-3 which 
promotes TERT interaction with the nuclear exportin CRM1 [211, 212]. The whole 
mechanism of TERT shuttling became more complete after identification of a 
Mitochondrial-Targeting Signal (MTS) at the enzyme N-terminus and a Nuclear 
Export Signal (NES) at the C-terminus of hTERT, which play crucial roles in 
regulating the subcellular localisation of telomerase protein component [211, 213, 
214]. Furthermore, Kovalenko et al., (2010) showed that a mutation in the NES 
disrupts nuclear export of TERT [215]. The mechanism by which hTERT enters the 
mitochondrial matrix was recently described by Haendeler et al., (2009). The authors 
of this report showed that hTERT physically interacts with the mitochondrial outer- 
and inner membrane translocator complexes TIM23 and TOM20/TOM40 – the main 
channels for transporting proteins in and out of mitochondria (Figure 1.4) [206]. 
Interestingly, it was reported that hTERT localises in the cytoplasm also under basal 
conditions in CD4
+ 
T-lymphocytes as well as in human ovarian cancer cells, and 
upon activation it might be shuttled into the nucleus through pathways involving 
estrogen and Akt kinase [212, 216]. Therefore, it is possible that TERT localisation 
can be different in various cell types. 
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The only factor that triggers shuttling of TERT into mitochondria described 
to date is oxidative stress. Accumulating data supports the finding that treatment with 
H2O2 or cultivation of cells in 40% O2 conditions are able to activate telomerase 
shuttling out of the nucleus in vitro [61, 206]. Furthermore, it was shown that 
irradiation and chemical treatments with etoposide or paraquat also affect 
mitochondrial localisation of hTERT. The potential function of TERT in 
mitochondria will be reviewed in the next subchapter. 
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Figure 1.4. Shuttling of TERT protein into mitochondria. Upon oxidative stress (1) TERT protein 
is phosphorylated by Src kinase on Tyr 707 (2) and is shuttled into the cytoplasm (3). Next, it interacts 
with TIM and TOM proteins and enters the mitochondrial matrix (4). Picture adapted from Saretzki, 
(2010) [217]. 
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1.5.2. Functions of TERT protein in mitochondria 
To date, there exists some contradicting data about TERT function in mitochondria. 
Early studies from Santos et al., (2004 and 2006) showed that hTERT shuttling into 
mitochondria increases mtDNA damage and promotes apoptosis after H2O2 
treatment [210, 213]. In contrast, Ahmed et al., (2008) and Haendeler et al., (2009) 
reported a protective function of hTERT against mtDNA damage [61, 206]. Ahmed 
and colleagues showed that in MRC5 hTERT-over-expressing cells the amount of 
mtDNA damage is reduced after hydrogen peroxide treatment and under hyperoxia, 
when compared with telomerase negative MRC5 cells. In addition, hTERT over-
expressing cells showed improved resistance to apoptosis when compared to normal 
MRC5 cells. Furthermore, hTERT-over-expressing cells displayed a decrease of 
ROS production and increased mitochondrial membrane potential [61]. Similarly, 
Haendelers’ group showed that localisation of telomerase in mitochondria not only 
reduced ROS production but also improved respiration in HEK cells. Furthermore, 
the same study showed that silencing of endogenous TERT via shRNA increases 
mitochondrial ROS formation. Moreover, the same group showed in an mTert+/+ 
and mTert-/- mouse model that mTert improves respiration of heart mitochondria and 
protects against UV-induced degradation of mtDNA in isolated primary lung 
fibroblasts [206].  
Interestingly, recent studies from Santos’ group brought further evidence for 
a protective function of TERT in mitochondria. This group reported that cells with 
mutated NES (nuclear export signal for TERT) were unable to shuttle TERT protein 
from the nucleus while maintaining telomerase activity. Mutation in NES in this 
study resulted in increased mitochondrial ROS production, elevated oxygen 
consumption and increased mtDNA damage. [215]. This is additional evidence for a 
protective function of telomerase shuttling into mitochondria. 
To test directly whether localisation of TERT in mitochondria reduces 
oxidative stress, our group used organelle specific vectors to express TERT protein 
in different subcellular compartments. This method enabled us to deliver TERT on a 
plasmid construct directly into mitochondria or the nucleus using the multiple NLS 
(nuclear localisation signal) or MLS (mitochondrial localisation signal) [218]. In this 
recent study Singhapol et al., (2013) showed, in cancer cells, that only mitochondrial 
TERT but not nuclear was efficient to reduce oxidative stress induced by ionising 
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irradiation and H2O2 - providing direct evidence for the protective function of TERT 
in mitochondria [218]. 
It is still debatable what the exact working mechanism of TERT in 
mitochondria is. Haendeler and colleagues demonstrated that the catalytic subunit of 
telomerase binds to mtDNA at regions coding for polypeptides of the ETC complex I 
(ND1 and ND2). Subsequently, proposing that the function of TERT is vital in the 
protection and/or repair of mammalian mtDNA [206].   
Another proposed function of hTERT in mitochondria is its role as a reverse 
transcriptase independent from hTERC. Sharma et al., (2012) showed in NHF cells 
that hTERT binds to mtDNA, various mitochondrial RNAs and tRNAs. Interestingly, 
this newly discovered mitochondrial complex, hTERT-tRNA’s, showed reverse 
transcriptase enzymatic activity [219]. Moreover, in this study the authors showed 
that TERT is localised in liver mitochondria of mouse and rat. The authors also 
confirmed previous findings that lack of mitochondrial TERT indeed increases the 
amount of mtDNA mutations and raises ROS production. However, there is still no 
direct evidence for the hypothesis that TERT is a part of the mitochondrial DNA 
replication system or mtDNA repair machinery [219].  
A list of proposed functions of telomerase related to its cellular localisation is 
summarised in Figure 1.5. 
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Figure 1.5. Function of telomerase depends on its localisation. Adapted from Saretzki, (2010) 
[217]. 
Functions of 
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1.6. Telomerase in mammalian brain and its role in neurodegenerative diseases 
The brain is a central organ of the nervous system in all vertebrae. Its functions 
include the control of all the organs in the body, processing of perception and co-
ordinating motor functions [220]. Age is a major risk factor for neurodegenerative 
diseases like Alzheimer's and Parkinson's. The general phenotype of these conditions 
includes neuronal death and synaptic alterations [1]. When conducting in vivo 
research on the brain it has to be considered that this organ consists of different cell 
types which play different roles in the healthy organ and during neurodegeneration. 
On the cellular level brain primarily consist of neurons and glial cells. The role of 
glia is as a structural and metabolic support, while neurons process and transmit 
information via electrical and chemical signals [220]. Although broadly discussed, it 
was shown recently that there is a close to 1:1 ratio of glial cells to neurons in the 
central nervous system of humans and primates. However, this ratio might be 
different in particular brain areas. For instance, it was shown in human and rat, that 
in the frontal cortex glia cells outnumber neurons three fold while in the cerebellum 
there is three fold more neurons than glia [221, 222].  
Telomerase shows a high enzymatic activity in brain during development in 
mammals along with a high abundance of TERT protein [223, 224]. However, in the 
postnatal brain the activity of telomerase decreases sharply, although, TERT mRNA 
and TERT protein are still detected in different brain areas in adult mice, mostly in 
neuronal progenitors, stem cells, pyramidal neurons of the hippocampus and Purkinje 
neurons of the cerebellum [223, 225, 226]. Furthermore, it was shown recently by 
Eitan et al., (2012) that abundance of mTert protein is reduced in mouse brain with 
age [226]. 
 Cell turnover is rare in adult mammal brain. However, areas like the 
hippocampus and olfactory bulbs are regularly supplied with new progenitor and 
stem cells for neurogenesis in the adult brain. The source of these multipotent cells is 
localised in the subgranular zone of the denate gyrus and in the subventricular zone 
of lateral ventricle [227, 228]. Neural stem cells require telomerase activity for their 
maintenance and differentiation potential. Thus TERT protein and TA are mostly 
detected in areas of brain with cell turnover [229]. However, the exact function of 
TERT in brain remains unclear. 
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An anti-apoptotic role was one of the first reported non-telomere dependent 
functions of telomerase in brain. There are a number of reports suggesting that 
telomerase can attenuate apoptosis during brain development [224, 230]. For 
example, Zhu and co-workers showed that over-expression of TERT in mouse 
protects neurons against apoptosis triggered by β-amyloid peptide and by trophic 
factor withdrawal, suggesting that TERT may protect against Alzheimer’s disease 
[231].  
Furthermore, Klapper and colleagues have shown that neural stem cells 
gradually loose telomerase activity during differentiation into neurons, which is 
highly correlated with increased vulnerability of neurons to apoptosis [223]. Another 
report by Fu et al., (2000) showed in mice and rats that suppression of mTert 
expression by antisense oligonucleotides in cultured hippocampal and cortical 
neurons increased vulnerability for oxidative stress, increased the number of 
apoptotic nuclei and reduced survival of the cells, supporting a protective function of 
TERT [230].  
Similar results were reported by Kang et al., (2004) where authors showed in 
mTert over-expressing transgenic mice that telomerase protects cortical neurons 
against NDMA and hypoxic-ischemic injury. Furthermore, in the same study authors 
showed an increased expression of mTert mRNA in neurons as a response to 
permanent occlusion of the middle cerebral artery in adult mouse brain and 
suggested that mTert protects against hypoxic-ischemic injury by reducing ROS-
mediated neuronal death [232]. More recently, the same group presented a study by 
Lee et al., (2009) where it was shown that mTert have a crucial role in mouse brain 
function. In this study first generation of mTert-/- (f1) mice showed an anxiety-like 
behaviour and this deficit was also significantly increased with age, suggesting that 
telomerase is necessary for maintaining normal brain function and behaviour during 
ageing. Furthermore, in the same study mTert-/- animals also showed impaired 
olfactory function, however this was not affected with age [233]. More beneficial 
effects of telomerase in brain were shown recently by Jaskelioff et al., (2012) on a 
fourth generation of mTert-/- mouse model. In this study adult telomerase deficient 
mice had reactivated telomerase in vivo which reversed neurodegenerative changes 
in brain and restored proliferation capacity and function of neural progenitor cells in 
subventricular zone of the brain. Furthermore, reactivation of telomerase in f4 mTert 
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deficient mice restored myelination of neurons and olfactory function to the level of 
wild type animals. However, these effects were telomere length dependent since f4 
mTert-/- animals have significantly shorter telomeres [194].  
Similar results were obtained by Eitan et al., (2012) by chemical activation of 
telomerase in mouse brain. In the reported experiments animals were treated with a 
new aryl compound AGS-499 which is potently increases telomerase activity in the 
forebrain, brain stem and spinal cord of a CD-1 mouse strain in a time and dose 
dependent manner. As a result animals treated with AGS-499 extended lifespan and 
showed higher resistance of neurons for NMDA induced neurotoxicity. Furthermore, 
in the same study, a mouse model of Amyotrophic Lateral Sclerosis (ALS) – 
transgenic SOD1 mutant showed improved neuromuscular coordination and 
neurological parameters after AGS-499 treatment. Interestingly, activation of 
telomerase by AGS-499 was also efficient to delay the onset and progression of 
ALS. In addition, the treatment resulted in improved motor function (improved 
survival of motor neurons) and increased lifespan of ALS animals [198].  
In humans, the role of telomerase in brain in vivo was studied in patients with 
dyskeratosis congenita – a disease caused by mutation in telomerase genes and 
characterised by short telomeres, bone marrow failure (anaemia) and increased 
cancer incidents. Interestingly, individuals with dyskeratosis congenita also show 
neurological dysfunctions like learning difficulties, microcephaly and mental 
retardation, showing that telomerase and telomeres are key players in brain function 
and development. However, the precise mechanism of these symptoms remains 
unknown [234, 235].   
To conclude, there is accumulating data on the beneficial and protective 
effect of telomerase on brain biology and function. It seems that telomerase is a 
strong therapeutic candidate for neurodegenerative diseases. Thus, further 
experiments on the molecular mechanisms of TERT function in brain are required. 
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1.7. Telomerase in mammalian liver  
Non-telomeric functions and mitochondrial localisation of telomerase in mammalian 
liver have not been studied so far. However, the protective role of TERT associated 
with telomere lengthening and its impact on oxidative stress in disease and ageing of 
liver was shown previously to be crucial [236, 237]. Potentially, the enzymatic 
component of telomerase might be also involved in development and the ageing 
processes of this organ in a non-canonical way, similar to brain. 
Telomerase in liver is mainly studied due to its association with 
hepatocellular carcinoma as a cancer marker and treatment target [238, 239]. 
Moreover, TERT in liver has been investigated in studies on liver regeneration in 
correlation with insulin signalling. For example, Tseng et al., (2009) found that in 
insulin-deficient rats after hepatectomy, rTert mRNA level and telomerase activity 
was lower than in normal rats.  Furthermore, liver restitution mass was lower in 
insulin-deficient rats, this may suggest a relation between insulin signalling and 
telomerase in this organ, although not directly [240].   
Liver is the organ being mostly studied among all organs under dietary 
restriction due to its connection with insulin, fatty acids metabolism and general 
nutrient sensitivity [80, 241]. It was reported that DR counteracts age related changes 
in mouse liver. Results published by our group recently showed that DR significantly 
reduced the number of senescent cells in mouse liver. Moreover, in the same model 
Wang et al., (2010) showed a reduced ROS production and less DNA damage under 
DR in liver and small intestine, although changes in telomerase activity after 
restricted diet were not significant in this study [80].  
 
 
 
 
 
 
 
 
35 
 
1.8. Aims        
Since dietary restriction and TERT protect mitochondria we hypothesised that part of 
the protective effect of DR might be an effect of TERT translocation into 
mitochondria. The aim of this thesis is to characterise the possible roles of 
telomerase expression and its cellular localisation in brain under basal and dietary 
restricted conditions. 
Specific aims of this thesis are: 
1. To analyse whether telomerase might be involved in the mechanisms and 
beneficial effects of dietary restriction and rapamycin supplementation in brain. 
The protective function of hTERT is well described in vitro, thus a natural 
question is whether telomerase is localised in mitochondria of mouse neurons in 
vitro and in the mouse and human brain in vivo? Moreover, since dietary 
restriction and telomerase through its telomere dependent function are able to 
attenuate ageing, the question arises: does DR influence expression of telomerase 
genes, telomerase activity and mTert protein status in vivo?  
2. To study whether lack of telomerase in (f1) mTert-/- animals might influence 
mitochondrial function. It is known that DR protects and improves mitochondria 
function. Thus, in this project, I aimed to analyse oxygen consumption and 
reactive oxygen species generation in primary cell lines (i.e. fibroblasts, stem 
cells) derived from animals of different mTert status. Furthermore, respiration and 
ROS production by brain mitochondria after DR was analysed in different mTert 
genotypes of mice. In addition, an aim was to address whether mTert status 
influences physiological parameters known to be altered during ageing like 
glucose tolerance, insulin sensitivity and neuromuscular coordination under the 
condition of dietary restriction. 
3. To investigate the potential connection between mitochondrial telomerase and 
mTOR signalling pathway, which is known to regulate the lifespan in response to 
nutrient availability? Thus, we aimed to analyse whether there are any changes in 
mTOR activation in the mouse brain after DR and what might be the influence of 
rapamycin supplementation on telomerase in mouse brain mitochondria? 
Furthermore, we aim to study the effect of mTOR inhibition by rapamycin on 
mitochondrial ROS generation and oxygen consumption in mouse brain.  
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Chapter 2 - Materials and methods 
2.1. Mice 
In the late onset dietary restriction study (experiment 1), male mouse strain ICRFa on 
a C57Bl/6 background was used [242]. Male mice used in experiments 2 and 3 were 
pure C57BL/6 strain purchased form Charles River, UK. Heterozygotes of mTert-/- 
(strain:B6.129S-Tert, tm1Yjc/J) and mTerc (strain: B6.Cg-Terc tm1Rdp/J) on 
C57BL/6 background mice were purchased form The Jackson Laboratory and were 
inbred to obtain wild type, first generation (f1) knockout and heterozygote mice for 
the mTert and mTerc genotypes. The mTert-/- line was originally described by 
Chiang et al., (2004) [243] and mTerc-/- by Blasco et al., (1997) [244]. Moreover, 
mice tissues from a different mTert knock-out construct, originally described in Liu 
et al., (2000), were generously donated by Prof. Lea Harrington, University of 
Edinburgh, UK [245], and used as negative controls in mTert expression 
experiments. Animals used in all experiments were housed in the same room and 
were provided with sawdust as well as paper bedding. All animals had ad libitum 
access to water. Control animals in dietary restriction experiments had 24h access to 
standard rodent pelleted chow (Special Diets Services, Witham). Mice were 
accommodated at 20 ± 2 °C under a 12 h light/12 h dark photoperiod with lights on 
at 7 am. The project was approved by the Faculty of Medical Sciences Ethical 
Review Committee, Newcastle University. Experiments were conducted in 
accordance with UK Home office legislation under the Animals (Scientific 
Procedures) Act 1986. 
2.2. Genotyping 
DNA obtained from digestion of mouse ear notches was used for genotyping 
transgenic animals. Tissue in a buffer consisting of 25mM NaOH and 0.2mM EDTA 
was placed in a thermocycler (Hybaid) for 1 hour at 98°C and held afterwards at 
15°C. Next, 40nM Tris-HCl (pH 5.5) was added and the samples were centrifuged at 
4000 rpm for 3 minutes. Afterwards, 4µl of DNA rich supernatant was used in a PCR 
reaction where denaturation was carried out at 95°C for 3min. Then, 35 programmed 
cycles at 94°C for 30s, 68°C for 30s (annealing of mTert primers and 62°C for 
TERC) and 72°C for elongation. Primers for genotyping were purchased from 
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SIGMA (Table 1). PCR amplification products were visualised on a 3% agarose gel 
with SYBR
®
 Safe DNA gel stain (Invitrogen) (Figure 2. 1.). 
 
 
 
 
 
 
 
Table 1. Sequence of primers used for mouse genotyping 
  
Primer name sequence 5’-3’
mTert
oIMR5359 FW GGTCCTGGCTGTTTTCTAAG
oIMR5358 REV CCCCAGGCGCCGCACAAAGG
oIMR5363 NEON2 CTGGATTCATCGACTGTGGC
mTerc
oIMR1912 WT FW      CTCGGCACCTAACCCTGAT
oIMR1913 WT REV CGCTGACGTTTGTTTTTGAG
oIMR6916 KO FW CTTGGGTGGAGAGGCTATTC
oIMR6917 KO REV AGGTGAGATGACACGAGATC
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Figure 2.1. Genotyping of mTert and mTerc mice. A. Representative visualisation of PCR products 
from mTert genotyping on a 3% agarose gel. The 420bp band represents the allele of mTert knockout 
and the 150bp band corresponds to the wild type allele. Two bands indicate heterozygotes. B. 
Visualisation of genotyping of mTerc animals. A band size of 280bp represents the knockout mTerc 
allele; the smaller 150bp band is a wild type and two bands indicate a heterozygote genotype. DNA 
for PCR was isolated from ear notch tissue.  
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2.3. Design of the dietary restriction experiments  
Four independent DR experiments on male mice were performed in collaboration 
with Prof Thomas von Zglinicki and Dr Satomi Miwa. The control group of mice had 
free access to food (ad libitum). The restricted group (DR) was limited by 40% and 
food intake was calculated from the food intake of the AL group. The 60% chow 
amount was calculated based on the weight taken at the beginning of the experiment 
and remained unchanged over time. In experiment 1 (late onset DR), restriction 
started at 14 months of age and lasted for 3 months. Experiment 2 started with 3 
months old animals and lasted for 6 months. The experiment 3 was started with 3 
month old mice while dietary restriction was applied for another 3 months. Finally, 
the fourth experiment was performed on mTert+/+ and mTert-/- mice and started 
when animals were 6 months old and lasted for 16 months (Table 2). In this 
experiment, there were 12 mTert wild type animals and 11 mTert knock-outs in the 
control (AL) group. In the dietary restricted group there were 7 mTert wild type and 
10 mTert knock-out animals.   
 
Table 2. Design of dietary restriction experiments  
 
2.4. Rapamycin supplemented diet experiment in vivo 
In total 38 male mice were used in the rapamycin diet experiment. The control group 
contained 7 mTert wild type animals and 9 mTert knock-outs. The rapamycin fed 
cohort contained 6 mTert wild type and 9 mTert knock-outs. Mice were 12 months 
old at the onset of the experiment and rapamycin supplementation lasted for 4 
months. The dose was 0.067mg of rapamycin per day/per mouse. The experimental 
chow was a gift from John Strong, Texas [246, 247]. 
2.5. ROS generation in female mice brain mitochondria 
To test if generation of hydrogen peroxide production in mouse brain is sex specific, 
female mice mTert+/+ and mTert-/- were used. In total 12 animals were tested. 
% of DR             beginning of DR                end of DR   duration
Exp. 1              40%                  14 months old          17 months old          3 months
Exp. 2              40%                    3 months old         9 months old          6 months
Exp. 3              40%                    3 months old         6-7 months old         3 months
Exp. 4              40%                    6 months old         22 months old        16 months 
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Three young animals (aged 3-6 months) per genotype, and three old mice per 
genotype (aged 22 months) were tested. 
2.6. Mouse and human cell lines  
Commercially available 3T3 J2, MRC5 (human embryonic lung fibroblast, bought 
from ECACC), MCF7 (human breast adenocarcinoma) and HeLa (human cervix 
adenocarcinoma) cell lines were used (both from ATCC). In addition, as a positive 
control in a range of experiments MRC5/TERT overexpressing cells, constructed by 
retroviral transfection of MRC5 fibroblasts with the plasmid pLCP-hTERT 
(Clontech), were used [61]. Cells were cultured in high glucose (4.5g/L) DMEM 
(PAA Laboratories) medium supplemented with 10% Foetal Bovine Serum (FBS), 
2mM L-glutamine, 50U/mL penicillin with 10mg/mL streptomycin (all from PAA 
Laboratories). Incubation was carried out under normoxic condition with 5% CO2 at 
37°C in a humidified water jacketed incubator, (Series II incubator, Forma 
Scientific).  
2.7. Isolation of primary mouse neurons from embryos (E16)  
Pregnant female mice were sacrificed by cervical dislocation at day 16 after 
fertilisation.  Embryos were removed from the uterus, culled by cervical dislocation 
and brains were removed. Afterwards brains were cut into 3-4 pieces and placed in 
1mL HBSS buffer at 37°C. Then, tissue was incubated with 0.025% trypsin at 37°C 
for 30 min. Next, the digested tissue was centrifuged at 1500rpm for 3 min. and 
resuspended in plating medium (Gibco Neurobasal
®
, Life technologies), containing 
5% FBS (PAA Laboratories), 5% horse serum (SIGMA), 2mM L-glutamine (PAA 
Laboratories), 100 U/mL penicillin and 10mg/mL streptomycin (PAA Laboratories). 
Isolated cells were seeded on a 6 well plate coated with Poly-D-Lysine (SIGMA) at a 
concentration of 0.5x10
6 
cells/mL and cultured in 5% O2 at 37°C. Growth of 
astrocytes was inhibited by 1µM AraC
®
 (SIGMA) in order to avoid over-growth of 
neurons. After 5 days of AraC
®
 treatment, the medium was gradually substituted 
(50% every 3 days) for Gibco Neurobasal
®
 media supplemented with: Gibco B27
®
 
(Life technologies), 2mM L-glutamine, 50 U/mL penicillin and 10mg/mL 
streptomycin (all from PAA Laboratories).  
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2.8. Isolation and cultivation of epidermal neural crest stem cells  
Epidermal Neural Crest Stem Cells (EPI-NCSC) were isolated from bulges of 
mouse whisker hair follicles. Whisker pads were dissected from mice culled as above 
and submerged in buffer HBSS containing 5mM HEPES. Excess of skin and fat 
tissue was removed and whisker follicles were dissected with microsurgery tools. 
Follicles were cut longitudinally, and afterwards, below and above of the bulge area. 
Next, bulges were removed from the collagen capsule and transferred from HBSS to 
a 12 well tissue culture plate coated with CELLstart
®
 (Invitrogen) according to the 
manufacturer’s instructions (solution 1:50 in DPBS). Bulges were incubated for 1 
hour at 37°C in 3% O2 without any medium or buffer to allow attachment to the 
surface. For proliferation of EPI-NCSC, alpha modified MEM (PAA Laboratories) 
media was gently added to the bulges which contained the following supplements: 
5% chicken embryo extract (Sera Laboratories), 10% FBS (Sigma) treated with 
Chelex-100 (Bio-Rad), 50U/mL penicillin and 10mg/mL streptomycin (PAA 
Laboratories), 2mM L-glutamine (PAA Laboratories) and 2.5µg/mL amphotericin B 
(Sigma). Emigrating EPI-NCSC were observed after 3 to 8 days after bulg isolation. 
Approximately 60% of isolated bulges released EPI-NCSC, similar to a report by 
Sieber-Blum et al. [248, 249]. Staining with Sox10 antibody was used as a marker of 
EPI-NCSC.  
2.9. Isolation and cultivation of mouse ear fibroblasts  
Mouse ear notches or whole ears were collected and stored in cold Serum Free 
Media (SFM) until processed, Gibco
®
 Advanced DMEM/F12 (Life Technologies). 
Firstly, tissue was chopped and incubated in SFM with 1mg/mL of collagenase A 
(Roche) for 1.5h at 37°C in 5% O2. After digestion, the tissue was passed through an 
18G syringe needle and then centrifuged for 10 minutes at 1000 rpm. Next, pellets 
were resuspended in Gibco Advanced DMEM/F12 medium enriched by 10% FBS 
(PAA Laboratories), 2mM L-glutamine (PAA Laboratories) and a mix of 50U/mL 
penicillin and 10mg/mL streptomycin (PAA Laboratories). Isolated cells were 
incubated at 37°C in 3% O2. The first fibroblasts to attach to the surface were 
observed at 2-3 days after isolation. 
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2.10. Generation of mouse tissue homogenates and isolation of mitochondria  
2.10.1. Generation of mouse brain homogenate and isolation of mitochondria  
Mice were culled by cervical dislocation, then dissected with the brain being 
removed from the skull and placed into isolation buffer (composition: 250mM 
sucrose, 10mM Trizma base, 0.5mM EDTA and pH 7.4 at 4°C). Next, brains were 
chopped and washed to remove blood. Afterwards, brains were homogenised in a 
glass Dounce homogeniser (type TKW-120-070J, Fisher). The obtained 
homogenates were sampled and the remaining material was used for the isolation of 
mitochondria [250].  
Briefly, homogenates were centrifuged for 3 min. at 2000 x g at 4°C. Pellets 
were discarded and supernatants rich in mitochondria were further centrifuged at 
12500 x g for 10 min. at 4°C. Then, pellets were separated from the remaining blood 
and resuspended in 3% Ficoll
®
 (SIGMA). The obtained solution was suspended on 
top of 6% Ficoll
®  
, in a centrifuge tube to obtain a visible phase between layers and 
centrifuged for 15 min. at 11500 x g at 4°C. Next, supernatants were sharply 
decanted and pellets were resuspended in the isolation medium and centrifuged for 
10 min. at 11500 x g. The resulting pellets were used for functional experiments 
immediately or stored at -80°C for protein assays.  
2.10.2 Generation of mouse liver homogenate and isolation of mitochondria  
Livers from culled mice were chopped and homogenised in STE buffer 
(composition: 250mM Sucrose, 5mM Trizma base, 2mM EGTA and pH 7.5 at 4°C). 
Homogenates were aliquoted and the remaining material underwent an initial 
centrifugation for 3 min. at 1047 x g at 4°C. Supernatants with mitochondria 
underwent further centrifugation for 10 min. at 11630 x g at 4°C. Afterwards, 
supernatants were discarded; pellets rich in mitochondria were separated from the 
remaining blood with a glass rod and resuspended in STE buffer. This solution 
underwent additional centrifugation at 11630 x g for 10 min. at 4°C. Then, pellets 
were resuspended in STE, layered on top of 80%, 52% and 26% Percoll
®
 gradient 
(SIGMA) and centrifuged at 41100 x g for 10 min. at 4°C. The mitochondrial layer 
was aspirated from the 26% - 52% Percoll
®
 interface. Next, the mitochondria 
solution was centrifuged 11630 x g for 10 min. at 4°C to obtain pure mitochondria 
43 
 
pellets.  Purified mitochondria were used immediately in functional assays or stored 
at -80°C.  
2.11. Mitochondrial function 
2.11.1. Hydrogen peroxide generation  
Mitochondrial superoxide generation linked to complex I, II and III was measured 
using AmplexRED
®
 technique (Invitrogen) which is a highly sensitive, fluorogenic 
substrate for horseradish peroxidase. In total, 0.4mg of protein from freshly isolated 
mitochondria were used per reaction containing: 0.2mg/mL oligomycin, 50µM 
AmplexRED
®
, 2U/mL horse radish peroxidase, 1U/μL and KHE/BSA buffer 
(composition: 115mM KCl, 10mM KH2PO4, 2mM MgCl2, 3mM HEPES, 1mM 
EGTA, 0.2% fatty acid free BSA; all from SIGMA). Measurements of fluorescence 
was conducted in real time at an excitation of A544nm and an emission of A590nm using 
a Fluostar Omega
®
 plate reader (BMG Labtech). Gain was set at 5% for male and 
10% for female brain mitochondria. Gain was established experimentally higher for 
females due to lower ROS production in female brain mitochondria. After 
establishing the basal H2O2 production level, 5mM pyruvate/malate (substrate for 
complex I) or 4mM succinate (substrate linked to complex II) were added to each 
reaction. Next, production of superoxide was inhibited with 2.5µM of rotenone 
(blocker of electron transport in complex I). Then, 2.5µM of antimycin A (SIGMA) 
was added to block complex III which results in maximal superoxide production. The 
final step was to measure the fluorescence increase after addition of the standard of 
1pmole H2O2 to calibrate the fluorescence units and calculate the pmoles of H2O2 
release in the samples per minute. Each sample was measured in triplicate.  
2.11.2. Oxygen consumption
 
Oxygen consumption rate in isolated mitochondria and intact cells was analysed by 
an Extracellular Flux Analyser - XF24
®
 (Seahorse Bioscience). This instrument 
measures O2 and H
+ 
levels with solid state probes which are submerged in solution 
above a monolayer of intact cells or isolated mitochondria [251]. The probe cartridge 
is also equipped with 4 injection channels to deliver reagents altering ETC. 
Mitochondrial oxygen consumption was measured according to the following 
protocol. First, 5µg of freshly isolated liver or brain mitochondria (see paragraph 2.8 
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for isolation and purification method) was plated in Seahorse 24 well plates and 
centrifuged at 2500g for 10min. at 4°C. Afterwards, substrates for complex I (10mM 
pyruvate) diluted in KHE/BSA buffer were added to the supernatant above 
mitochondrial pellets and the plate was incubated in 37°C for 8 min. Next, the plate 
with mitochondria was assembled with a calibrated cartridge and measurements were 
conducted in the XF24
®
 instrument at 37°C after delivery of the following reagents 
added trough cartridge channels: 4mM ADP, 2.5µg/mL oligomycin, 4µM FCCP 
(carbonyl cyanide p-[trifluoromethoxy]-phenyl-hydrazone) and 4µM Antimycin A 
(all reagents and substrates from SIGMA). Readout of the assay is shown as Oxygen 
Consumption Rate (OCR) in pmoles O2 / min.  
A similar protocol was applied for the analysis of oxygen consumption of 
cells in culture. Briefly, 25000 mouse ear fibroblasts or neural crest stem cells were 
seeded per well of a Seahorse
®
 plate and incubated overnight at 37ºC in 5% O2 and 
5% CO2 atmosphere of an incubator. Afterwards, cells were incubated with XF assay 
medium for 1h in atmospheric oxygen. The medium for the oxygen consumption 
experiment contained DMEM (SIGMA), 1xGlutaMax-1 (Gibco), 5mM glucose 
(SIGMA), 3.7g/L NaCl (SIGMA), 30mg/L phenol-red (SIGMA) and 10mM of 
pyruvate (SIGMA). After incubation, measurements were conducted in a XF24 
analyser with the following reagents added through the cartridge channels: 1µg/mL 
oligomycin, 2µM FCCP, 0.5µM FCCP and 2.5µM antimycin A (all from SIGMA). 
Results are presented as OCR in pmoles O2 / min /1x10
5
 cells. Results were 
normalised to cell number (counted after DAPI staining). 
2.11.3. Flow cytometry analysis 
Levels of ROS production in mitochondria of wild type and knock-out mTert mouse 
cells were measured
 
using flow cytometry based on MitoSOX
®
 (Invitrogen) and 
dihydrorhodamine 123 – DHR (Molecular Probes) staining. Prior to measurements, 
the flow cytometry apparatus PAS
®
 (Partec) was calibrated using fluorescence 
stained 3µM yellow calibration beads (Partec) - in order to adjust the laser optics and 
stream flow. Cell populations were analysed using forward (FSC) and sideway 
scatter (SSC), and fluorescence was detected in channels FL1 (green) and FL3 (red). 
Autofluorescence was measured on unstained control cells and the value was 
subtracted from the FL3 fluorescence of measured samples. 
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Briefly, cells were trypsinised, washed with PBS and stained with 5µM of 
MitoSOX
® 
in SFM for 15 min. at 37°C. After incubation, cells were centrifuged at 
1600rpm for 2 min. and pellets resuspended in fresh SFM. Next, cells were gated in 
FSC/SSC and peak of red (FL3) fluorescence intensity was used to estimate 
superoxide production for at least 1x10
4 
cells. Measurements were conducted in 
triplicate. Similarly, cellular peroxide production was measured by staining with 
DHR. Cells were incubated with 30µM DHR for 30 min. at 37°C and centrifuged at 
800rpm for 5 min. Next, the pellet was resuspended in SFM and measurement for at 
least 1x10
4 
cells in triplicate was conducted using the flow cytometry instrument. 
The gated FL1 and FL3 fluorescence peak was used to estimate cellular peroxide 
production.  
2.12. Human post mortem brain tissue 
Paraffin embedded and frozen human brain sections and tissue were provided by 
Newcastle Brain Tissue Resource (NBTR), Institute of Ageing and Health, 
Newcastle University, Newcastle, UK. Frozen brain samples were ground in liquid 
nitrogen using a mortar and pestle ceramic grinder. The obtained powder was used 
for RNA and protein isolation.     
2.13.  TERT ELISA 
TERT protein abundance in cells, tissues and mitochondrial fractions was assessed 
by TERT ELISA Assay (GenWay). Cell pellets, homogenised or powdered tissue and 
mitochondria pellets were lysed in CHAPS (Roche) buffer (3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate), for 30 min. on ice. Protein content was 
measured by Bradford assay (Bio-Rad). A total of 100μg protein was used per 
reaction. Samples were usually tested in duplicates or triplicates. During the first 
reaction at room temperature for 1h the TERT protein from tested samples and 
standard calibrators (recombinant TERT protein supplied with the kit) were bound to 
TERT antibody-precoated 96 microwell plate. Standard curve was prepared with 
following concentrations of recombinant TERT protein: 50ng/mL, 25ng/mL, 
12.5ng/mL, 6.25ng/mL, 3.12ng/mL, 1.56ng/mL and 0.78ng/mL. After washing 3 
times for 30s with washing buffer supplied with the kit, a biotin conjugated anti-
TERT antibody was added at room temperature and incubated for 1h on a horizontal 
shaker (100rpm). Next, the wells were washed 5 times for 30s and streptavidin (HRP 
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– horseradish peroxidise labelled) was added. After further washing the substrate 
(tetramethylbenzidine – TMB) was added which turned the solution blue. To stop the 
reaction 100µl of sulphuric acid provided with the kit was added. After 10min. 
absorbance was measured (A450nm) by Multiskan Ascent
®
 plate reader (Thermo 
Labsystems). TERT protein concentration in the samples was calculated from 
absorbance of final product compared to absorbance of the standard curve made from 
provided recombinant TERT protein of a known concentration. Principles of the 
TERT ELISA technique are shown in Figure 2.2. 
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Figure 2.2. Principles of the TERT ELISA technique. A. An antibody to TERT is precoated to the 
plastic microwell plate. B. During the incubation TERT protein from sample binds to an antibody. 
Subsequently, unbound proteins are washed three times for 30 seconds with the washing buffer 
supplied with the kit. C. During second incubation an anti-TERT antibody bids to protein 
(“sandwich”) and wells are washed afterwards. D. Incubation with secondary antibody conjugated 
with streptavidin-HRP. E. Substrate TMB is added to the reaction what results with blue colour 
solution. Next, sulphuric acid solution is added to the wells what stops reaction and turns the solution 
yellow. TERT protein levels are quantified by measuring the absorbance of solution at 450 nm.  
 
 
  
48 
 
2.14. Telomeric Repeat Amplification Protocol (TRAP-assay)  
Telomerase activity was assessed by TeloTAGGG Telomerase PCR ELISA kit – 
TRAP assay (Roche) which measures the potential enzymatic activity of telomerase 
in sample of tissue or in cell lysate. In principle, the TRAP assay quantifies the 
extension of a telomere - like primer (TS – primer) by telomerase from the particular 
lysate. Cell pellets, homogenised or powdered tissue and mitochondrial pellets were 
lysed in CHAPS buffer for 30min. on ice. A total of 100ng protein per sample was 
used in the reaction. The first step – the elongation of the TS – primer (labelled with 
biotin) with telomeric repeats by telomerase from the sample was carried at 25°C for 
30min. Then, after telomerase inactivation at 94°C for 5min. the product was 
amplified in the following steps: denaturation at 94°C for 30s, annealing at 50°C for 
30s and polymerization at 72°C for 30s (30 cycles). First, 5µl of the generated 
amplicons were denatured for 10min. with a denaturation buffer (20µl) supplied with 
the kit at room temperature. Then 225µl hybridisation mixture that contains a 
digoxigenin labelled probe against the telomeric repeats were added. Afterwards, the 
PCR products were detected by ELISA. 100µl of each sample were incubated on 96 
well microplate precoated with streptavidin (provided with the kit) for 2h at 37°C on 
a horizontal shaker (300rpm). In this step the hybridisation product was immobilised 
by the biotin labelled primer to the streptavidin. Afterwards, wells were washed 4 
times with washing buffer and product incubated with an anti-digoxigenin antibody 
conjugated to horseradish peroxidase. In the final step, the probe was visualised by 
the reaction of peroxidase and substrate (TMB) which resulted in a blue colour 
product. Finally, the reaction was stopped with sulphuric acid and the intensity of 
resulting yellow colour was measured on a microplate reader - Multiskan Ascent
®
 
(Thermo Labsystems). The absorbance readings at 450nm were considered negative 
when the value was lower than 0.2 A.U. As a positive control MRC/TERT and 
3T3J2 cells were used. MRC5 cells were used as negative controls. Principles of 
TRAP assay are shown in Figure 2.3. 
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Figure 2.3. Principles of the TRAP assay technique. In the 1
st
 step telomerase from the samples 
adds telomeric repeats to the P1-TS primers and TTAGGG – telomeric like elongates are amplified by 
PCR. During 2
nd
 step amplification product is denatured and hybridise with telomere specific probe 
conjugated with digoxigenin. In the 3
rd
 step (ELISA) product is immobilised to streptavidin precoated 
well. In the final 4
th
 step product is detected by anti-DIG-POD antibody and substrate TMB is 
transformed into blue colour product which turns yellow after reaction with sulphuric acid.  
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2.15. Western blotting   
Cell pellets, tissue homogenates and mitochondria were lysed using CHAPS buffer 
(Roche) as described in previous subchapter. A total of 60-100µg protein per sample 
was loaded. After preparing samples by mixing them with Laemmli
® 
(SIGMA) 
buffer, lysates were denaturised on a heating block at 95°C for 5 min. and shocked 
on ice afterwards. Proteins from samples were separated on an 8 – 12% SDS – 
polyacrylamide gel at 35mA and blotted to nitrocellulose-ECL membrane (GE 
Healthcare) at 100V for 90 min. at 4°C. The following step was blocking the 
membrane for 1h at room temperature with 5% low fat milk or with 5% BSA (when 
phosphorylated proteins were detected) diluted in TBST (composition: 10mM Tris, 
50mM NaCl, 0.1% Tween 20, pH 7.5, all from SIGMA). Next, the membrane was 
incubated with the primary antibody diluted in blocking solution over night at 4°C 
and washed 3 times for 10min. with TBST. Then, membranes were subjected to 
incubation with a peroxidase labelled secondary antibody for 1h at room 
temperature. For membrane development the Amersham Western Blotting detection 
kit (GE Healthcare) was used. Images were taken with a chemiluminescence camera 
LAS 3000
®
 (Fujifilm). Afterwards, stripping buffer (Thermo Scientific) was used to 
draw off bound antibodies from the membrane for re-incubation with further 
antibodies and loading controls. Images were quantified by densitometry 
measurements and normalised to expression of loading controls (β-tubulin) by 
AIDA
®
 software (Raytest).   
2.16. Polymerase Chain Reaction - PCR 
Gene expression was evaluated by the standard Polymerase Chain Reaction (PCR) 
and Quantitative Real-Time PCR (qPCR). Firstly, frozen tissue was powdered using 
mortar and pestle on liquid nitrogen and total RNA was isolated from ~30mg of 
material using the RNeasy
®
 kit (Qiagen) according to the manufacturer’s protocol. 
Similarly, mouse and human cell pellets (~1x10
6
) were processed using a RNeasy
®
 
kit. Next, cDNA was obtained by Reverse Transcription PCR (RT-PCR). Briefly, 
1μg of total RNA measured on a NanoDrop® ND-1000 spectrophotometer 
(Nanodrop technologies, Inc.) was mixed with 2 µl of random primers (Promega), 
denatured for 7 min. at 75°C and chilled on ice. Then, a mix of reverse transcriptase, 
RNase inhibitor, 10mM dNTP, 0.1M DTT and first strand buffer was added (all from 
Invitrogen). Next, reverse transcription was carried out in a thermocycler at 42°C for 
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90 min. afterwards the enzyme was inactivated at 95°C for 5 min. and hold at 4°C. 
For PCR, 1μl of cDNA was mixed with a solution of ddH2O (double distilled H2O), 
forward and reverse primers (0.5µM each) and Taq PCR Master Mix (Qiagen). PCR 
was conducted in a thermocycler (Hybaid) programmed for denaturation at 94°C for 
2 min. followed by 24 cycles for GAPDH or 40 cycles for TERT/TERC: denaturation 
at 94°C for 2 min., annealing at 55°C-68° for 1 min. (temperature depends on 
primers, see Table. 3) and elongation at 72°C for 1 min. When finished, the reaction 
was hold at 4°C. Products obtained by standard PCR were visualised by 
electrophoresis on 2% agarose gel with SYBR
®
 Safe DNA gel stain (Invitrogen) and 
detected with a UV camera - GelDoc 2000
®
 (Bio-Rad).   
 Quantitative PCR (Real-Time PCR) was performed in a Step One Plus
®
 
instrument (Applied Biosystems). 1 µl of cDNA was mixed with ddH2O (Qiagen), an 
internal reference dye (SIGMA), SYBR
®
 Green Jump Start Taq Ready mix (SIGMA) 
and sets of primers (50nM of each forward and reverse primer). The instrument was 
programmed for denaturation at 95°C for 10min. followed by 40 cycles consisting of 
the following steps: denaturation at 95°C for 30s and annealing at 55°C-68°C for 
1min. Afterwards, the quality of the PCR products was analysed by a melting curve 
stage performance with the following steps: 95°C for 15s, 60°C for 1min. and 95°C 
for 15s. The expression of the genes of interest was normalised to the expression of 
GAPDH and mRNA quantity was related to a reference sample (known lack of gene 
expression) according to a comparative threshold cycle method (ΔΔCT). Sequence 
and annealing temperatures of all used primers are detailed in Table 3.  
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Table 3. Oligonucleotides used in standard PCR and qPCR 
 
 
 
 
 
 
 
 
  
mTert fw exons 2-3-4             GGATTGCCACTGGCTCCG 68 C
mTert rev                                TGCCTGACCTCCTCTTGTGAC
mTert fw exon 2                      TCGCGTCGATACTGGCAGAT     55 C
mTert rev CTTGTTCTCCATGTCTCCCGA
mTert fw exons 11-12-13       GCAAAAACCTTCTCAGCACC                 58 C
mTert rev ACTTCAACCGCAAGACCGAC 
mTert fw exons 6-7                TGGTGGAGGTTGTTGCCAA                         58 C
mTert rev                                ACTGGCATCTGAATCCTGC 
mTerc fw TCATTAGCTGTGGGTTCTGGT 60 C
mTerc rev TGGAGCTCCTGCGCTGACGTT
mGapdh fw GAACGGGAAGCTCACTGGC                        62 C
mGapdh rev GACAACCTGGTCCTCAGTGT
hTERT fw TATGGCTGCGTGGTGAACTTG                    55 C
hTERT rev CATAGCTGGAGTAGTCGCTCT  
hTERC fw GCCTTCCACCGTTCATTCTA                        58 C
hTERC rev                             CCTGAAAGGCCTGAACCTC
hGAPDH fw AAACATCACCATCTTCC 60 C
hGAPDH rev                         GACTCCACGACGTACTCAGC
Primer name sequence 5’-3’                                   annealing 
temperature
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2.17. Immunofluorescence on cells  
Proteins in cultured cells were localised using immunofluorescence. The following 
staining protocol was applied: cultivated cells grown on glass coverslips (VWR) in 12 
well plates were washed with PBS and fixed with 4% paraformaldehyde (PFA), 
(SIGMA) in PBS for 10 min. Following permeabilisation with PBG (composition: 
1xPBS, 0.5% BSA, 0.2% fish skin gelatine, and 0.2% Triton-X 100, all from 
SIGMA) for 45 min. at room temperature cells were incubated with the primary 
antibody over night at 4°C on a slow shaker. After three washes for 5 min. with PBS 
cells were incubated with a specific fluorescently labelled secondary antibody. A list 
of all antibodies used and their concentrations are shown in Table 4. Next, the 
coverslips were washed with PBS three times for 5 min. and incubated for 10 min. at 
room temperature with DAPI (Partec) for nuclear staining. Images were acquired 
using fluorescent microscopes: Leica DM 5500B, Axio Imager Z1 (Zeiss) and Axio 
Vision with filters for green and red fluorescence (Zeiss). Images were analysed with 
ImageJ
®
 (free access software developed by Wayne Rasband - NIH) and Axio 
Vision
® 
(Zeiss). 
2.18. Immunofluorescence on tissues 
Freshly dissected mouse brain tissue was fixed in 4% PFA for at least 24 hours in 
room temperature and afterwards embedded into paraffin (Zeiss). Next, 4µm sections 
were cut and attached to glass slide coated with 4% 3-Aminopropyltriethoxysilane, 
APES (SIGMA) and stored at room temperature. Paraffin embedded human brain 
sections were obtained from NBTR, Institute of Ageing and Health, Newcastle 
University. 
To rehydrate tissue, slides were placed in decreasing concentrations of 
methanol (90% for 5 min. and 70% for 5min.) and submerged in water two times for 
5 minutes. Then, the tissue was subjected to antigen retrieval by boiling them in 
10mM citrate buffer with 0.05% Tween 20 (SIGMA) for 15min. Cooled sections 
were incubated with 70% formic acid for 10min. and blocked against unspecific 
antibody binding for 30min. in room temperature  with blocking solution (10% goat 
serum and 0.1% BSA in PBS, all from SIGMA). Afterwards, the sections were 
incubated with the primary antibody in a humidified chamber over night at 4°C. 
Slides were then washed 4 times with PBS for 5 min. and incubated with a specific 
fluorescently labelled secondary antibody (Table 4.) for 90min. at room temperature 
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in a dark humidified chamber. Once incubation was finished the glass slides with 
tissues were washed three times for 5 minutes with PBS and incubated with DAPI 
for 15min. After further washing the tissue sections were subjected to a reaction with 
Sudan Black III (SIGMA) for 30 min. in room temperature to reduce background 
autofluorescence. Following a short wash with PBS sections were mounted with 
Vectashield
®
 medium (Vector Laboratories). Images were acquired with the same 
microscopes as described above for immunofluorescence of cells.  
 
Table 4. List of primary and secondary antibody used in Western blotting (WB), 
immunofluorescence on cells (IFC) and in immunofluorescence on tissue (IFT) 
 
 
 
  
Antigen conc./technique                       manufacturer
Primary antibody
hTERT 1:500 WB; 1:1000 IFC; 1:100 IFT          Rockland
βtubulin 1:1000 WB                            Abcam
p-mTOR (Ser2448) 1:500 WB Calbiochem
mTOR 1:500 WB Abcam
Sox10 1:500 IFC Abcam
Tuj1 1:500 IFC; 1:200 IFT  Neuromics
COX II 1:200 WB 1:500 ITC; 1:100 IFT         Santa Cruz Bio.
FOX3 1:200 IFT Abcam
HDAC 1:800 WB Abcam
Secondary antibody
HRP labelled goat anti rabbit                  1:2000 WB Abcam
HRP labelled donkey anti rabbit             1:2000 WB                           Abcam
Alexa Fluor® 594 goat anti-rabbit    1:2000 IFC 1:1000 IFT               Invitrogen
Alexa Fluor® 488 goat anti-rabbit    1:2000 IFC 1:1000 IFT               Invitrogen
Alexa Fluor® 488 goat anti-chicken 1:2000 IFC 1:1000 IFT               Invitrogen
55 
 
2.19. Neuromuscular coordination test 
Neuromuscular coordination of mice of different ages, genotypes and diets was 
assayed using a tightrope test. The equipment consisted of a 60cm long and 2mm in 
diameter rope which was tied up 40cm high between two rods (chemical stands) 
above bedding cushioned with polystyrene foam and paper shredding (Figure 2. 4.). 
Mice were suspended above the tightrope for 20 seconds at the distance of their 
whiskers. Afterwards, the mouse was placed with its front paws in the middle of the 
rope and time between grabbing the rope and ability to pulling up the hind legs was 
recorded. There was 60 seconds period to complete the task and three attempts.  
  
56 
 
 
    
 
Figure 2.4. Principles of the tightrope test. A. Equipment used in tests. B. Mouse suspended above 
rope for 20 seconds. C. Mouse grabs the rope and trying to lift hind legs. D. Successful animal is 
moving to the rod and using four limbs.   
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2.20. Insulin ELISA 
Blood samples were collected during mouse dissection or from the tail vein. Tubes 
with blood were centrifuged for 10 min. at 4°C and 2800 rpm to obtain serum. To 
determine the insulin level an ELISA method was used according to the 
manufacturer’s instructions (Ultra-Sensitive Mouse Insulin ELISA kit, Crystal Chem 
Inc.). 
The kit used for the determination of insulin level is a classic sandwich 
ELISA and requires only 5µl of blood serum per sample. During the first reaction 
insulin is bound to an anti-insulin guinea pig antibody coated on the 96 well plates. 
After washing with the supplied washing buffer, a horse radish peroxidase (POD)-
conjugated antibody bound to an immobilised complex of insulin and the guinea pig 
antibody. Following washing steps, TMB substrate solution was added to detect 
bound POD conjugates what resulting in a colour reaction. Absorbance was 
measured using a Fluostar Omega
®
 plate reader (BMG Labtech). Readouts for A630nm 
were subtracted from A450nm values. Concentration of the insulin in serum was 
calculated in ng/ml from a standard curve evaluated by readout of the absorbance of 
the known concentration of mouse insulin standard supplied with the kit.      
2.21. Glucose tolerance test 
Determination of blood glucose clearance in mice under different dietary condition 
and in different genotypes was performed using a Glucose Tolerance Test (GTT) 
according to a protocol described in Selman et al., (2008) [107]. Glucose was 
delivered by abdominal injection (20% solution of d-glucose, SIGMA). Blood was 
obtained from a punctured tail vein and the glucose concentration was measured by a 
glucose monitor Accu-Chek
®
, Aviva Nano, (Roche).  
Glucose clearance from the blood was measured at 4 time points. The first 
measurement was performed after an overnight fast and just before glucose 
abdominal injection (2mg/g of body mass). Afterwards, glucose clearance was 
assessed after 15, 30, 60 and 120 minutes. Animals were fed immediately after the 
last measurement.   
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2.22. Statistical analysis    
All data presented in this thesis are results from duplicate or triplicate measurements 
and with at least three mice per group. To examine statistical significance of the 
parametric data a One Way Anova and Two Way Anova tests were performed using 
Sigmaplot
®
 software. Non-parametric data sets where tested by One Way Anova on 
ranks or Mann-Whitney Rank sum test. All other calculations were completed by 
Excel Office
®
 2003 and 2010 (Microsoft). Error bars on the graphs represent 
standard error of the mean (±SEM) if not stated differently. Results were considered 
as statistically significant for two groups when the p value was <0.05.  
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Chapter 3 – Mouse Tert protein localises in neurons and acumulates 
in mitochondria after dietary restriction 
3.1. Introduction 
Telomerase shows high expression of its protein component (TERT), and has 
elevated activity in the brain during embryonic development in mammals [223, 224]. 
In the postnatal brain the activity of the enzyme decreases sharply, although TERT 
mRNA and TERT protein are still detected in different brain areas in adult mice - 
mostly in neuronal progenitors, stem cells, pyramidal neurons of the hippocampus 
and Purkinje neurons of the cerebellum [223, 225, 226]. Interestingly, it was shown 
recently by Eitan et al., (2012) that mTert protein is expressed in the cytoplasm of 
Purkinje neurons in mouse brain cerebellum. However, the exact localisation of 
mTert was not tested in this research [226]. So far there is very little data published 
showing mitochondrial localisation of mTert protein in mouse cells. For example, 
Haendeler et al., (2003) initially showed that TERT localised in the cytoplasm of 
HEK293 cells after treatment with H2O2 [207]. The cytoplasmic as well as 
mitochondrial localisation of hTERT was later confirmed independently by other 
groups in human fibroblasts and cancer cells [61, 209, 210].  
It has been shown previously that improvement of mitochondrial function and 
reduction of ROS production is a major causal mechanism for the beneficial effects 
of DR. Furthermore, TERT was shown to protect mitochondrial function and reduce 
ROS production. Hence, the aim of this part of my research was to analyse: 1) 
whether telomerase is localised in mitochondria of mouse neurons in vitro, and in the 
mouse and human brain in vivo; 2) whether DR influences expression of telomerase, 
telomerase activity and mTert protein status in vivo in mice. 
 
3.2. TERT co-localises with mitochondria in mouse and human brain 
Since there are several publications showing extra-nuclear localisation of hTERT in 
vitro, the question emerged whether mouse cells and tissues also show a similar 
cytoplasmic or mitochondrial localisation. To obtain evidence for the hypothesis that 
mTert co-localises with mitochondria in mice similarly to in vitro human cells a 
series of fluorescence stainings with a specific antibody for the telomerase enzymatic 
component TERT was performed.   
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 Firstly, the specificity of a commercially available antibody (Rockland) was 
confirmed on mouse cells. Surprisingly, mouse ear fibroblasts did not show a 
specific staining, although these cells show specific telomerase activity in the TRAP 
assay as will be shown later (Figure 3.5.). In contrast, in vitro cultivated neurons 
isolated from E16 mouse embryos expressed sufficient amounts of mTert protein and 
the specificity was confirmed by immunofluorescence on neurons isolated from wild 
type animals and mTert knock-out animals (Figure 3.1). Interestingly, the strongest 
signal of mTert expression was observed in the cytoplasm of neurons with negligible 
staining in the nuclear area. Furthermore, staining with an antibody against the 
mitochondrial marker coxII confirmed that mTert co-localises with these organelles 
(Figure 3.2). Remarkably, immunofluorescent staining with a TERT antibody in 
mouse and human brain paraffin sections exhibited the same expression pattern as 
isolated neurons. Human and mouse neurons identified by the neuronal marker Tuj1, 
showed a strong expression of telomerase protein component mostly in the 
cytoplasm of neurons in the frontal cortex and cerebellum (Figure 3.3).  
Interestingly, telomerase was localised in mouse and human neuronal 
mitochondria in basal conditions without applying external oxidative stress in 
contrast to previous studies on human cell lines [61]. This may suggest a new 
function of the protein in this cell type. 
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Figure 3.1. TERT antibody (Rockland) is specific for the detection of the protein in cultivated 
mouse embryonic neurons. A. Neurons isolated from mTert wild type mice. B. Neurons isolated 
from first generation mTert knockout mice. The red signal shows expression of mTert protein. Green 
fluorescence shows expression of Tuj1 – a neuronal marker. Nuclei are stained with DAPI (blue).  
62 
 
 
 
Figure 3.2. Mouse and human TERT protein co-localise with mitochondria. A. Cultured mouse 
embryonic neurons immunolabelled with TERT (red) and mitochondrial COXII antibody (green). B. 
TERT staining (red) in human brain cortex and mitochondrial marker CoxII (green). Blue – DAPI 
staining for nuclei. Yellow colour = co-localisation of red and green signal.  
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Figure 3.3. TERT protein is expressed in the neurons of mouse brain. A. Immunofluorescence 
staining on cerebellum - Tert (red), Tuj1 (green). Arrows show Purkinje neurons stained with TERT 
and Tuj1 antibodies. B. Mouse frontal cortex shows expression of Tert protein in neurons. Tert protein 
(red) is localised mostly in the cytoplasm. Neurons were stained with the neuron specific marker 
FOX3 (green). 
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3.3. TERT ELISA - validation of the method 
Until recently, the quantitative measurement of TERT protein was based on 
estimates from western blotting or immunofluorescence. However, these estimations 
are technically laborious and not very precise. A newly developed TERT ELISA 
(GenWay) measures the amount of TERT protein by using a recombinant TERT 
protein as a standard in an ELISA format. Quantification is performed using a 
standard curve from consecutive dilutions of recombinant TERT protein of a known 
concentration as described in the Material and Methods chapter. Before using the 
TERT ELISA kit, which was a very new kit on the market it had to be verified 
whether it indeed was applicable for the purposes of this study. Several mouse and 
human cell lines as well as tissues were tested (Figure 3. 4 A). A total protein extract 
of 100µg from either cells, whole organs/tissue homogenate and from mitochondria 
were assayed. Moreover, the standard curve was modified. Originally, the highest 
concentration of recombinant TERT protein was 500ng/ml. It was established 
experimentally, that our samples were in a range from 0 to 50ng/mL (Figure 3. 4 B). 
Therefore, the standard curve was adapted for this range in order to optimise the 
accuracy for the required concentration range. However, one has to be aware that the 
main disadvantage of this ELISA is the lack of a loading control. In general, the 
highest abundance of TERT protein was found in human MRC/TERT cells (high 
overexpression of TERT shown by Ahmed et al., 2008 [61]) and 3T3 mouse 
fibroblasts. As expected, no TERT protein was found in human MRC-5 fibroblasts 
and in fibroblasts from mTert knockout mice. Furthermore, established positive and 
negative controls were confirmed with Western blotting (Figure 3. 4 C). Thus, the 
TERT ELISA kit was confirmed to be reliable for this study.  
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Figure 3.4. Verification of the TERT ELISA technique. A. The TERT ELISA is applicable for 
human cells and mouse cells as well as tissues. B. A standard curve obtained from recombinant TERT 
protein was adapted and used for calculation of TERT amounts in the sample. C. The amounts of 
TERT protein in control samples obtained by ELISA antibody (GenWay) were confirmed by Western 
blotting with an anti TERT antibody (Rockland).  
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3.4. Comparison of telomerase activity and mTert protein in mouse cells, tissues 
and isolated mitochondria 
Telomerase contains two main components – the catalytic subunit TERT that acts as 
a reverse transcriptase during telomere elongation, and the RNA part TERC that 
contains the template for telomeric repeats. Both subunits are necessary for 
telomerase activity (TA) and it was shown that TA is not always correlated with 
TERT or TERC gene expression levels due to additional regulatory mechanisms of 
telomerase activity [243, 245]. Hence, it was tested here whether the amount of 
mTert protein (by ELISA) was correlated with TA measured by TRAP assay in 
mouse tissues and mitochondria as well as in primary ear fibroblasts derived from 
mTert+/+ and mTert-/- animals.  
Primary mouse fibroblasts showed high telomerase activity. Thus, to test the 
correlation between TA and mTert protein abundance, I used MEaF’s generated from 
mTert wild type and knock-out mice, both by TERT ELISA and TRAP assays. As 
expected, I found that there was no telomerase activity in the MEaF’s cells lysates 
from mTert knock-out and mTerc knock-out mice. Heterozygotes for the mTerc gene 
showed ~50% reduced telomerase activity when compared to fibroblasts from wild 
type mice. However, heterozygotes for the mTert gene did not show a significant 
decrease in TA. Moreover, ELISA results showed that the lack of enzymatic activity 
of telomerase is not evidential of deficiency or the presence of mTert protein. Lack 
of mTert was observed, as expected, only in fibroblasts from mTert-/- mice (Figure 
3.5). The same samples were tested in parallel in the TRAP assay and TERT ELISA 
and Pearson coefficient test between TERT protein and telomerase activity showed a 
positive correlation between protein abundance and enzymatic activity (r = 0.68, 
Figure 3.5 C.). 
There was none or only a background level (below the cut-off threshold of 
0.2450nm A.U.) of telomerase activity (measured by TRAP assay) in mitochondria 
isolated from mouse brain and liver (Figure 3.6 A.). The whole tissue lysates from 
liver showed a rather high TA compared to brain (Figure 3.6 A.). Interestingly, the 
finding of measurable amounts of TA in brain lysates from 6 months old mice 
contradicts my observation in brain tissue lysates from young (18 days) and adult (11 
months) mouse brain lysates prepared from tissue disrupted with a mortar and pestle 
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in liquid nitrogen (Figure 3.6 C.). However, these differences might depend on the 
method used for sample preparation. 
To clarify, brain samples were prepared on a Dounce homogeniser from 
freshly dissected mouse brain tissue (Figure 3.6 A. B.). Thus, this finding might 
suggest that samples prepared by mortar grinding in liquid nitrogen may lose some 
TA during preparation. The ground tissue stored previously in -80°C from adult 
mouse brains (6-11 months old mice) showed no TA. In contrast, brain lysates from 
one day old and eighteen days old mice pups prepared with the same (powdered) 
method confirmed, as previously reported, a tendency for the gradual decrease of TA 
in a postnatal mouse brain [223]. In the TA experiment on brains from young 
animals, as negative controls I used age matched mTert-/- animals and as expected 
there was no telomerase activity. However, there were no 11 month old, age-matched 
wild type animals available at the time of the experiment (Figure 3.6 C.). 
Interestingly, there was more mTert protein in mitochondria isolated from 
brain and liver than in the respective homogenates generated using Dounce 
homogeniser (Figure 3.6 B.). This finding suggests that only the protein part (mTert) 
of telomerase shuttles to mitochondria, corresponding to data from Sharma et al., 
(2012) [219]. Furthermore, these results confirm findings from immunofluorescence 
staining, where mTert localised in mitochondria under basal condition without 
applying oxidative stress (Figure 3.3).  
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Figure 3.5. Comparison of telomerase activity and mTert protein abundance in mouse ear 
fibroblasts from telomerase wild type, mTert-/- and mTerc-/- as well as heterozygous mice. A. 
TRAP assay on MEaF’s cell lysates isolated from mTert and mTerc knock-out, wild type and 
heterozygote animals. B. TERT protein expression in MEaF’s from a different genotype of mTert and 
mTerc. 3T3 cells were used as positive controls. 2 animals per genotype were analysed in duplicates. 
Error bars represent standard deviation. C. Pearson correlation coefficient between TERT protein and 
telomerase activity, r = 0.68.  
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Figure 3.6. Comparison of telomerase activity and telomerase protein abundance in mouse liver 
and brain. A. Telomerase activity measured by TRAP assay in mitochondrial fractions and whole 
tissue homogenates from liver and brain of 6 months old animals per 100ng of total protein (mito – 
mitochondrial fraction; homo – whole tissue homogenate). 3 animals were used for homogenates and 
mitochondria preparation, measured in duplicates B. TERT protein concentration measured by ELISA 
in 100µg of total protein in the same samples as used in TRAP assay. C. TA decreases with age in 
postnatal mouse brain (sample prepared by grinding on liquid nitrogen). 1 animal used per genotype 
in duplicate. Error bars represent standard deviation. 
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3.5. Mouse Tert protein abundance, telomerase enzymatic activity and mRNA 
in mouse brain and liver after dietary restriction 
Dietary restriction (DR) is a non-genetic intervention known to result in lower 
oxidative stress and improved mitochondrial bioenergetics [32, 78, 81]. Thus, I 
wanted to investigate the role of telomerase in brain during DR and analyse the 
localisation changes of the protein component – mTert.  
To investigate potential changes in mTert protein abundance under DR in 
brain, I analysed the mitochondrial fractions and whole organ lysates. Furthermore, I 
analysed whole organ homogenates and mitochondria fractions from liver to test 
whether a potential DR effect on mitochondrial mTert is tissue-specific. In this 
analysis samples from three different dietary restriction experiments were used 
(Table 2). Animals were separated into an ad libitum (AL) and dietary restricted 
(DR) group. Three to seven animals per group and experiment were used.  
Interestingly, results from TERT ELISA experiments showed a significant 
increase of mTert protein abundance in brain mitochondria under DR in all three 
independent experiments (Figure 3.7). Remarkably, there was no difference between 
AL and DR in whole organ homogenates in the tested samples. The oldest animals 
(17 months old) showed the highest difference in mTert protein level in mitochondria 
between AL and DR (Figure 3.7 A.). The younger animals (3 and 6 months old 
groups from experiment 2 and 3) showed a similar ~50% increase of mitochondrial 
mTert (Figure 3. 7 B. and C.). 
Since abundance of mTert protein does not always correlates with activity of 
the enzyme, brain samples from the DR experiment were analysed by TRAP assay to 
determine whether there was a change in telomerase activity in whole tissue. 
Therefore, TA was measured in the homogenates of whole mouse brain. The same 
samples as used in the ELISA experiments were tested. According to the 
manufacturer’s protocol, absorbance below 0.2450nm A.U. was considered negative 
for the TRAP assay.  
Similar to the data shown in the previous subchapter, there was a low but 
detectable activity of telomerase in whole brain homogenates prepared by Dounce 
homogeniser from fresh tissue (the influence of lysate preparation on TA was shown 
in the previous subchapter). Interestingly, in the TRAP experiments the TA 
decreased significantly only in experiment 3 where 3 months old animals were 
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restricted for 3 months (Figure 3.8 C.). This could be due to the fact that the largest 
number of animals were tested in this experiment (5 per group and only 3 per group 
in experiments 1 and 2), or because they were the youngest animals among the three 
experiments. In contrast, in homogenates from experiment 1 and 2 the decrease in 
TA after dietary restriction was not significant due to large variation between 
animals from both groups (Figure 3.8).  
To establish potential changes in mTert and mTerc gene expression levels 
under dietary restriction, mRNA levels in mouse brain were assayed. Tissues ground 
in liquid nitrogen from snap-frozen samples were used for total RNA isolation. Then 
RT-PCR (reverse transcription) was performed in order to obtain cDNA followed by 
conventional PCR with mTert and mTerc primers. There were only tissues from 
experiment 1 (17 months old animals) available. Altogether, there were eleven brain 
samples tested. Five were from control animals and six from dietary restricted mice. 
Products from the conventional PCR visualised on agarose gels showed no visible 
difference neither in mTert or mTerc mRNA abundance between the AL and DR 
groups (Figure 3.9 A.).  
In order to analyse changes in mTert and mTerc mRNA in a more quantitative 
manner, a qPCR method was used (Real-Time PCR). The same samples were used as 
in the conventional PCR. I found that mTert gene expression in mouse brain 
decreased significantly after adult-onset of dietary restriction (experiment 1), which 
is in agreement with the results from the TRAP assay (both were from whole tissue, 
although the samples for the TRAP assay were processed using a Dounce 
homogeniser and for PCR on liquid nitrogen) (Figure 3.9 B.). However, the decrease 
in mTert transcript did not correspond to the findings from the TERT ELISA, where 
there was no change in mTert protein abundance in whole tissue homogenates. 
Interestingly, mTerc transcription level did not change significantly after DR (Figure 
3.9 C.). This means that the decrease in TA correlates with a decrease in mTert 
mRNA.  
To test whether the mTert response to DR was tissue specific, I tested the 
potential changes in the protein abundance and its activity in mouse liver 
homogenates and mitochondria fractions from three independent dietary restriction 
experiments (Figure 3.10). 
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Interestingly, similar to the brain, DR tended to enhance mTert protein 
concentrations in liver mitochondria in all three separate experiments, although the 
differences were not significant (Figure 3.10). Surprisingly, there were no consistent 
effects of DR on whole tissue mTert amounts. Remarkably, there was a significant 
increase of mTert in whole liver from experiment 1 (Figure 3.10 A.).  In experiment 
2 and 3 there were no changes in the mTert amount observed (Figure 3.10 B. and C.). 
Interestingly, telomerase activity in liver lysates after DR showed a similar pattern to 
those observed in brain homogenates. There were no changes in TA after DR in 
experiment 1 and 2, however, activity of telomerase declined significantly after DR 
in experiment 3 (Figure 3.11). Hence, it is probable, that accumulation of mTert in 
mitochondria may be differently regulated in brain and liver, while activity of 
telomerase during dietary restriction may share a similar mechanism in both organs. 
However, further investigation would be required to elucidate this question.  
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Figure 3.7. Mouse Tert protein in brain after short term dietary restriction. DR significantly 
increased accumulation of mTert in brain mitochondria. The average of mTert protein in ad libitum 
samples (AL) was set as 100%, and values from DR were compared per animal to the mean of the 
controls. A. Experiment 1 (late onset: 17 months old animals); mitochondria AL – mitochondria 
fraction from the control – ad libitum group; mitochondria DR – mitochondria from the restricted 
group; homogenates – whole tissue homogenates; 3 animals per group. B. Experiment 2 (3 months 
old animals restricted for 6 months); 4 animals per group were used. C. Experiment 3 (3 months old 
mice restricted for 3 months); 4 animals from AL and 7 animals from DR group were tested. 
*Statistical significance was tested by One Way Anova test. Error bars show S.E.M 
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Figure 3.8. Telomerase activity in mouse brain homogenates after dietary restriction. A. TA in 
mouse brain after DR in experiment 1, 3 animals from the AL group, 3 animals form DR group were 
used. B. Experiment 2, 3 animals per group were used. C. Experiment 3, 5 animals per group were 
used. *Statistical significance was tested by One Way Anova test. Error bars represent S.E.M.  
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Figure 3.9. Telomerase gene expression in mouse brain after dietary restriction. Brain samples 
shown here are from experiment 1. A. Expression of mTert in mouse brain after DR by conventional 
PCR, L- 100bp ladder; N/C- negative control; 1AL-5AL- control brain samples, 1DR-6DR- brain 
samples from 6 dietary restricted mice, mGapdh - reference; B. Expression of mTert measured by 
qPCR. 3T3 mouse fibroblasts and MEaF’s form a mTert+/+ mouse were used as positive controls. 
Brain samples and MEaF’s form mTert-/- mice were used as negative controls. C. Expression of 
mTerc gene in mouse brain after dietary restriction. MEaF’s and a brain from an mTerc-/- mouse were 
used as negative controls. Results in B. and C. are presented as log10 of gene expression relative to 
the negative control evaluated by the ΔΔCT method, CT values were normalised to mGapdh 
expression. Five animals per group in triplicate were used. *Statistical significance was tested on the 
means of 5 samples per group by One Way Anova test. Error bars represent S.E.M. 
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Figure 3.10. Mouse Tert protein levels in liver after dietary restriction. The average of mTert 
protein in ad libitum samples (AL) was set as 100% and values from DR were compared per animal to 
the mean of the controls. A. Experiment 1, mitochondria AL – mitochondria from control – ad libitum 
group; mitochondria DR – mitochondria from dietary restricted group; homogenates – whole tissue 
homogenates; 4 animals per group. B. Experiment 2, 4 animals per group were used. C. Experiment 3, 
7 animals per group of mitochondria and 3 animals per group of homogenates were tested. *Statistical 
significance was tested by One Way Anova test. Error bars shows S.E.M 
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Figure 3.11. Telomerase activity in mouse liver homogenates after dietary restriction. A. 
Experiment 1, 4 animals per group were used. B. Experiment 2, 3 animals per group were used. C. 
Experiment 3, 5 animals per group were used. *Statistical significance was tested by One Way Anova 
test. Error bars represent S.E.M.  
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3.5.1. Purity confirmation of brain mitochondria  
To establish whether the analysed brain mitochondrial fractions used in the described 
experiments were free from nuclear and cytoplasmic contamination, a series of 
western blotting experiments were performed. The aim of this analysis was to 
confirm that the detected mTert protein was indeed originating from the 
mitochondrial fraction only. A histone deacetylase II (HDACII) antibody was used to 
analyse whether the mitochondrial fractions were not contaminated with nuclear 
proteins. Mitochondrial proteins where detected by a specific marker – an antibody 
for cytochrome c oxidase II (coxII). In order to test for the presence of cytoplasmic 
proteins in mitochondrial fractions a β-tubulin antibody was used.  
As shown in Figure 3.12 there were no cytoplasmic proteins in the brain 
mitochondrial fraction and only a trace of nuclear protein was observed. Thus, the 
detected mTert protein was indeed of mitochondrial origin. The purity of liver 
mitochondria was not tested in this study. 
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Figure 3.12. Purity of brain mitochondria fraction. There were no cytoplasmic proteins in brain 
mitochondria and only a trace of nuclear contamination; Cox II – (cytochrome c oxidase II) was used 
as mitochondrial protein marker; HDAC II – (histone deacetylase II) was used as nuclear protein 
marker; β-tubulin – cytosolic protein; mito – mitochondrial fraction lysate; homo – whole brain 
homogenate.  
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3.6. TERT protein and enzymatic activity in different mouse and human brain 
areas 
It was reported that telomerase is expressed in embryonic and adult mouse brain, as 
well as in human brain [141, 223, 230]. TERT protein and telomerase activity in the 
central nervous system (CNS) is mostly observed in neural stem cells of the dentate 
gyrus in the hippocampus and the subventricular zone of the lateral ventricle [229, 
252]. Furthermore, mTert protein was localised by Eitan et al., (2012) in 
differentiated Purkinje neurons in adult and old mouse brain cerebellum in vivo using 
immunofluorescence [226]. Moreover, previous reports were focused on telomerase 
in whole brain lysates or gene expression tested by in situ hybridisation [232, 253]. 
However, quantitative analysis of TERT protein abundance and TA in different brain 
areas has not been comprehensively reported so far. 
To test telomerase protein expression in different mouse brain areas, TERT 
ELISA experiments were performed and compared with human samples from 
relevant brain regions. Mouse frontal cortex showed a high mTert protein 
concentration and it was greater than cerebellum and hippocampus in brains from 
three different mice. Results of the experiment on human brain tissue showed a 
similar abundance of hTERT in corresponding areas (Figure 3.13 A). The fact that 
the human brain samples came from an 89 year old donor suggests that hTERT is 
expressed even in old human brain. Human hippocampus samples were not available 
at the time of performing this experiment.  
In order to analyse any potential changes with age in mTert abundance in 
mouse brain I tested cerebellum and cortex of young (6 months) and old (17 months) 
mice. Three animals per group were used. Results from TERT ELISA experiments 
showed that in both areas the amount of mTert was reduced significantly with age 
(Figure 3.13 B).   
Further experiments on brain were focused on TA. In mouse cerebellum, 
hippocampus and frontal cortex from 6 months old animals the enzymatic activity 
was tested by TRAP assay. There was negligible TA detected only in mouse 
cerebellum and that readout was consistent in two separate measurements in 
duplicates in brains from three different animals (Figure 3.13 C.).  Only absorbance 
above 0.2450nm A.U. is considered positive according to the manufacturers’ 
instructions. Low telomerase activity in cerebellum and no activity in mouse cortex 
81 
 
and hippocampus might be explained by the respective tissue processing method. As 
explained in Chapter 3.4. preparation of brain tissue on liquid nitrogen may result 
with reduced or diminished telomerase activity in TRAP assay. Furthermore, there 
was no telomerase activity detected in cortex and cerebellum of human brain areas 
prepared by frozen tissue grinding (data not shown). However, human tissue was 
available from only one donor. Thus, these findings must be confirmed with a larger 
sample number.   
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Figure 3.13. Telomerase expression in different areas of mouse and human brain. A. Expression 
of TERT protein in mouse and human brain, cbll – cerebellum, hippo - hippocampus B. Expression 
of mTert in young (6 months) and old (17 months) mouse brain, 3 animals per group were tested, 
*Statistical significance was calculated by One Way Anova test. C. Telomerase activity in mouse 
brain areas, only the cerebellum showed activity above 0.2450nm A.U. Three mouse brains were tested. 
Error bars represent in panel A. show standard deviation and in panel B. and C. show S.E.M. 
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3.7. Critical appraisal of the mTert knock-out design used in the project 
In order to establish reliable controls for experiments on telomerase in my project, 
two types of mTert knock-out mice were tested. The main mTert-/- animals used in 
most of the experiments in this study were designed and described by Chiang et al., 
(2004) (Figure 3. 14 A.) [243]. In this knock-out design the green fluorescent protein 
gene (GFP) and a neomycin resistance gene (neo) were inserted into the full length 
mTert gene into exon 1 on 5’site of the ATG starting codon [243]. Thus, these 
animals are rather a knock-in of the gene. In the paper Chiang and co-authors showed 
the absence of the wild type allele and the presence of a new allele (called knock-out) 
by southern blotting of material from mouse tails by using a specific probe; however 
there was no evidence in the publication for deletion of any part of the mTert gene. 
Moreover in the same publication, no mTert mRNA was detected in activated spleen 
lymphocytes from mTert-/- animals by conventional PCR [243].  
Surprisingly, in my analysis five brains from Chiang’s mTert-/- animals were 
tested for mTert mRNA expression and all showed to be positive in conventional 
PCR (Figure 3.14 B.), as well as in qPCR using primers matching different regions 
of the gene (Figure 3.14 D.). To confirm these findings liver tissue and MEaF’s cells 
from matching animals were used. Interestingly, all tested livers from mTert-/- 
animals with several sets of different primers were negative for mTert gene 
expression. Fibroblasts isolated from Chiang’s knockouts showed fewer transcripts 
than wild type in the PCR but were not completely negative. Moreover, results for 
MEaF’s were not consistent and depended on the primer sets used. Furthermore, two 
different animals showed different expression of the mTert gene in MEaF’s (Figure 
3. 14 B.).  
Since Chiangs’s construct seemed to have a “leaky” mTert expression in 
brain and in MEaF’s, we looked for an alternative negative control for mTert 
expression analysis. Thus, I used another mTert knock-out, generously provided by 
Professor Lea Harrington (University of Edinburgh, UK) and originally described by 
Liu et al., (2000) [245]. There is no difference in phenotype between mTert+/+ and 
first generation of mTert-/- reported in neither the Chiang nor Liu publications. The 
design of Liu knock-out was significantly different from Chiangs’s mTert-/-. 
Namely, exons two to six were replaced by a neomycin resistance gene (neo), which 
makes it a genuine knock-out (Figure 3.14 A.). The difference between the two 
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described knock-outs can be seen in the gene expression analysis (Figure 3. 14 C. 
and D.). Interestingly, liver in both knock-out designs was negative for mTert (Figure 
3.14 B. and C.). In contrast to Chiangs’s mTert-/-, brains from the knock-out 
designed by Liu et al., (2000) showed no mTert expression in the same experiments 
with the same sets of primers (Figure 3.14 D.). Hence these samples were used as 
accurate negative controls in gene expression experiments (Figure 3.9, Chapter 3.4). 
All other experiments described in this thesis were conducted with Chiang’s mTert -
/- design due to fact that all samples obtained from these animals were negative for 
telomerase activity and showed no mTert protein expression in neurons and brain. 
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Figure 3. 14. Expression of mTert gene in two different mTert knock-outs constructs. A. 
Comparison of wild type mTert mRNA and two mTert knock-outs. Wild type mTert+/+ contains 16 
exons. The knock-out described by Chiang et al., (2004) contains a GFP and a neomycin resistance 
gene (neo) inserted into exon 1[243]. The knock-out described by Liu et al., (2000) has 5 exons 
replaced by a neo gene [245]. B. Expression of mTert in brain, liver and MEaF’s form Chiang mTert-
/- design. There is an expression of mTert in brain from knock-out mice. Liver from mTert-/- mice 
showed no expression of the gene. MEaF’s showed low or no expression of the gene, dependent of the 
sample and primer set. C. Expression of mTert in brain and liver from the knock-out described by Liu. 
As expected mTert-/- show no expression of the gene in brain and liver. D. Expression of mTert in 
mouse brain measured by qPCR; mTert+/+ (L)-brain from mTert-/- described by Liu; mTert+/+ (C)-
brain form mTert-/- described by Chiang using primers complementary to exon 2-4. Data are 
presented as log10 of gene expression relative to the negative control, CT values were normalised to 
mGapdh expression. Error bars show standard deviation.  
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3.8. Discussion 
Telomerase has been shown to localise in mitochondria of hTERT over-expressing 
human fibroblasts, HEK cells and human cancer cells. Furthermore, it was shown 
that this localisation has a protective effect against various internal and external 
stress factors [61, 206, 218]. The aim of this part of my research was to test whether 
the mTert protein localises in mitochondria from mouse tissue in vivo. Furthermore, 
my goal was to test whether there were any potential changes in the levels of mTert 
protein and telomerase activity after dietary restriction in vivo. 
I have shown here by immunofluorescence that TERT protein is expressed in 
adult mouse brain as well as in human brain tissue. Furthermore, I have shown that 
telomerase protein in both species mainly accumulates in the mitochondria of 
neurons in the cerebellum and cortex. Similar results to those from brain were 
observed in isolated embryonic neurons as well as in adult mouse brain where mTert 
protein co-localises with the mitochondrial marker cox II. Data for hTERT 
accumulation in human brain mitochondria has not been published so far and 
findings in mouse brain and neurons are in agreement with data from a recent 
publication by Eitan et al., (2012), who showed by immunofluorescence that mTert 
protein localises in Purkinje neurons cytoplasm [226]. Furthermore, the same authors 
showed by Western blotting that mTert was expressed in mouse forebrain in the 
nuclear and cytoplasmic fractions. However, mitochondrial co-localisation was not 
reported [198, 226]. Surprisingly, in my Western blotting experiments mTert protein 
was not detected in mouse brain by using the same antibody as Eitan et al., (2012) as 
well as by an antibody from other manufacturers (i.e. anti mTert from Abcam and 
LSBio; data not shown) [198, 226].     
Interestingly, 6 to 17 months old mouse brain samples showed some 
telomerase activity in my analysis. Moreover, there was no telomerase activity in 
isolated mitochondria in brain and liver which suggests that only mTert protein 
without mTerc shuttles into mitochondria. However, Sharma et al., (2012) showed 
that hTERT protein in mitochondria acts as a reverse transcriptase by associating 
with mitochondrial RNA’s in human cancer cells, and these complexes showed 
reverse transcriptase activity - although independently of the hTERC template. 
Furthermore, the same authors showed by qPCR on RNA isolated from highly 
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purified mitochondria that hTERC was not detected in these organelles, suggesting 
that the RNA part of telomerase is not imported into mitochondria [219].  
To obtain a fast and reliable method for the evaluation of TERT protein 
abundance, a new commercially available TERT ELISA kit (GenWay) was validated 
and applied in this study. Since there was no publication of data available with this 
new kit I had first to evaluate its potential use for mouse and human samples. 
Application of the TERT ELSIA for both species was confirmed by testing the same 
samples with two alternative methods – Western blotting and immunofluorescence. 
Reliable controls for mouse and human material were successfully established.  
To test differences between telomerase protein expression and telomerase 
activity in a quantitative manner I conducted TERT ELISA and TRAP experiments 
on the same samples of mouse brain and liver. Interestingly, TA was high in whole 
tissue homogenates and negligible in mitochondrial extracts, while mTert protein 
tested by ELISA was significantly higher in mitochondria than in homogenates of 
liver and brain (Figure 3. 5). My findings for liver are in agreement with previous 
findings of Martin-Rivera et al., (1998) [141]. However, localisation of mTert 
protein in adult mouse brain was shown only recently by Eitan et al., (2012) in 
Purkinje neurons of the cerebellum [226]. Interestingly, mitochondrial mTert 
localisation in our study was observed in isolated neurons and brain tissue without 
any external stress, in contrast to what had been shown previously in human 
fibroblasts, endothelial cells and various cancer cell lines by our group and others 
[61, 206, 218]. This might suggest that mTert, in addition to its protective function 
during stress, may be an important regulator of the mitochondrial processes already 
under basal conditions, at least in mice.  
The beneficial effects of dietary restriction were discussed in Chapter 1. 3. 
For example, several studies have revealed that the generation of new neurons can be 
stimulated by DR. Moreover, it has been shown on mouse models that restriction of 
food was efficient in restoration of neuronal plasticity and improved cognitive 
abilities of ageing animals [93]. According to the results from this part of the project, 
telomerase activity decreased in mouse brain under DR in whole brain lysates. 
Although significant data was obtained only from experiment 3, results in 
experiments 1 and 2 also showed a trend for TA reduction. These findings may be 
explained by the reduced proliferation events in tissues under DR. It has been 
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reported, that reduced cell proliferation is correlated with reduced telomerase activity 
in f4 mTert knock-out mouse model by Lee at al., (1998) [192].  However, further 
research would be required to elucidate what is the influence on proliferation of cells 
in brain during DR, and more importantly what type of cell divide during this 
intervention. 
It was shown previously in vitro that the hTERT protein shuttles into 
mitochondria under oxidative stress [61, 207, 218]. Thus, since it is known that DR 
reduces oxidative stress we expected that restriction of food in vivo might reduce the 
abundance of TERT protein in mitochondria. This hypothesis might be also 
supported by findings of Haendeler at al., (2004) who had shown that incubation of 
endothelial cells with antioxidants inhibited the exclusion of hTERT protein from the 
nucleus [254]. Interestingly, in my study in three independent DR experiments, 
mTert protein significantly increased in mitochondria of mouse brain. Remarkably, 
there was no change in mTert abundance in whole tissue homogenates in all 3 
experiments. These findings might suggest a new important role of telomerase in 
mouse brain mitochondria. Furthermore, mTert gene expression in mouse brain was 
significantly reduced after dietary restriction in adult mice (experiment 1), and mTerc 
expression showed no changes in the same samples (Figure 3.9). This outcome, 
together with reduced TA, might suggest that mTert may play an important role in 
brain mitochondria, independently from telomerase activity during dietary 
restriction. It also suggests that protein localisation was not dependent on mTert 
transcription or increase in total mTert protein in lysates. 
A final step in this part of my research was to establish the distribution of 
telomerase in different mouse and human brain areas. Preliminary results from TERT 
ELISA tests on human and mouse samples showed that both species seem to have a 
similar abundance of TERT protein in cortex and cerebellum. These results might 
suggest a conserved function of the protein in mouse and human brain.   
Interestingly, I showed here that the amount of mTert protein in lysates of 
mouse frontal cortex and cerebellum was significantly reduced in old animals (17 
months) when compared to young mice (6 months). These data are in agreement with 
new findings by Eitan et al., (2012), who showed that telomerase protein is 
significantly reduced in Purkinje cells, brain stem and frontal cortex from 24 months 
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old animals when compared to 3 months old mice. However, no biological effect of 
the observed changes was reported [226]. 
In conclusion, in this study telomerase was expressed in mouse and human 
brain and the highest protein abundance was observed in cerebellum and in frontal 
cortex. Furthermore, accumulation of the mTert component in brain mitochondria 
after dietary restriction and its reduction in cortex and cerebellum with age suggest a 
new possible link between telomerase, brain mitochondria function and ageing. The 
potential functional role of mitochondrial localisation of mTert in mouse brain will 
be analysed and discussed in the forthcoming chapter. 
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Chapter 4 – Mouse Tert status and dietary restriction influences 
mitochondrial function, metabolism and neuromuscular 
coordination  
4.1. Introduction 
To date there are few publications about the function of TERT in the mitochondria of 
eukaryotic cells. For example, Ahmed et al., (2008) and Haendeler et al., (2009) 
reported a protective function of hTERT in mitochondria against mtDNA damage 
[61, 206]. It was reported that in MRC5 hTERT-over-expressing cells, the amount of 
mtDNA damage was reduced after H2O2 treatment and under hyperoxia when 
compared with telomerase negative MRC5 cells. In addition, hTERT over-expressing 
cells showed better resistance to apoptosis when compared to normal MRC5 cells. 
Moreover, hTERT-over-expressing cells showed a decrease of ROS production and 
increased mitochondrial membrane potential [61]. Similarly, Haendelers’ group 
showed that localisation of telomerase to mitochondria not only reduced ROS 
production but also improved respiration in HEK cells. Furthermore, the same study 
showed that silencing of endogenous TERT via shRNA increases mitochondrial ROS 
formation. Moreover, the same group showed in a model of mTert+/+ and mTert-/- 
mouse that mTert improves respiration of heart mitochondria and protect against 
UV-induced degradation of mtDNA in isolated primary lung fibroblasts. The same 
group also suggested that the catalytic subunit of telomerase binds to mtDNA at 
regions coding for polypeptides of ETC complex I (ND1 and ND2). Subsequently, 
proposing that the function of TERT is vital in the protection and/or repair of 
mammalian mtDNA [206]. Recent studies from Santos’ group brought further 
evidence for a protective function of TERT in mitochondria. This group reported that 
cells with mutated NES (nuclear export signal for TERT) were unable to shuttle 
TERT protein from the nucleus while maintaining telomerase activity. Mutation in 
NES in this study resulted in increased mitochondrial ROS production, increased 
oxygen consumption and increased mtDNA damage. [215]. This is additional 
evidence for the protective function of telomerase shuttling into mitochondria.  
To test directly whether localisation of TERT in mitochondria reduces 
oxidative stress our group used organelle specific vectors to express TERT protein in 
different subcellular compartments. In this method TERT was delivered on a plasmid 
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construct directly into mitochondria or the nucleus using the multiple NLS (nuclear 
localisation signal) or MLS (mitochondrial localisation signal) [218]. In a recent 
study, Singhapol and colleagues showed in cancer cells that only mitochondrial 
TERT but not nuclear was capable to reduce oxidative stress induced by ionising 
irradiation and H2O2, bringing direct evidence for the protective function of TERT in 
mitochondria [218]. 
The aim of this part of the project was to analyse oxygen consumption and 
reactive oxygen species generation in mice primary cell lines derived from animals 
of different mTert status. Furthermore, respiration and ROS production by brain 
mitochondria after dietary restriction was analysed in different mTert genotypes of 
mice. In addition, an aim was to address whether the mTert status influence 
physiological parameters known to be altered during ageing like glucose tolerance, 
insulin sensitivity and neuromuscular coordination under the condition of dietary 
restriction. 
 
4.2. Reactive oxygen species production and oxygen consumption in EPI-NCSC 
and MEaF’s isolated from mTert wild type and f1 knock-out mice 
To test the hypothesis that mTert might be involved in the regulation of oxygen 
consumption and have the potential to reduce ROS production in mouse cells, I used 
isolated EPI-NCSC (epidermal neural crest cells) and MEaF cells (mouse ear 
fibroblasts). To compare the potential difference in the mitochondrial phenotype 
between mTert wild type and f1 knock-out mice ROS production was measured 
using MitoSOX
®
 staining (mitochondrial superoxide) and DHR staining 
(intracellular peroxides) of intact cells. Fluorescence intensity was measured by flow 
cytometry as described in subchapter 2.10.3.  
Interestingly, there was no difference in ROS production in both primary cell 
cultures (stem cells and ear fibroblasts) isolated form mTert wild type and mTert 
knock-out animals (Figure 4.1). To complete this research further experiments are 
required. For instance, it would be beneficial to test ROS production in MEaF and 
EPI-NCSC isolated from different age groups, genders and after application of 
oxidative stress i.e. incubation for 5 – 7 days in 20% or 40% O2 environment. To test 
respiration levels in both cell lines, oxygen consumption rates were tested in a 
Seahorse XF24 extracellular flux analyser. The level of basal respiration in cells was 
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established by measurements of oxygen consumption without any chemical blockers 
of respiration and after delivery of oligomycin to the cell culture (which blocks 
complex V of ETC and completely abolishes ATP production). The difference 
between O2 consumption before and after oligomycin delivery reports a basal 
respiration level dependent on ATP production. Next, mouse cells were tested for 
maximal respiratory capacity of mitochondria by adding 2μM (final concentration) of 
the uncoupler FCCP that artificially enhances proton leakage into the inner 
mitochondrial membrane. To test whether maximal respiration capacity was reached, 
additional FCCP was added (to reach a final concentration of 2,5μM). Finally, O2 
consumption was completely inhibited with antimycin A (complex III blocker).  
Both mTert genotypes showed similar oxygen consumption in stem cells and 
in mouse ear fibroblasts under all conditions (Figure 4.2). However, oxygen 
consumption experiments on MEaF’s and EPI-NCSC’s were conducted on cultures 
isolated from only two male mice (6 months old) per genotype. Thus, further studies 
are required in order to draw any final conclusion. 
Interestingly, during cultivation of EPI-NCSC I found a reduced cell isolation 
efficiency and proliferation of cells derived from the f1 mTert knock-out mice 
(Figure 4.3). To confirm stemness and purity of EPI-NCSC cultures staining with 
sox10 – a neural crest stem cell marker – was conducted (Figure 4.3 B.). Isolation 
efficiency and proliferation of mouse ear fibroblast from different mTert genotypes 
was not quantified due to the difference in the amount of primary material used.   
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Figure 4.1. Reactive oxygen species levels in primary cultures from mTert wild type and f1 
knock-out mice. A. Mitochondrial superoxide levels in EPI-NCSC’s measured by flow cytometry 
using MitoSOX, FL3 – quantification of red fluorescence in channel 3 of flow cytometer (Partec), 
n=2 animals per genotype; B. Intracellular peroxide levels in EPI-NCSC’s by DHR staining, FL1 – 
quantification of green fluorescence in channel 1, FL3 – quantification of red fluorescence in channel 
3, n=2 animals per genotype; C. Mitochondrial superoxide levels measured by MitoSOX in MEaF 
cells, n= 5 animals per genotype; D. Intracellular peroxide levels in MEaF’s evaluated by DHR 
staining, n=5 animals per genotype. Statistical significance was tested by One Way Anova test. In 
panel A. and B. error bars show standard deviation. In panels C. and D. error bars represent S.E.M. 
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Figure 4.2. Oxygen consumption in mouse primary cell culture. A. O2 consumption of EPI-NCSC 
from mTert +/+ and mTert-/- male mice, two animals per group shown separately, oxygen 
consumption measured after oligomycin (OLIGO), FCCP – uncoupler (maximal respiratory 
capacity), Antimycin A (AA) – complex III blocker. B. O2 consumption of MEaF from mTert +/+ and 
mTert-/- male mice, two animals per genotype were used. OCR – Oxygen consumption rate measured 
in pmoles/min. Data presented as OCR – oxygen consumption rate in pmoles of O2 consumed per 
minute, normalised to basal respiration calculated per 1x10
5
 cells. Each primary culture is shown 
separately, named 1 and 2 of each genotype. Error bars show standard deviation of the average from 
measurements in quintuplicates.  
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Figure 4.3. Isolation and proliferation of EPI-NCSC form mTert +/+ and mTert -/- mouse 
whisker bulges. A. Whisker hair follicle, expression of neural crest stem cell marker sox10 (red) in 
the EPI-NCSC niche (white arrows) in a whisker bulge, staining performed by Talveen Purba [255]; 
B. Stemness and purity of EPI-NCSC colony was confirmed by sox10 staining. Red fluorescence 
shows expression of sox10; C. Stem cells release from whisker bulges after 6 days from dissection, 
representative bulges from mTert+/+ and mTert-/- adult male mice (6-9 months); D. Proliferation of 
EPI-NCSC form mTert wild type and knock-out mice (two weeks after isolation); E. EPI-NCSC 
number after 20 days from whisker bulges isolation. Graph bars show average cell number derived 
from 5 animals per genotype. Error bars represent S.E.M. *Statistical significance was tested by One 
Way Anova test.  
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4.3. Oxygen consumption and hydrogen peroxide production in mouse brain 
mitochondria from mTert wild type and f1 knock-out mice after 16 months of 
dietary restriction  
I have shown in the previous chapter that dietary restriction increases mTert protein 
content in brain mitochondria in mice. Thus, the question emerged what could be the 
role of this mitochondrial localisation of telomerase? The first hypothesis was that 
mTert might reduce oxidative stress and improve mitochondrial respiration. To test 
this hypothesis a dietary restriction experiment was performed on mTert wild type 
and f1 knock-out animals. Restriction started when the animals were 6-7 months old 
and lasted for 16 months. Only male animals were engaged in the experiment. By the 
end of the experiment four body weight matching animals per group and genotype, 
were chosen for dissection, mitochondria isolation and functional evaluation.   
The bioenergetics experiments were conducted in the presence of 
pyruvate:malate (complex I substrate), and separately with succinate (complex II 
substrate). Consumption of O2 by isolated mitochondria during active state 3 
respiration (ATP being produced) was measured after adding ADP (substrate for 
ATP) to the mitochondria. Next, state 4 respiration (resting state) was measured after 
delivery of oligomycin to mitochondria, which blocks complex V of ETC and 
completely inhibits ATP production.  Afterwards, the uncoupler FCCP was added to 
mitochondria and maximal capacity for oxygen consumption was measured. Finally, 
antimycin A was delivered to mitochondria to block complex III and fully inhibit 
mitochondria respiration. The readout from the XF24
®
 Seahorse extracellular flux 
analyser is OCR (Oxygen Consumption Rate) shown as pmoles O2/min/5μg of 
mitochondrial proteins. Moreover, the Respiratory Control Ratio (RCR) for 
mitochondria was calculated. RCR characterises the state3/state4 respiration ratio 
and its value corresponds to the coupling of mitochondria. The greater the RCR 
value the more coupled the mitochondria are. Mitochondria are considered coupled 
when all protons H
+
 pumped into the inner membrane space are used by complex V 
(ATP synthase) for production of ATP. Uncoupled mitochondria, on the other hand, 
have a leakage of protons bypassing complex V, which causes a reduction of 
membrane potential (ΔΨm). Another effect of uncoupling is oxygen consumption of 
mitochondria due to increased demand of O2 for faster electron flow. In other words: 
the more coupled mitochondria are, the more efficient respiration is.  
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Isolation of functional mitochondria from several animals is a laborious 
technique. Furthermore, freshly isolated mitochondria need to be used in two 
independent experiments immediately after isolation to keep their functional capacity 
intact (H2O2 generation and respiration). Thus, to obtain high quality data 
measurements, these experiments were conducted in collaboration with Dr Satomi 
Miwa and PhD student – Amy Johnson. 
In our experiments dietary restriction significantly increased oxygen 
consumption of brain mitochondria under basal condition (state 2 respiration) in the 
presence of pyruvate:malate (complex I substrate) (Figure 4.4 A.). Furthermore, 
consumption of O2 was increased in mTert+/+ mice after DR during state 4 
mitochondrial respiration (resting state after oligomycin delivery) in the presence of 
pyruvate:malate. Interestingly, this difference was not observed in mTert -/- animals. 
Moreover, DR caused an increase in O2 consumption after delivery of antimycin A. 
The addition of ADP (state 3 respiration) and the uncoupler (FCCP) showed no 
changes in the consumption of oxygen between genotypes or dietary groups. 
Surprisingly, the delivery of antimycin A also revealed the highest consumption of 
oxygen in mitochondria from the mTert+/+ dietary restricted group (Figure 4.4 A.).  
Oxygen consumption rates measured in the presence of succinate (complex II 
substrate) showed no significant difference between mTert wild type and knock-out 
in all respiration states. There was also no significant difference in oxygen 
consumption between the ad libitum group and dietary restricted animals. 
Furthermore, there was no significant difference in RCR values in brain 
mitochondria when the measurements were performed with pyruvate:malate or 
succinate, this means there was no significant change in the coupling of mitochondria 
after DR or dependent on genotype (Figure 4.5). Moreover, comparable RCR values 
means that mitochondria preparations from all tested groups were conducted 
consistently.  
In addition to oxygen consumption, isolated brain mitochondria were 
analysed for H2O2 generation by AmplexRED
®
, a method described earlier. This 
technique measures H2O2
 
production, which is derived from O2
.-
 via interaction with 
SOD which results in a fluorescent product during reaction with the AmplexRED
®
 
reagent. Readout from the measurement of fluorescence was used for the calculation 
of H2O2 in pmoles/min/mg of mitochondrial proteins. Initial measurements were 
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conducted during state 2 mitochondrial respiration in the presence of specific 
substrates for ETC complexes i.e. pyruvate:malate for complex I and succinate for 
complex II. Moreover, a specific inhibitor – rotenone – was used for the inhibition of 
complex I which resulted in maximal superoxide O2
.-
 production in the presence of 
pyruvate:malate due to the accumulation of electrons in the NAD
+
 reduction site. 
Furthermore, rotenone was added to mitochondria in the presence of succinate which 
allowe thed calculation the residual superoxide (O2
.-
) production seperate from 
complex I. Finally, in the reaction with succinate – antimycin A (blocker of complex 
III) was added allowing the calculation of maximal hydrogen peroxide generation 
linked to complex III.  
Surprisingly, there was no significant difference in hydrogen peroxide 
generation in mouse brain mitochondria between dietary groups or genotypes in all 
respiratory states as well as in the presence of substrates for complex I and complex 
II (Figure 4.6) 
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Figure 4.4. Oxygen consumption by brain mitochondria after dietary restriction from mTert 
wild type and knock-out mice. A. Oxygen consumption in brain mitochondria from mTert +/+ and 
mTert -/- animals after 16 months dietary restriction in the presence of complex I substrate – 
pyruvate:malate; B. Oxygen consumption in brain mitochondria in the presence of complex II 
substrate – succinate. Data are presented as OCR (oxygen consumption rate) measured in pmoles O2 
/minute/5µg proteins. OCR was measured during basal condition, after ADP delivery, after 
oligomycin (OLIGO), after FCCP and after antimycin A (AA). AL – ad libitum (control group), DR 
– dietary restricted group. Graph bars show average OCR measured in quintuplicates from 4 animals 
per dietary group and genotype. *Statistical significance was calculated by One Way Anova and Two 
Way Anova with treatment and genotype as factors. Error bars show S.E.M. 
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Figure 4.5. Respiratory control ratio (RCR) in mouse brain mitochondria after dietary 
restriction. A. RCR calculated for mitochondria respiration in the presence of complex I substrate – 
pyruvate:malate, the difference between mTert wild type and knock-out is not statistically significant; 
B. RCR calculated for mitochondria respiration in the presence of complex II substrate – succinate. 
AL – ad libitum (control group), DR – dietary restricted group. Graph bars show average RCR 
measured in quintuplicates from 4 animals per dietary group and genotype. Statistical significance was 
calculated by One Way Anova to compare two groups and Two Way Anova test with treatment and 
genotype as factors. Error bars show S.E.M. 
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Figure 4.6. Hydrogen peroxide production by brain mitochondria from mTert wild type and 
knock-out mice after DR (measurement and analysis performed by Amy Johnson). A.  H2O2 
production in mitochondria in the presence of complex I substrate (pyruvate:malate - PM) and 
rotenone (ROT); B. H2O2 production in mitochondria in the presence of complex II substrate 
(succinate - SUCC), after delivery of rotenone and antimycin A (AA), C. ROS production during 
reverse electron flow. Data are shown as pmoles of H2O2 per minute, per mg of mitochondria proteins. 
AL – ad libitum (control group), DR – dietary restricted group. Graph bars show average 
pmoles/H2O2/min/mg proteins measured in triplicates from 4 animals per dietary group and genotype. 
Statistical significance was calculated by One Way Anova test. Error bars shows S.E.M.  
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4.4. Hydrogen peroxide production by brain mitochondria in female mTert wild 
type and f1 knock-out mice 
Experiments described in the previous subchapter were performed only on male 
animals. Thus the question emerged: what would be effect of mTert status on 
hydrogen peroxide production in female brain mitochondria? 
  To address this question, brain mitochondria were isolated from different age 
groups/genotypes of female mice and tested by AmplexRED
®
 in the same conditions 
as described in the previous subchapter. Three animals were tested per group 
(age/genotype). Young mTert wild type female animals at the age of 3 to 6 months 
and old mice aged 22 months were matched with their knock-out littermates.  
Interestingly, analysis of freshly isolated mitochondria from female brains 
revealed different results than males. For complex I there was a higher H2O2 
generation in brain mitochondria from young mTert knock-out female animals 
compared to wild type in the presence of pyruvate:malate and oligomycin (complex I 
substrate, state 4 respiration). Under the same condition this difference was not 
observed in old female mice (Figure 4. 7 A.). However, 22 month old knock-out 
females showed a higher H2O2 release than wild type females, when maximal ROS 
production capacity was measured in the presence of rotenone. Strikingly, hydrogen 
peroxide release, linked to complex I by reverse electron flow, showed no difference 
between genotypes in young females. However, brain mitochondria from knock-out 
old females showed significantly higher free radical production by reverse electron 
flow than age-matching wild type female littermates (Figure 4. 7 C.). Interestingly, 
H2O2 release in the presence of succinate (complex II substrate) showed no changes 
in brain mitochondria of young and old females. Maximal capacity of ROS 
production linked to complex III measured after antimycin A inhibition also showed 
no difference between mTert genotypes in both age groups of females (Figure 4. 8).  
Altogether, data from hydrogen peroxide production in female brain 
mitochondria support the hypothesis of a protective function of mTert against age 
related increase of ROS production in vivo in brain. Furthermore, these results might 
suggest that telomerase may have a different role in the regulation of mitochondrial 
ROS production in male and female brains. 
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Figure 4.7. Hydrogen peroxide generation in mouse female brain mitochondria in the presence 
of pyruvate:malate. A. H2O2 generation in brain mitochondria form young animals (3-6 months), 
PM – measurement after delivery of complex I substrate (pyruvate:malate) during state 2 respiration, 
PM+ROT – measurement after delivery of rotenone (complex I blocked); B. H2O2 generation in the 
presence of pyruvate:malate in brain mitochondria form old animals (22 months); 3 animals per age 
group/genotype were used for each experiment. *Statistical significance was calculated by Anova test. 
Error bars show S.E.M. 
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Figure 4.8. H2O2 generation in female brain mitochondria in the presence of succinate. A. 
Hydrogen production linked to complex I and II in female brain mitochondria from young animals (3-
6 months), SUCC – measurement after delivery of complex II substrate (succinate), ROT – 
measurement after delivery of rotenone (complex I blocker), +AA – measurement after delivery of 
antimycin A; B. Hydrogen peroxide production in female brain mitochondria form old females (22 
months) in the presence of succinate; C. H2O2 release in brain mitochondria linked to complex I, 
during reverse electron flow. 3 animals per age group/genotype were used for each experiment. 
Statistical significance was measured by Anova test. Error bars shows S.E.M.  
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4.5. Physiological parameters in mTert wild type and f1 knock-out mice after 
dietary restriction  
Glucose tolerance and insulin resistance has often been associated with an age 
dependent physiological decline, and along with body weight as well as food intake, 
are suitable features for assessing general health of animal models [242, 256]. Hence, 
I asked whether the mTert gene status might influence basic physiological parameters 
in our dietary restriction model. 
 Male animals at the beginning of the DR experiment had similar body weight. 
For instance, in the AL group mTert+/+ animals were on average 32.23g ± 3.6; 
mTert-/- were 32.58g ± 3.6. In the DR group mTert+/+ animals were on average 
33.31g ± 2.3; mTert-/- had 33.76g ± 3.2 of body weight. Food intake was calculated 
per animal (3.14g ± 0.24 of chow) thus 40% restricted animals had access to 1.9g of 
food per individual per 24 hours. However, food intake was not adjusted during the 
experiment, thus during some periods food intake was restricted from 30 to 50%. 
Within the first 60 days of the experiment DR mice lost an average of 13 grams of 
body weight and it remained steady for the rest of the experiment in both genotypes. 
Ad libitum mice were gaining weight steadily until 250 days when it stabilised 
(Figure 4.9 A.). Food intake was fluctuating during all 16 months of the experiment 
from 3 to 4g/animal/24h (Figure 4.9). Interestingly, the body weight of AL mTert-/- 
animals started to decrease in the last few months of the experiment (although not 
significantly), while the weight of AL mTert+/+ mice was more stable (Figure 4.9 
A.) Thus, the general observation was that the mTert gene status did not influence 
weight or food intake significantly during dietary restriction. 
To test what impact dietary restriction might have on glucose metabolism of 
mTert wild type and knock-out mice I conducted a Glucose Tolerance Test (GTT). 
The GTT measures a fasting organism’s ability to clear injected glucose in the blood. 
Moreover, it is known that this ability is reduced with age and in diabetes. 
Furthermore, it was shown in humans and rodents that the ability for blood glucose 
clearance is increased by dietary restriction and reduced with age [75, 257]. Since 
impaired glucose clearance from the blood is an effect of increased insulin resistance, 
because this hormone negatively regulates glucose levels, I have investigated the 
additional question - what is the potential change in the insulin level after dietary 
restrictions in different mTert genotypes?     
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32 animals were tested in total at the end of 16 months of dietary restriction 
as described in the materials and methods - subchapter 2.3. Specifically, there were 
10 mTert wild type and 11 f1 knock-out mice in the ad libitum group. The DR group 
contained 4 wild type and 7 knock-out mice. Only male animals were used in the 
experiment.  
As expected, the obtained results showed that DR accelerates glucose 
clearance from the blood. Moreover, both genotypes in the DR group had a 
significantly lower basal fasting blood glucose concentration measured after 24h of 
fasting. However, glucose level in AL animals was on average 6.1mmol/L, which is 
usual for healthy mammals. Interestingly, there was no difference between genotypes 
in the AL group at all time points measured after the glucose injection: 15min., 
30min, 1h and 2h (Figure 4.10 A.). Surprisingly, there was a significant difference 
observed at the 1h and 2h time point in the DR group, where mTert-/- animals had 
significantly lower average blood glucose (Figure 4.10 B.). 
Similarly to glucose tolerance, insulin resistance becomes impaired with age, 
and DR is thought to diminish the age related increase of insulin levels in plasma. To 
test whether mTert plays a role in this phenomenon, the same animals as in the GTT 
were used in the analysis of insulin levels using an ELISA kit after dissection of the 
mice. As expected, after 16 months of dietary restriction the insulin levels in 
mTert+/+ animals was reduced significantly (Figure 4.10 C.). Interestingly, among 
the mTert-/- mice no difference was observed after DR. This may suggest an 
involvement of mTert in the regulation of insulin levels.   
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Figure 4.9. Body weight and food intake of mTert +/+ and mTert-/- mice during the DR 
experiment. A. Average body weight of mice during 16 months of dietary restriction, AL – ad 
libitum fed animals (control group) consisted of 10 mTert+/+ and 11 mTert-/- animals, DR – dietary 
restricted group consisted of 4 mTert+/+ and 7 mTert-/- animals, n/s – not significant, statistical 
significance was analysed using Anova; B. Average food intake per day per animal during DR 
experiment, food intake in the restricted group was limited to 1.9g per animal per day. Error bars show 
S.E.M. 
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Figure 4.10. Blood glucose clearance and insulin levels after dietary restriction in mTert+/+ and 
mTert-/- mice. A. Glucose tolerance test (GTT) in ad libitum fed animals after 12h fasting, the group 
consisted of 10 mTert+/+ and 11 mTert-/- animals; B. GTT in mTert +/+ mice, AL (n=10) vs. DR 
(n=4); C. GTT on dietary restricted animals, the DR group consisted of 4 mTert+/+ and 7 mTert-/- 
animals; D. GTT in mTert-/- mice, AL (n=11) vs. DR (n=7); E. Quantitation of area under the curve 
of glucose tolerance test (GTT) F. Fasting insulin levels in plasma of mTert+/+ and mTert-/- mice 
after 16 months dietary restriction, 4 mice per group/per genotype were analysed in duplicate. 
*Statistical significance was tested by One Way Anova on Ranks. Error bars show S.E.M. 
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4.6. The influence of mTert status and DR on neuromuscular coordination  
A beneficial effect of DR on brain function has been described previously [258]. To 
determine a potential effect of dietary restriction and mTert genotype on 
neuromuscular coordination a series of tightrope tests was performed on mice at the 
beginning of the DR and at the end of the DR experiment. The technique is a widely 
used method for assessing sensorimotor performance, strength and vigour of rodents. 
Particularly, the tightrope test is used in ageing and oxidative stress research focused 
on the function of the nervous system and muscles, particularly in their coordination 
[259-262]. 
The equipment for the tightrope test was described in chapter 2.18. It consists 
of a rope, which is tightly tied up between two chemical stands above cushioned 
bedding. Mice were suspended above the tightrope for 20 seconds at the distance of 
their whiskers. Afterwards, the mouse was placed with its front paws in the middle of 
the rope and the time between grabbing the rope and pulling up its hind legs was 
recorded. The experiment ran for 60 seconds and three trials were performed. The 
same male mice were tested at two time points i.e. at 8 months old – after 2 months 
of the DR and at 21 months old. The number of unsuccessful attempts (when the 
mouse fell down or did not lift its hind legs up) was averaged and analysed. 
Interestingly, young males (8 months old) at the beginning of the DR 
experiment (2 months DR which started at 6 month of age) performed similarly in all 
groups, with less than one unsuccessful attempt on average to lift hind legs up in the 
test. There was no significant difference between dietary groups or between the 
mTert genotypes (Figure 4.11 A.). After 14 months of DR experiment all groups 
apart from the mTert+/+ under DR had decreased their performance compared to the 
8 month time point (Figure 4.11 B.). Both genotypes in the AL group showed a two 
fold increase in the number of unsuccessful attempts (Figure 4.11 B.). However, in 
the DR group ability to perform the test was reduced only in mTert-/- animals, while 
wild type animals performed similarly as at the beginning of DR. Thus, these results 
suggest that: i) DR delays age-related neuromuscular coordination decline seen in the 
mTert wild type AL group and ii) mTert might play a possible role in neuromuscular 
coordination during ageing and dietary restrictions.  
To test whether the effect of mTert status on neuromuscular coordination is 
sex specific, young (5-6 months) female mice were also tested for their tightrope 
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performance. In total, 22 mTert+/+ and 14 mTert-/- female mice were tested. 
Interestingly, in females the effect of mTert status can be observed already in young 
animals. Knock-out female mice were significantly less successful in the experiment 
than their wild type littermates; however the number of mice was much higher than 
for males (Figure 4.11 C.). Moreover, there were no dietary restricted females 
available. 
111 
 
 
 
 
 
Figure 4.11. Neuromuscular coordination of mTert+/+ and mTert-/- mice during ageing and after 
dietary restriction. A. Unsuccessful attempts to lift up hind legs in young male mice (8 months) after 
2 months of dietary restriction, AL – ad libitum, the group consisted of 10 mTert+/+ and 11 mTert-/- 
animals, DR – dietary restricted, the group consisted of 4 mTert+/+ and 7 mTert-/- animals; B.  
Unsuccessful attempts to lift hind legs up in old male mice (20 months) after 14 months of dietary 
restriction, the same animals had been analysed as at the beginning of the experiment, statistical 
significance between age groups was performed by Mann-Whitney rank-sum test: #P=0.019, 
†P=0.050, ‡P=0573, ɨP=0.005; C. Unsuccessful attempts to lift hind legs up in young female mice (5-
6 months), the female cohort consisted of 22 mTert+/+ and 14 mTert-/- animals. *Statistical 
significance was measured by Mann-Whitney rank-sum test. Error bars show S.E.M.  
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4.7. Discussion  
The protective role of mitochondrial telomerase against oxidative stress was 
previously reported by our group and others. Human telomerase reverse transcriptase 
was shown to reduce apoptosis and generation of reactive oxygen species in a 
number of in vitro studies [61, 206, 218]. However, the role of mitochondrial TERT 
had not been sufficiently demonstrated to date in vivo except for data published by 
Haendeler et al., (2009), where it was shown that mTert deletion resulted in reduced 
respiration in mouse heart mitochondria but not in liver mitochondria [206]. Thus, 
we performed various relevant mitochondrial function experiments on cells and 
mitochondria isolated from brain of the same mTert wild type and mTert knock-out 
animals as Haendeler et al., (2009). Moreover, restriction of nutrients was used for 
elucidating a potential function of mTert in the bioenergetics of brain mitochondria 
under DR conditions. 
 The status of mTert in this project was shown to have no impact on ROS 
production in MEaF and EPI-NCSC cells isolated from different mTert genotype 
mice (Figure 4.1). This contradicts previous in vitro findings published by Ahmed et 
al., (2008) and Haendeler et al., (2009), where overexpression of hTERT resulted in 
reduced oxidative stress in human fibroblasts and HEK cells respectively [61, 206]. 
Similarly, in our study oxygen consumption in MEaF and EPI-NCSC cells was at the 
same level in both mTert genotypes (Figure 4.2). However, the respiration data is 
based on a small number of animals thus further experiments are required in order to 
draw any final conclusion. 
Interestingly, tests performed on cultivated EPI-NCSC from mouse whisker 
pads showed that the mTert status was crucial for the isolation efficiency and 
proliferation ability of those cells. This effect of mTert was shown here for the first 
time in (f1) mTert knock-out animals (Figure 4.3). Sahin et al., (2011) showed a 
similar reduction in proliferation of hematopoietic stem cells on fourth generation 
(f4) mTert knock-out animals, which was a telomere length dependent phenomenon 
[193]. Furthermore, Nitta et al., (2011) showed a decrease of proliferation in stem 
cells isolated from mouse hair follicle as a result of mTert deficiency and increased 
oxidative stress independently of telomere length [204]. Interestingly, Flores et al., 
(2008) showed that stem cells in mice have longer telomeres than cells in the 
surrounding tissue, however, there is no data on telomere length in (f1) mTert knock-
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out mice [24]. Thus our data suggests that perhaps stem cells depend more on 
telomerase not only due to its telomere length function, but also due to its function as 
regulator of the transcription of development genes (i.e. WNT/β-catenin) or due to 
protective role of the enzyme. Further systematic experiments, especially on stem 
cells are required to elucidate the role of mTert in oxidative stress (i.e. hyperoxia, 
irradiation) and proliferation in different generations of mTert knock-outs, age 
groups and genders. Moreover, a critical and accurate measurement of telomere 
length would help to better evaluate whether the diminished growth of mTert-/- stem 
cells could be attributed to telomere-dependent or independent functions of 
telomerase. 
 The next question we wanted to address was about the role of mTert in brain 
mitochondria function. Interestingly, published data on mitochondrial respiration in 
organs, other than the brain, after dietary restriction are often contradicting. For 
example, it was shown that DR reduces oxygen consumption (state 4 mitochondrial 
respiration) in mice brain, heart and kidney as well as in the skeletal muscle of rat 
[263, 264]. However, other groups showed antagonistic results. For instance, Nisoli 
et al., (2005) showed that DR increases significantly oxygen consumption in brain 
and liver mitochondria in mice [265]. Moreover, Hempenstall and co-workers 
showed recently that dietary restriction increases oxygen consumption in mouse 
skeletal muscle mitochondria [266]. In our dietary restriction experiment, oxygen 
consumption increased significantly in brain mitochondria from restricted animals in 
the presence of complex I substrate. This rise in respiration was only observed in 
mTert+/+ animals, which would suggest a possible role of mTert in mouse brain 
mitochondria function (Figure 4. 4). However, this DR effect in the mTert+/+ mice 
was observed only during resting state of mitochondrial respiration. After delivery of 
ADP no changes in oxygen consumption were observed. Surprisingly, O2 
consumption was not different between mTert+/+ and mTert-/- male mice in the 
presence of pyruvate:malate – complex I substrate (Figure 4. 4). Interestingly, 
Haendeler et al., (2009) showed that mouse heart mitochondria from mTert knock-
out animals had reduced respiration in the presence of complex I substrates (i.e. 
malate and glutamate), however in liver mitochondria there was no genotype effect 
on respiration. Probably one reason could be that the heart utilises high amounts of 
energy compared to liver and therefore mTert status effect could be more pronounced 
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[206]. Thus, the role of mTert on respiration may be tissue specific. However, 
research of Sahin et al., (2011) showed a significantly lower oxygen consumption in 
mitochondria from heart and liver in (f4) mTert-/- than in the wild type mice as an 
effect of telomere shortening [193]. 
 The next functional parameter we tested for brain mitochondria was hydrogen 
peroxide generation. It was shown by various groups in a number of animal models 
and tissues (i.e. mouse liver, intestine) that dietary restriction potentially attenuates 
ageing by reduction of oxidative stress [32, 79, 80]. A telomere dependent role in this 
process was also reported, showing that shortening of telomeres in late generations of 
mTert knock-out animals caused mitochondrial dysfunction, increased ROS 
production and accelerated ageing [193, 194]. However, the role of mitochondrial 
mTert was not analysed in vivo yet. In our experiments performed in collaboration 
with Dr Satomi Miwa and Amy Johnson, we found that dietary restriction did not 
reduce H2O2 production by mitochondrial complex I, II and III in brain (Figure 4. 6). 
That is in contrast to published data that DR significantly reduces ROS production in 
mouse and rat brain in different age groups [263, 267]. Moreover, in our study there 
was also no difference in brain mitochondria ROS production between different 
mTert genotypes in male mice. However, it would be interesting to test the dietary 
restriction effect on telomerase in female brain since it was shown that there are 
gender specific differences in mitochondria function after DR. For example, Colom 
and co-workers showed that in dietary restricted rat females there was reduction in 
ROS production in cardiac mitochondria to significantly higher extend than males 
when compared to the  corresponding ad libitum controls [268]. Most importantly, 
mitochondria from rat female brain, liver and skeletal muscles showed lower ROS 
production than from their male counterparts [269-271]. An explanation of this 
phenomenon might be fact that estrogen was shown to reduce ROS production in 
female rat brain and in males supplemented with estrogen in vivo [272].  
 Since, female mice were not used in our dietary restriction study, we could 
only analyse the potential influence of mTert on genotype and age in this gender 
group. Interestingly, H2O2 generation linked with complex I substrate was 
significantly higher in brain mitochondria from female mTert-/- animals than in wild 
type female littermates what was not observed in males (Figure 4.7). Remarkably, 
ROS production linked to complex II substrate showed no difference in both young 
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and old females. This data seems to suggest that mTert might be involved in 
mitochondrial complex I ROS production. Furthermore, free radical generation by 
reverse electron flow was similar in both genotypes in young animals but 
significantly increased in mTert-/- brain mitochondria from old females (Figure 4. 7). 
There was no influence of mTert status on hydrogen peroxide generation linked to 
complex III (blocked by antimycin A). Altogether these results suggest that: i) mTert 
seems to protect the female brain against oxidative stress; ii) mTert function in ROS 
generation seems to be differently regulated in male and female brain. Thus, it would 
be useful to conduct further research on the influence of telomerase on gender and 
sex steroids for the function of brain mitochondria. Interestingly, there are data 
published that might support this hypothesis. For example, it was described that 
estrogen is positive regulator of telomerase in human by two mechanisms: 1) 
estrogen is mediating expression of hTERT by estrogen response element on hTERT 
promoter and 2) estrogen is known for stimulation of c-Myc, a potent positive 
transcriptional hTERT regulator [273, 274]. Furthermore, withdrawal of testosterone 
was shown to be potent to elevate telomerase activity in healthy rat and monkey 
prostate [275, 276]. Taking all this points together, we propose that mTert function in 
brain mitochondria might be regulated by sex hormones. 
 Another question we addressed was the influence of telomerase on metabolic 
parameters in mice during dietary restriction. It was shown previously that dietary 
restriction decreased glucose and insulin levels in mammalian blood/serum, however 
the role of TERT in this effect was not tested to date [277, 278]. In this project, 
fasting insulin level was significantly decreased under dietary restriction as expected. 
Interestingly, the reduction of insulin concentration in fasting blood plasma was 
significantly reduced after DR only in mTert+/+ animals while mTert-/- mice showed 
no changes. This result might suggest that telomerase is a possible player in the 
regulation of insulin changes during DR. However, there were no significant changes 
in insulin level between mTert+/+ and mTert-/- under normal (AL) conditions that 
suggests that telomerase is rather indirectly involved in insulin regulation. On the 
other hand, while the glucose clearance was more efficient in the dietary restricted 
animals, mTert knock-out animals under DR showed a faster clearance of blood 
glucose in the first and second hour after glucose injection. Interestingly, this effect 
was not observed in the ad libitum group. These metabolic data confirm beneficial 
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effects of dietary restriction on mice. However, our glucose clearance data suggests 
that male mTert-/- mice might be more efficient in GTT after DR than mTert+/+ 
animals. No effect of first generation mTert knock-out on glucose metabolism and 
insulin level was reported so far. However, an influence of telomerase length on 
glucose tolerance and insulin level was reported recently by Kuhlow and co-workers 
[279]. Authors of this publication showed that telomerase deficient mouse (mTert-/-
(f4)) had significantly reduced glucose tolerance as well as diminished insulin 
secretion, all correlated with significantly reduced telomere length  in pancreatic 
islets [279]. 
Mouse Tert status also revealed interesting results on neuromuscular 
coordination. In my experiments it was tested whether telomerase and dietary 
restriction can protect mice against age related decrease in neuromuscular 
performance. Guyerbas et al., (2005) suggested that age related decrease in 
coordination can be restored by antioxidant supplementation, suggesting ROS levels 
as an important cause for the decline of the function of the nervous system and 
muscles [262]. Furthermore, it was shown that sensorimotor performance in a 
tightrope test was inversely proportional to the levels of oxidative stress markers in 
mouse brain like Cu/Zn-SOD and Mn-SOD [280]. Interestingly, my results from the 
tightrope experiments seem to show that mTert status has a significant influence on 
neuromuscular performance of mice. However, taking together the data from ROS 
production in male and female brains mitochondria it is surprising that mTert-/- in 
both genders have higher number of unsuccessful attempts in the test. It would be 
expected that female mTert knock-out with higher ROS production in the brain 
should perform worse in neuromuscular coordination test. Why then old male mTert-
/- with no changes in ROS production in brain also performed worse? The question 
could be addressed by analysing ROS generation in muscle mitochondria from both 
genotypes and genders, since tightrope test is directed to assess central nervous 
system and muscle.  
  
  
117 
 
Chapter 5 - Is mTert in mitochondria regulated via mTOR 
pathway? 
5.1. Introduction 
Life span extension mechanisms induced by DR are often explained mechanistically 
by down-regulation of the mTOR pathway. mTOR is a kinase that regulates signals 
for cellular growth control in response to nutrients. Furthermore, the mTOR pathway 
is widely studied due to its key role in apoptosis and cancer development. It was 
shown that elevated activation of mTOR signalling reduces apoptosis and increases 
proliferative capacity of cancer cells [108].  Furthermore, it was shown that mTOR 
can be a link between nutrients and energy signalling pathways [109]. Recently, the 
kinase was also described as a regulator of nutritional and hormonal signals in the 
brain [110]. There are reports suggesting that inhibition of the mTOR pathway 
extends the life span of yeast, worms, flies and mice [111-113]. Furthermore, it was 
shown that mTOR downstream targets are engaged in the reduction of oxidative 
stress, as well as the response for DNA damage and induction of apoptosis. For 
example, Schieke et al., (2006) reports that inhibition of mTOR with rapamycin 
resulted in disruption of the mTOR-raptor complex, which resulted in lower 
mitochondrial membrane potential, oxygen consumption and decreased ATP 
synthesis [117, 118]. Moreover, Wilkinson and colleagues showed that rapamycin 
supplementation decreases tumour incidence, and reduces degenerative age related 
changes in liver and heart [120]. Remarkably, a recent publication by Fok et al., 
(2012) suggests that rapamycin and dietary restriction might have a similar effect on 
mice [121]. In these experiments, mice were dietary restricted or supplemented with 
rapamycin, the authors reported similar inhibition of S6K1 – mTOR pathway 
downstream targets as well as a similar increase in autophagy in liver after both 
treatments. Interestingly, animals from the DR group and the rapamycin treated 
group showed opposite effects on blood glucose clearance and different insulin 
tolerance, showing the benefits of dietary restriction and the potential deteriorative 
effect of rapamycin [121]. 
Since mTert shows a response in mouse brain mitochondria to dietary 
restriction, the question emerged whether a decreased mTOR activity might be 
involved in this phenomenon? To address this question two separate approaches were 
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considered: 1) to analyse the phosphorylation level of mTOR protein in mouse brain 
after dietary restriction, 2) to inhibit mTOR activity by rapamycin dietary 
supplementation in vivo and investigate whether the response of mTert is similar to 
DR under this treatment and 3) to test if brain mitochondria from mTert+/+ and 
mTert-/- mouse treated with rapamycin shows similar bioenergetics to those from 
dietary restriction experiments.   
 
5.2. Rapamycin supplementation effect on mTert wild type and knock-out mice  
5.2.1. Inhibition of mTOR pathway in mouse brain after rapamycin and DR 
Rapamycin was shown to be a potent mTOR inhibitor. Thus, a short term 
supplementation experiment was conducted in mice. There were a total of 31 male 
mice in the experiment. In the control group, there were 7 mTert+/+ and 9 mTert-/- 
mice, while in the rapamycin fed cohort there were 6 mTert+/+ and 9 mTert-/- 
animals. All the mice had a similar weight (40.7g ± 7.5g) and were twelve months 
old when the supplementation started (Figure 5.1 C.). Rapamycin supplementation 
lasted for 4 months. Body weight during the rapamycin study did not change in either 
group. Furthermore, food intake, although it fluctuated, was similar in all tested 
groups.  
Mouse brain tissue from experiment 1 (late onset short term DR) were tested 
by Western blotting to detect potential changes in mTOR protein phosphorylation in 
mouse brain. The ratio of phosphorylated to non-phosphorylated mTOR was 
quantified by densitometry analysis of protein visualisation on a Western blotting 
membrane. The phosphorylation of mTOR was significantly reduced after dietary 
restrictions in mouse brain from experiment 1 (Figure 5.1 A.). Furthermore, 
activation of mTOR was tested in mouse brain tissue after rapamycin 
supplementation. Western blotting experiments revealed that rapamycin treatment 
was efficient to significantly reduce mTOR phosphorylation in brain, with a similar 
effect to the one observed in brains after dietary restriction (Figure 5.1 B.). Thus, 
these results support the hypothesis that rapamycin supplementation might mimic the 
effects of dietary restrictions on mTOR in brain. 
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Figure 5.1. Phosphorylation of mTOR in mouse brain and body weight of mice after rapamycin 
supplementation. A. A decrease of mTOR activity after dietary restriction in mouse brain after 3 
month of dietary restriction (exp. 1), upper panel: immune-blot with phosphor-mTOR and total mTOR 
antibodies, lower panel: densitometric quantification, the graph shows the average ratio of 
phosphorylated mTOR to non-phosphorylated mTOR, AL1-AL4 – ad libitum fed animals, DR1-DR4 
– dietary restricted mouse; B. A decrease of mTOR activity after rapamycin supplementation for 4 
months in mouse brain, C1-C4 – mTOR in control animals, R1-R4 – animals fed with rapamycin, C. 
Body weight of mice before and after 4 months of rapamycin treatment. *Statistical significance was 
calculated by One Way Anova. Error bars show S.E.M.  
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5.2.2. The influence of rapamycin supplementation on mTert protein expression in 
mouse brain  
To analyse the effect of rapamycin on mouse brain and potential ability to mimic 
dietary restriction response in mouse brain, mitochondrial mTert protein levels were 
measured after 4 months of rapamycin treatment. In addition, insulin levels in plasma 
of mice from the rapamycin experiment were evaluated by ELISA. 
 It was shown earlier in this study that dietary restriction increased the 
abundance of mitochondrial mTert in brain - in three independent experiments. 
However, this effect of DR on mTert in liver mitochondria varied between 
experiments. Thus, a TERT ELISA was performed on mouse brain mitochondria and 
whole brain tissue homogenates from rapamycin fed mice compared to controls. 
Moreover, mitochondrial fractions from livers were also tested for mTert protein 
amount under this condition. 
 Strikingly, the effect of rapamycin on mTert in mitochondria was the same as 
observed in dietary restriction. In brain, mTert abundance was higher for 38% in 
brain mitochondria from rapamycin treated animals compared to controls, very 
similar to all three DR experiments. Furthermore, the total amount of mTert in whole 
brain homogenates remained unchanged (Figure 5.2 A.). Interestingly, the results 
from liver mitochondria in the rapamycin experiment were also similar to those 
obtained from DR experiments where no difference in mTert protein amount was 
observed (Figure 5.2 B.). Liver homogenates from rapamycin treated mice were not 
tested. Altogether, this data strongly supports the hypothesis that the dietary 
restriction effect on an increase of mTert in brain mitochondria can be mimicked by 
rapamycin dietary supplementation. Therefore, the shuttling of mTert into brain 
mitochondria might be regulated by the mTOR pathway. 
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Figure 5.2. The influence of rapamycin on mTert protein abundance in brain and liver 
mitochondria, brain homogenates and plasma insulin level. A. Telomerase concentration in mouse 
brain mitochondria and whole organ homogenates after 4 months of rapamycin supplementation, 5 
animals were used per group in the experiment; B. Telomerase concentration in mouse liver 
mitochondria after rapamycin supplementation, 5 animals were used per group; *Statistical 
significance was tested by Anova. Error bars show S.E.M.  
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5.2.3. The influence of rapamycin on insulin level in mouse blood 
To test what effect rapamycin supplementation has on mouse metabolism I tested 
insulin levels in plasma of mTert+/+ and mTert-/- animals. Blood samples were 
collected from all animals during dissection (after feeding) and after blood serum 
isolation insulin levels were quantified by ELISA. Interestingly, in this experiment 
insulin levels after 4 months of rapamycin supplementation were significantly 
increased in mTert+/+ animals, which is in contrast to our findings from DR. 
However, this increase was not observed in mTert-/- animals. Interestingly, insulin 
levels in mTert-/- animals were significantly increased in the control and rapamycin 
treated group when compared to wild type control animals (Figure 5.3). This 
observation might suggest that mTert is involved in the metabolism of insulin. 
However, these results also show that rapamycin potentially can have deteriorative 
effects on liver, thus a lowered dosage of rapamycin is recommended in future 
experiments. Therefore, liver should be tested for functional markers to confirm a 
potentially toxic effect of rapamycin. 
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Figure 5.3. Insulin concentration in mouse serum after rapamycin supplementation. Graph bars 
show an average insulin concentration from 4 animals per group/genotype measured in duplicates. 
*Statistical significance was tested by One Way Anova. Error bars show S.E.M.  
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5.3. Oxygen consumption and reactive oxygen species generation in brain 
mitochondria after rapamycin supplemented diet  
 
To determine a potential influence of rapamycin dietary supplementation for the 
function of brain and liver mitochondria we measured ROS generation and oxygen 
consumption levels. Experimental settings were identical to those used to analyse 
mitochondria from animals after dietary experiments. Due to the complex nature of 
functional parameters the experiment on freshly isolated mitochondria was 
conducted in cooperation with Dr Satomi Miwa and another PhD student – Amy 
Johnson. 
 Oxygen consumption was tested in the presence of pyruvate:malate as a 
substrate for complex I and independently with succinate a complex II substrate. 
Respiration of isolated brain mitochondria was measured during active respiration 
state 3 by adding ADP to mitochondria. Moreover, respiration state 4 was analysed 
after introduction of oligomycin to mitochondria to block complex V. Furthermore, 
as earlier described, the uncoupler FCCP was added to mitochondria to measure 
maximal capacity of oxygen consumption. Finally, antimycin A was added to block 
complex III and stop oxygen consumption. Moreover, the level of mitochondria 
coupling was quantified by calculation of the RCR value. 
 In our experiments rapamycin had no effect on O2 consumption in both 
genotypes in all states of respiration as well as with inhibitors and the uncoupler 
(Figure 5.3). Furthermore, RCR during respiration of brain mitochondria also 
remained unchanged after 4 months of rapamycin supplementation in both mTert 
genotypes, which means that rapamycin have no influence on coupling of 
mitochondria. Moreover, comparable RCR values indicate consistent mitochondria 
preparation (Figure 5.4). 
 Production of ROS by brain mitochondria after rapamycin treatment was 
measured by AmplexRED
®
 under the same conditions as during measurements on 
mitochondria from the DR study. Briefly, hydrogen peroxide release was analysed 
during mitochondrial respiration state 4 (with oligomycin) in the presence of specific 
substrates for complex I and II. Furthermore, rotenone was used for the inhibition of 
complex I (maximal capacity of superoxide O2
.-
 production in the presence of 
pyruvate:malate). In the presence of succinate, rotenone was added to block complex 
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I and calculate O2
.-
 generation during reverse flow, associated with complex I. 
Antimycin A was added to calculate the maximal H2O2 release linked to complex III.  
 Results from ROS production experiment revealed that rapamycin was able 
to significantly reduce maximal (in presence of rotenone) superoxide release linked 
to complex I in mTert+/+ animals (Figure 5.5 A.). Interestingly, brain mitochondria 
isolated from mTert-/- showed no difference in generation of H2O2 after rapamycin 
supplementation. Furthermore, there was no difference in H2O2 production after 
rapamycin when only substrate for complex I (pyruvate:malate) was present in all 
genotypes (Figure 5.5 A.). Thus, this data strongly suggests that regulation of 
superoxide production in mouse brain mitochondria during inhibition of mTOR 
pathway depends on mTert status. Moreover, ROS generation in the presence of 
succinate (complex II substrate) also seemed to be strongly influenced by rapamycin. 
In the presence of succinate only brain mitochondria from mTert+/+ rapamycin 
treated mice showed significantly reduced H2O2 production when compared to 
control samples (Figure 5.5 B.). In contrast, there was no difference observed among 
mitochondria from mTert-/- mice. After addition of rotenone there was no difference 
in ROS production in all groups and genotypes.  
 Hydrogen peroxide production during reverse electron flow, linked to 
complex I can be calculated, as described earlier, from values obtained during 
measurements of ROS in presence of succinate and rotenone. Interestingly, 
rapamycin strongly reduced H2O2 production in brain mitochondria during reverse 
electron flow (Figure 5.5 C.). This reduction was only observed in mTert+/+ mice, 
while mitochondria from mTert-/- animals shows no difference between control and 
rapamycin supplemented group what suggests that mTert seems to be crucial for the 
response to rapamycin.  
Surprisingly, data form AmplexRED experiments showed that brain 
mitochondria from mTert-/- animals produced less H2O2 (P<0.001) than 
mitochondria from mTert+/+ male animals when subjected to complex I substrate 
(pyruvate:malate). However, this effect was not observed in control wild type and 
knock-out in experiments on animals from dietary restricted group. Although similar 
animal number was tested, the age of animals in both experiments was different. 
Mice from dietary restriction analysis were 22-23 months old and animals from 
rapamycin study were 16 months old.  
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Figure 5.4. Oxygen consumption in mouse brain mitochondria after rapamycin 
supplementation. A. Oxygen consumption in the presence of complex I substrate – pyruvate:malate, 
brain mitochondria form mTert +/+ and mTert -/- animals after 4 months of rapamycin 
supplementation, 5 animals per group/per genotype were analysed; B. Oxygen consumption in brain 
mitochondria in the presence of complex II substrate – succinate. Data presented as OCR (oxygen 
consumption rate) measured in pmoles of O2 per minute, per 5µg of proteins. OCR was measured 
during basal condition, after ADP delivery, after oligomycin (OLIGO), after FCCP and after 
antimycin A (AA). Statistical significance was calculated by Anova. Error bars show S.E.M. 
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Figure 5.5. Respiratory control ratio (RCR) in mouse brain mitochondria after rapamycin 
treatment. A. RCR calculated for mitochondria respiration in the presence of complex I substrate – 
pyruvate:malate; B. RCR calculated for mitochondria respiration in the presence of complex II 
substrate – succinate. Statistical significance was calculated by Anova. Error bars show S.E.M. 
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Figure 5.6. H2O2 generation of brain mitochondria from mTert+/+ and mTert-/- mice after 
rapamycin treatment (measurements performed by Amy Johnson). A.  H2O2 generation in 
mitochondria in the presence of pyruvate:malate - PM (complex I substrate) and rotenone (ROT); B. 
H2O2 generation in the presence of succinate - SUCC (complex II substrate), after delivery of 
rotenone and antimycin A (AA), C. ROS production during reverse electron flow; 4 animals per group 
and genotype were analysed in triplicate. *Statistical significance was calculated by Anova. Error bars 
shows S.E.M.  
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5.4. Discussion 
Mammalian target of rapamycin (mTOR) and its downstream targets (i.e. S6K1) 
were shown to play a crucial role in regulation of lifespan [113]. It was shown by 
genetic manipulation as well as by treatment with rapamycin that inhibition of 
mTOR pathway extends lifespan of many animal models [113, 281-283]. 
Importantly, mTOR signalling was recognised to coordinate nutrient sensing in 
dietary restriction response and be responsible for a lifespan increase effect when 
food was limited [109]. Furthermore, inhibition of mTOR pathway by rapamycin 
was shown to protect the mouse brain against cognitive decline in normal aged 
C57BL/6J mice as well as in Alzheimer’s disease model (PDAPP mice) [284, 285].  
The role of telomerase in ageing due to its telomere length related function 
has been previously established [175, 286]. However, its potential interaction with 
mTOR is poorly understood. Interestingly, it was shown that rapamycin inhibited 
growth of cervical cancer cells, leukaemia and endometrial cancer cells in vitro 
through reduction of the hTERT mRNA expression [287-289]. Strikingly, there are 
also reports suggesting that hTERT protein interacts physically with mTOR forming 
hTERT-mTORC1-RAPTOR complex in prostate cancer cells and NK (natural killer) 
cells which was suggested to influence telomerase activity [290, 291].  
To test whether the mTert effect of dietary restriction in brain mitochondria 
might be regulated by the mTOR pathway, the level of mTOR phosphorylation (i.e. 
its activity) in tissue was tested. Interestingly, both dietary restriction and rapamycin 
treatment decreased the phosphorylation of mTOR in mouse brain. Similar results 
were shown previously in mouse liver, where short term dietary restriction and 
rapamycin supplementation decreased phosphorylation of S6K1 to the same extent 
[121]. This suggests that telomerase shuttling to mitochondria during dietary 
restriction and rapamycin supplementation might be regulated via the mTOR 
pathway. 
The body weight of animals remained unchanged during our rapamycin 
supplementation study. It was shown by Miller et al., (2011) that rapamycin reduces 
the body weight of mice, however the changes were observed after 5 months of 
supplementation and our study lasted for only 4 months [292]. Strikingly, the insulin 
level in serum at the end of the rapamycin experiment was significantly increased in 
mTert wild type animals (Figure 5.3), while the DR intervention attenuated insulin 
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levels in mouse plasma. This data is in agreement with reports from similar 
experiments on mice published recently, suggesting that DR and rapamycin might 
influence insulin metabolism by distant mechanisms [121, 293]. Glucose tolerance 
was not tested in our rapamycin experiment. However, Fok et al., (2013) showed that 
DR improved clearance of glucose from mouse blood while rapamycin 
supplementation significantly increased glucose levels in GTT [121]. In addition, 
recent data of Lamming and co-workers showed that rapamycin, apart from 
inhibiting the mTORC1 complex, also decreased the activity of the mTORC2 
complex in vivo what resulted in decreased hepatic gluconeogenesis as an effect of 
increased insulin level [294]. Altogether, data from this study and others’ suggests 
that rapamycin might result in impaired liver function (high glucose and insulin), 
however, surprisingly, without affecting longevity [121, 294]. Furthermore, a recent 
study by Lamming et al., (2013) suggests that rapamycin influence on glucose and 
insulin metabolism may be dependent on the genetic background of mice. The 
authors show that in contrast to the study on C57BL/6 mice, heterogeneous HET3 
mice exhibit glucose intolerance after rapamycin treatment, but insulin levels as well 
as insulin tolerance remain unchanged in young and old animals [295]. Interestingly, 
my results showed that telomerase seems to be involved in the rapamycin effect since 
the elevation of insulin levels was not observed in mTert-/- mice. Remarkably, 
absolute values of insulin in all groups in the rapamycin study were higher than 
levels measured in blood from the dietary restriction experiment. This result could 
probably be due to the collection of blood from fed animals which is not 
recommended, whereas the dietary restricted animals were tested after overnight 
fasting, hence data on insulin in our experiments cannot be compared since blood in 
the dietary restriction study was collected from fasted animals and in the rapamycin 
experiment blood was obtained after feeding of the mice. 
The rapamycin supplementation experiment was performed on first 
generation mTert knock-out mice to understand the potential role of mTert protein in 
brain mitochondria during mTOR inhibition on parameters such as hydrogen 
peroxide generation and oxygen consumption. Although rapamycin is able to cross 
the blood-brain barrier, the level of the substance was shown to be two fold lower in 
brain than in blood after supplementation of mice [296]. There is no data so far about 
the effect of rapamycin on ROS generation in brain mitochondria. However, 
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rapamycin intervention was shown to significantly reduce ROS production in 
dendritic cells [297], in human corneal endothelial cells [298] and in lung carcinoma 
cells [299]. Furthermore, it has been shown in vitro and in vivo on mouse models that 
increased ROS production might elevate the activity of mTOR and rapamycin was 
potent to reverse this process and reduce oxidative stress [300, 301].  
Interestingly, in our study rapamycin treatment was sufficient to reduce H2O2 
generation linked to complex I (only with rotenone) and II in mouse brain 
mitochondria. Surprisingly, this effect was not observed in mitochondria isolated 
from mTert-/-. Thus, these results suggest that telomerase accumulating in 
mitochondria might be a novel and important participant in mediating the effects of 
the mTOR pathway and its influence on mitochondria function. As shown in Chapter 
4, mitochondria isolated from mouse brain after dietary restriction showed increased 
oxygen consumption after DR in basal and resting respiration states in the presence 
of pyruvate:malate. Interestingly this effect was not observed in mTert-/- mice. In the 
rapamycin supplementation experiment these changes were not observed. 
Stimulation of ETC complexes by pyruvate:malate and succinate resulted in no 
changes in O2 consumption in isolated mitochondria in all tested groups. 
Furthermore, coupling of mitochondria (represented quantitatively by RCR values) 
remained also unchanged after rapamycin supplementation in both mTert genotypes 
as it was observed after DR.  
Rapamycin supplementation was potent to reduce ROS production in our 
experiment in the presence of pyruvate:malate with rotenone in mTert wild type 
animals. Furthermore, beneficial effect of rapamycin treatment on ROS production 
was also observed in the presence of succinate (complex II blocker). Interestingly, 
these changes were not observed in mTert knock-out animals. The most surprising 
result, however, was that control mTert-/- animals showed less ROS production than 
their wild type littermates in the presence of complex II inhibitor – succinate. This 
effect was not observed in the dietary restriction experiments. To clarify, there was a 
similar animal number in all groups of tested males in both experiments (DR and 
rapamycin treatment). The explanation might be the difference in age of the analysed 
animals in DR and rapamycin experiments or a methodological error in measuring of 
hydrogen peroxide. To elucidate this phenomenon further experiment would be 
required to assess what is the influence of mTert status on H2O2 production in male 
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and female mouse brain mitochondria from different age groups. ROS production 
linked to complex III remained unchanged after rapamycin similarly to the results 
obtained after dietary restriction.  
Our data did not answer clearly the question whether mTert protects mouse 
brain mitochondria under rapamycin treatment. However, we showed that telomerase 
might be potentially important in regulation of the response for rapamycin on ROS 
production. Different results from our dietary restriction and rapamycin study 
suggest that we not fully understand how much similarity there is between both 
treatments. Although published to date results from oxygen consumption studies are 
ambiguous, ROS generation was shown consistently to decrease after dietary 
restriction and rapamycin treatment in many models [77, 117, 302, 303].  
Altogether, data from this part of my project suggests that rapamycin was 
able to mimic dietary restriction on mTOR phosphorylation. However, mitochondrial 
function in brain showed distinctive effect on mTert status. Furthermore, the 
influence of rapamycin and DR on liver function was also diverse. This study 
showed that mTert might be an important new player in the mTOR signalling 
pathway and its influence on mitochondrial function. Further research is required in 
order to elucidate how mTOR and rapamycin might influence male and female brain 
mitochondria since this study was conducted only on male mice. Moreover, 
experiments are required to elucidate what is the exact regulatory mechanism of 
coordination between mTOR and telomerase since both are known for their crucial 
role in ageing and senescence processes. 
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Chapter  6 - General discussion 
Telomerase is a well-recognised key player in the ageing and senescence processes, 
mainly due to its canonical function – telomere elongation [194, 200]. However, 
there is a growing number of publications supporting the fact that the protein part of 
telomerase – TERT – shuttles from the nucleus as a response to stress and localises 
in mitochondria. This mitochondrial localisation was shown by various groups to 
have beneficial and protective effects against oxidative stress [61, 207, 209]. In my 
project I was aiming to show that TERT also localises in mammalian brain/neurons 
and that mitochondrial localisation of the protein has a beneficial effect on the 
organelle in vivo. 
 Research on mitochondrial telomerase to date was conducted mostly on 
human fibroblasts and cancer cell lines. Saretzki’s group was one of the first to show 
that shuttling of telomerase to mitochondria in hTERT overexpressing human 
fibroblasts has a protective effect against oxidative stress and apoptosis induced by 
H2O2 and etoposide [61]. More recently the same group showed in Singhapol et al., 
(2012) that mitochondrial telomerase also protects human cancer cells against 
nuclear DNA damage and apoptosis induced by oxidative stress and irradiation 
[218]. Furthermore, Haendeler et al., (2009) reported that telomerase binds to the 
mtDNA regions coding complex I genes (i.e. ND1 and ND2) leading to an increase 
of respiration efficiency and complex I activity. Moreover, the same group showed 
that binding of hTERT to mtDNA protects the mitochondrial DNA against damage 
caused by UV and ethidium bromide. In addition, mitochondrial TERT was 
responsible for increase of respiration efficiency in mice heart mitochondria and 
reduction of ROS production in HEK cells [206]. However, there was still no 
evidence whether hTERT is shuttling into brain mitochondria in vivo.  
 The first comprehensive data on the expression and role of telomerase in 
mammalian brain was published by Mark Mattson in the beginning of the last decade 
[223, 231, 304]. For example, Fu et al., (2000) showed that telomerase is present in 
mouse and rat brain and in cultivated primary rodent’s neurons [230]. Furthermore, 
the group of Han-Woong Lee also showed by in situ hybridisation the expression of 
mTert and mTerc in rat and mouse brain [232, 233]. Both mentioned groups as well 
as Caporaso et al., (2003) reported a detectable telomerase activity in whole brain or 
its particular regions (i.e. cerebellum, subventricular zone) of neonatal and adult 
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rodents [229]. However, mitochondrial localisation of mTert in mammalian brain 
was not discussed so far. Only recently Eitan et al., (2012) showed mTert protein 
expression in the cytoplasm of Purkinje neurons in mouse cerebellum, however, 
without discussing its exact localisation [226]. Using a new TERT ELISA method I 
found that the enzymatic component of telomerase is localised in mitochondria of 
mouse brain and liver. Furthermore, this cytoplasmic localisation was observed in 
normal condition, without application of any external stressor. To establish what type 
of brain cells contained telomerase, I isolated mouse embryonic neurons. I showed 
here that mTert localises in neurons and co-localises with mitochondria using an 
immunofluorescence method. Furthermore, staining of brain sections of mouse and 
human brain also confirmed that telomerase is expressed in the CNS and it localises 
outside nucleus and mostly in mitochondria. Moreover, abundance of mTert was 
significantly reduced with age in frontal cortex and cerebellum in mouse. These 
findings are in accordance to a recent publication by Eitan et al., (2012), where it 
was shown that mouse telomerase localises mostly in the nucleus as well as 
cytoplasm (not specified what organelle) of Purkinje neurons and that the abundance 
of the protein decreases with age [226]. Thus, telomerase appears to be a new 
potential factor in the ageing of brain. Moreover, due to its cytosolic localisation this 
new unknown role of TERT is clearly not related to telomere maintenance function. 
To investigate a potential functional role of telomerase in brain, a dietary 
restricted mouse model was used. DR was shown by many groups to have beneficial 
effects on health and longevity in number of species. The DR regimen was shown to 
reduce oxidative stress in brain and improve neuronal mitochondria function [258, 
303]. Furthermore, Mattson et al., (1999) had previously shown that restriction of 
nutrients causes mild stress effects in rodent neurons with increased levels of HSP-70 
and GRP-78 proteins, what resulted in an increased expression of the neuroprotective 
trophic factors such as NGF [305-307]. This findings are in accordance with the 
theory of hormesis which suggest that physiological amount of ROS are required for 
normal function of the organelle and causes an adaptive and/or protective reaction 
against oxidative stress beneficial for longevity [308]. Thus we asked what would be 
the role of mTert in mitochondria in vivo during dietary restriction. 
Recent experiments published by our group showed that telomerase under 
stress protect mitochondria against damaging agents such as reactive oxygen species. 
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In this study we demonstrated that mitochondrial hTERT decreased oxidative stress 
in human cancer cells [218]. In my experiments in mice in vivo the enzymatic part of 
telomerase – mTert was significantly increased in brain mitochondria after short term 
dietary restriction. This finding was confirmed in three independent DR experiments, 
while there was no increase of mTert amount in whole tissue homogenates. 
However, telomerase in liver mitochondria was not increased in any DR experiment, 
what might suggest a specific function for mTert in brain (for example protection of 
neurons by reducing ROS production). Surprisingly, telomerase activity and mTert 
gene expression in brain were decreased after DR that suggests mTert shuttled from 
the nucleus to mitochondria without de novo transcription on the gene. These 
findings were surprising for us since dietary restriction is expected to reduce 
oxidative stress; hence mTert content should be reduced in brain mitochondria. In 
conclusion, it means that there seem to be additional triggers for the TERT shuttling 
process to oxidative stress. Increase of telomerase in brain mitochondria as a 
response for nutrient limitation is shown here for the first time. Next, we asked what 
effect this accumulation of mTert might have on the organelle function.  
Haendeler et al., (2009) showed that respiration in heart mitochondria in mTert-/- 
mice was significantly lower than mTert+/+. However, there was no difference between 
genotypes in liver mitochondria suggesting a tissue specific role of mTert in this 
organelle [206]. Interestingly, in our experiments there was no difference between mTert 
genotypes in respiration of brain mitochondria. Comparable results were obtained from 
two experiments on control animals in DR experiment and rapamycin study (i.e. ad 
libitum fed mice from the DR experiment and the control mice form the rapamycin 
study). Interestingly, dietary restriction increased oxygen consumption in brain 
mitochondria from mTert+/+ animals during basal and resting respiration state in the 
presence of pyruvate:malate (complex I substrate) and in the presence of complex III 
blocker antimycin A. However, there was no difference during active state 3 respiration 
(delivery of ADP to mitochondria) and in the presence of succinate – complex II 
substrate. This result suggest that mTert might improve complex I function by protection 
of mtDNA accordingly to the results from Haendeler at al., (2009) that TERT binds to 
mtDNA sequence coding subunits of complex I, namely ND1 and ND2 [206].  
The changes in oxygen uptake by mitochondria during dietary restriction are 
under ongoing debate [263-266]. However, our results on brain mitochondria and recent 
findings of Hempenstall et al., (2012) suggest that DR causes an increase in 
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mitochondrial oxygen consumption [266]. Furthermore, since mitochondrial respiration 
decline with age [309] and DR was shown to protect the organelle against age related 
dysfunction [77], it would be expected that dietary regimen would increase oxygen 
consumption. However, the effect of DR on mitochondrial respiration might be species-, 
age-, gender-, and tissue specific. Furthermore, in our DR experiments there was no 
difference in H2O2 generation in brain mitochondria, neither between mTert genotypes 
or dietary groups. Although it was shown by others that DR reduces ROS production and 
oxidative stress in different mammalian tissues, recent findings of Radak et al., (2013) 
showed there is no difference in ROS production in rat brain between ad libitum and 
restricted groups [310]. Thus further experiments are required in order to establish the 
influence of DR on brain ROS production. Interestingly, supplementation of mice with 
rapamycin which is believed to mimic DR effect showed a reduction of hydrogen 
peroxide production linked to complex II of mitochondrial ETC.  
Rapamycin was shown to slow ageing and to be potent to mimic some beneficial 
effects of dietary restriction due to a common regulation via mTOR pathway [119, 121, 
246, 311, 312]. However, it was shown that rapamycin might increase liver 
degeneration, cataract severity, testicular degradation in mice and increase glucose 
intolerance [120, 313]. In our experiments dietary restriction and rapamycin show 
distinct effect on insulin content in mouse serum. While DR significantly reduced insulin 
levels, rapamycin significantly increased the content of this hormone. However, in the 
rapamycin experiment blood was collected from fed animals. Thus, the results cannot be 
comprehensively compared. Nevertheless, it was suggested by others that rapamycin 
might have detrimental effects on liver function [294]. Interestingly, a recent study by 
Lamming et al., (2013) suggests that rapamycin influence on glucose and insulin 
metabolism might be dependent on the genetic background of mice. The authors 
show that in contrast to the study on C57BL/6 mice, heterogeneous HET3 mice 
exhibit glucose intolerance after rapamycin treatment but insulin level as well as 
insulin tolerance remain unchanged in young and old animals [295]. Furthermore, in 
our DR study glucose tolerance was improved and although we did not analyse glucose 
tolerance in the rapamycin experiment it was show by others that inhibition of mTOR 
reduced the ability to clear glucose from the blood [294]. 
To test the hypothesis that mTert shuttling in brain is regulated by the mTOR 
pathway experiments with rapamycin supplementation were conducted on mTert wild 
type and knock-out mice. I have shown in this thesis that indeed mTOR activation was 
decreased in mouse brain after dietary restriction and after rapamycin treatment to a 
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similar extend. Similar mTOR pathway inhibition after DR and rapamycin were shown 
on mice liver by Fok and co-workers [121]. In addition, rapamycin treatment in our 
experiments also increased mTert protein in brain mitochondria and remained unchanged 
in whole organ homogenates similarly to the dietary restriction study. Telomerase 
activity was not tested in our rapamycin experiment. Nonetheless, it was shown on a 
different model by Zhou et al., (2003) that rapamycin is potent to decrease TA by 
reduction of hTERT transcription in cancer cells [288]. Interestingly, in our study 
rapamycin was also capable to reduce hydrogen peroxide production linked to complex 
II of ETC in brain and this phenomenon was dependent on the mTert status. Brain 
mitochondria from mTert-/- animals did not show any difference in the generation of 
H2O2 as a response for rapamycin. These findings suggest that telomerase might be a 
new player in the mTOR pathway and for ROS production in brain mitochondria. The 
oxygen consumption rates were unchanged in brain mitochondria from both mTert 
genotypes after the mTOR pathway inhibition by rapamycin in all tested respiration 
states. However, Schieke et al., (2006) showed that rapamycin disrupted the complex of 
mTOR and raptor in vitro in cancer cells what resulted with reduced oxygen 
consumption [117].Surprisingly, in the rapamycin experiment we found that brain 
mitochondria from mTert-/- animals produced less ROS than mTert+/+. These findings 
are in contrast to our results from the control group (AL) from dietary restriction 
experiment where no differences between mTert genotypes were observed. Moreover, 
Haendeler et al., (2009) showed that knock-down of mTert increased significantly ROS 
production in vitro [206].  
Since only male animals were tested in both experiments (DR study and 
rapamycin treatment), I was interested in analysing mitochondria isolated from female 
mice brain. Interestingly, mitochondria from female brains generated less H2O2 in mTert 
wild type animals when compared to the knock-out littermates, supporting a protective 
role of telomerase in females but not in males. Furthermore, this protective effect was 
observed in young and old animals. Remarkably, the difference between male and 
female brain ageing is under extensive research [314]. It was suggested that sex 
hormones influence brain physiology and are important factors during stem cells 
differentiation into neurons [315]. For example it was shown by Diaz et al., (2007) that 
there is gradual increase in expression of estrogen and progesterone receptors genes 
during differentiation of stem cells into neurons [316]. Thus, it could be beneficial to 
analyse for example estrogen receptor α (ERα) level in mouse brain from different mTert 
genotype after DR and test its correlation with ROS levels. Furthermore, there are data 
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showing gender dependent response to DR. For example, it was shown that dietary 
restriction reduces ROS production in cardiac mitochondria significantly higher in 
rat females than in males [268]. Finally, estrogen was shown to reduce ROS 
production and oxidative stress in brain of rat female as well as male supplemented 
with the hormone [272].   
Protection against oxidative stress was shown to improve neuromuscular 
coordination in mouse brain [262]. Interestingly, in this project mTert was shown to be 
efficient in protection against age related decline in neuromuscular coordination. Dietary 
restricted animals from the mTert-/- genotype were performing significantly worse that 
their wild type littermates while there was no significant difference between genotypes 
in the ad libitum group. These data strongly support the hypothesis that telomerase 
preserves neuromuscular coordination ability of ageing mice and the mTert protein 
might play a role in the dietary restriction response. However, brain function per se (i.e. 
spatial memory and learning) needs to be tested by more specific methods such as 
Barnes maze, which tests the ability of rodents to learn and remember the location of a 
target zone. Interestingly, the protective function of DR on neuromuscular coordination 
might be also dependent on the mTOR pathway. It was shown that supplementation of 
mice with rapamycin significantly improved cognitive function of the brain like learning 
and memory [284]. 
To further develop this project there are still areas which should be 
investigated. Further experiments on ROS generation and oxidative damage in mouse 
brain mitochondria from different genotypes of mTert male and female animals are 
necessary. Besides, it would be interesting to elucidate what is the exact pathway of 
telomerase shuttling into mitochondria in vivo. Is it mTOR as suggested in this 
thesis? It was proposed that research on the inactivation of mTOR by rapamycin is 
more robust when the phosphorylation of downstream targets like S6 kinase or 4EBP 
is probed instead of mTOR itself [121, 284]. Furthermore, a comprehensive analysis 
of DNA damage in telomeric regions in brains from mTert wild type and knock-out 
mouse would deliver evidence whether the observed results are independent from the 
telomere-dependent role of telomerase. Since our group and others showed that 
mitochondrial localisation of hTERT reduced mtDNA damage, the question is what 
level of mtDNA damage could be observed in brain when mTert is deleted and what 
effect it might have on brain function [206, 218, 219]. Finally, our results might be 
used to investigate a potential role of telomerase in neurodegenerative diseases. For 
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example, it was shown recently by Eitan et al., (2012) that telomerase has a 
protective effect on brain in an amyotrophic lateral sclerosis mouse model. In this 
study chemical activator of telomerase (AGS-499) was shown to be effective in the 
delay of the disease onset and progression as well as survival. Furthermore, increased 
expression of mTert protected motor neurons against oxidative stress and apoptosis 
[198].  
To conclude, telomerase was shown here to be an important new player in the 
response to the dietary restriction and mTOR inhibition. It was shown that TERT co-
localises with mitochondria in mouse and human brain. Moreover, I showed here for 
the first time that mTert accumulates in brain mitochondria during short term dietary 
restriction. Interestingly, the same accumulation of mTert was observed after 
rapamycin supplementation that together with similar inhibition of mTOR in both 
treatments shows a close interaction between telomerase and the mTOR pathway 
(Figure 6.1). However, DR and rapamycin showed distant effect on brain 
mitochondria function. While restriction of nutrients increased oxygen consumption 
linked to complex I of ETC, rapamycin reduced generation of hydrogen peroxide 
linked to complex II. Moreover, whereas DR significantly reduced insulin level in 
mouse serum, rapamycin seemed to impair liver function what resulted in increased 
insulin level. Finally, mTert and DR showed beneficial, age dependent effect on 
brain function in neuromuscular coordination test what might suggest that mTert 
could be a possible new therapeutic target in neurodegenerative diseases like 
Alzheimer’s or Parkinson’s.  
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Figure 6.1. Summary of the results from dietary restriction and rapamycin experiment. Both 
interventions have no influence on total mTert protein in whole brain homogenates while result with 
significant increase of protein abundance in brain mitochondria. Mechanistically the observed effect 
might be correlated with the decrease in mTor phosphorylation. Dietary restriction resulted with 
increased oxygen consumption in isolated mitochondria and rapamycin decreased hydrogen peroxide 
production in these organelles.   
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Appendix: Abstracts of publications 
1. Article in Impact Ageing journal, September, 2010 
Article title:  Adult-onset, short-term dietary restriction reduces cell senescence in 
mice 
Authors: Chunfang Wang, Mandy Maddick, Satomi Miwa, Diana Jurk, Rafal 
Czapiewski, Gabriele Saretzki, Sabine A.S. Langie, Roger W.L. Godschalk, Kerry 
Cameron, Thomas von Zglinicki 
Abstract:  
Dietary restriction (DR) extends the lifespan of a wide variety of species and reduces 
the incidence of major age related diseases. Cell senescence has been proposed as 
one causal mechanism for tissue and organism ageing. We show for the first time 
that adult‐onset, short‐term DR reduced frequencies of senescent cells in the small 
intestinal epithelium and liver of mice, which are tissues known to accumulate 
increased numbers of senescent cells with advancing age. This reduction was 
associated with improved telomere maintenance without increased telomerase 
activity. We also found a decrease in cumulative oxidative stress markers in the same 
compartments despite absence of significant changes in steady‐state oxidative stress 
markers at the whole tissue level. The data suggest the possibility that reduction of 
cell senescence may be a primary consequence of DR, which in turn may explain 
known effects of DR such as improved mitochondrial function and reduced 
production of reactive oxygen species. 
 
2. Article in PlosONE journal, January, 2013  
Article title: Mitochondrial telomerase protects cancer cells from nuclear DNA 
damage and apoptosis 
Authors: Chatchawan Singhapol; Deepali Pal; Rafal Czapiewski; Mahendar Porika; 
Glyn Nelson; Gabriele Saretzki 
Abstract:  
Most cancer cells express high levels of telomerase and proliferate indefinitely. In 
addition to its telomere maintenance function, telomerase also has a pro-survival 
function resulting in an increased resistance against DNA damage and decreased 
apoptosis induction. However, the molecular mechanisms for this protective function 
remain elusive and it is unclear whether it is connected to telomere maintenance or is 
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rather a non-telomeric function of the telomerase protein, TERT. It was shown 
recently that the protein subunit of telomerase can shuttle from the nucleus to the 
mitochondria upon oxidative stress where it protects mitochondrial function and 
decreases intracellular oxidative stress.  
Here we show that endogenous telomerase (TERT protein) shuttles from the 
nucleus into mitochondria upon oxidative stress in cancer cells and analyzed the 
nuclear exclusion patterns of endogenous telomerase after treatment with hydrogen 
peroxide in different cell lines.  Cell populations excluded TERT from the nucleus 
upon oxidative stress in a heterogeneous fashion. We found a significant correlation 
between nuclear localization of telomerase and high DNA damage, while cells which 
excluded telomerase from the nucleus displayed no or very low DNA damage. We 
modeled nuclear and mitochondrial telomerase using organelle specific localization 
vectors and confirmed that mitochondrial localization of telomerase protects the 
nucleus from inflicted DNA damage and apoptosis while, in contrast, nuclear 
localization of telomerase correlated with higher amounts of DNA damage and 
apoptosis.  
It is known that nuclear DNA damage can be caused by mitochondrial 
generated reactive oxygen species (ROS). We demonstrate here that mitochondrial 
localization of telomerase specifically prevents nuclear DNA damage by decreasing 
levels of mitochondrial ROS. We suggest that this decrease of oxidative stress might 
be a possible cause for high stress resistance of cancer cells and could be especially 
important for cancer stem cells.  
 
3. Oral communication on Neuroscience North-East Conference, Durham 2011 
Talk title: Mitochondrial TERT protects neurons and increases in brain during 
dietary restriction via TOR pathway 
Abstract: 
The central nervous system is particularly exposed to oxidative stress due to high 
energy demand and high oxygen consumption rate. It was shown that reactive 
oxygen species (ROS) - products of respiration - play a crucial role in development 
and progress of neurodegenerative diseases in animal models as well as in human. 
Hence research for factors that protects brain and neurons in particular seems to be 
high priority. 
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It appears that one of important neurons protectors might be telomerase 
– an enzyme consisting two major components TERT (protein) and TERC (RNA) 
best known for its function in telomere maintaining. However, recently it was 
shown that TERT has telomere- and TERC-independent functions. 
Our lab was one of the first to show that telomerase shuttles to 
mitochondria improving their function and decreasing cellular oxidative stress. 
Oxidative stress and mitochondrial dysfunction are well known to increase 
during ageing and have been implicated as a cause for age-related 
neurodegenerative diseases. We now demonstrate that using targeted 
localisation of TERT into mitochondria but not nuclei significantly decreases 
mitochondrial ROS levels under basal and stressed conditions. 
Although telomerase activity is negligible in brain we found considerable 
amounts of the telomerase protein TERT in mouse and human brain. 
Immunohistochemistry showed extra nuclear localisation of TERT in neurons 
from human cortex, hippocampus and cerebellum. Moreover, TERT was co-
localised by fluorescence immunocytochemistry with the mitochondrial marker 
COXII in isolated neurons from E16.5 mouse as well as in human brain sections.  
Dietary restriction (DR) has been shown to ameliorate hallmarks of 
neurodegenerative diseases such as Alzheimer’s disease and cognitive decline 
including hyperphosphorylated tau protein deposits and amyloid. To test how 
DR influences TERT we conducted three independent short term DR 
experiments on mice. We found that TERT protein resides in mouse brain 
mitochondria already in control animals and increases in brain tissue from 3 
independent DR experiments. Furthermore, we demonstrate that ROS 
generation is significantly decreased in brain mitochondria from DR mice. 
Decreased signalling through mTOR has been described as a major 
mechanism of DR. Accordingly; we found that mTOR phosphorylation was 
significantly down regulated in brains from DR animals. These findings were 
confirmed by rapamycin (TOR inhibitor) treatment of cells. Moreover, 
rapamycin increased the extra nuclear TERT amounts while decreasing 
intracellular oxidative stress. We conclude that down-regulation of mTOR is a 
possible mechanism to increase TERT protein levels within mitochondria under 
DR. 
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Finally, our preliminary data shows that neurons from human 
hippocampus and frontal cortex with hyperphosphorylated tau protein do not 
express TERT and vice versa. Together, our data suggest that mitochondrial 
TERT can protect neurons and improve mitochondrial function and delay or 
prevent age related neurodegenerative diseases. 
 
 
4. Oral communication on BSRA meeting, Birmingham 2012 
Talk title: Does mitochondrial TERT protect the brain? 
Abstract: 
Dietary restriction (DR) is the only manipulation proven to increase lifespan in wide 
range of animal models such as yeast, worms, flies and mammals. The exact 
mechanism for the delay of is not clear yet. It has been shown that DR significantly 
reduces the reactive oxygen species production, improves mitochondrial function and 
seems to delay cell senescence in mammals. 
Telomerase is an enzyme well known for protecting and maintaining 
telomeres consisting of the catalytic subunit TERT and the RNA component TERC. 
Recently our group showed that telomerase protects mitochondria under oxidative 
stress. We hypothesise that mitochondrial TERT could play a role for the beneficial 
effects of DR in vivo in mice. 
We did not find telomerase activity (using TRAP PCR) in isolated 
mitochondria but high levels in homogenates of whole organs. In contrast, the 
mitochondrial amount of TERT was significantly higher in the mitochondrial 
fraction than in tissue homogenates. These results suggest that only TERT but not 
TERC localised to mitochondria.  
By using TERT ELISA assay (GenWay) we measured TERT protein level in 
mitochondrial fractions from liver, brain and muscle in three independent short term 
DR experiments. We found highly significant increase in TERT protein abundance in 
brain mitochondria under DR in all three experiments. There is also clear tendency of 
increase in TERT protein in mitochondria and homogenates in liver. 
We suggest that catalytic component of telomerase might be involved in 
mitochondrial protection and that this effect is increased under conditions of dietary 
restriction and therefore contribute to the beneficial health effects of DR. 
